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Summary 
 
Marfan Syndrome is a genetic, cardiovascular disease caused by a defect in the fibrillin 
1 gene on chromosome 15.  This defect causes abnormal deposition of elastin 
throughout the body.  Elastin is found in many organs including the aorta.  Marfan 
Syndrome is diagnosed by the Ghent criteria.  The mean age at death is 44 years for 
men and 47 years for women, and about 70% die from acute cardiovascular 
complications, mainly aortic dissection. 
The assessment and treatment of the aortic complications of Marfan Syndrome has not 
changed for many years.  Serial echocardiography is performed to measure the aortic 
root diameter.  If thought to be increasing in size, beta blockers are prescribed to delay 
aortic dilatation and surgery, and to prevent aortic dissection or rupture despite the 
paucity of good research data.  I have investigated three novel diagnostic tools:  Tissue 
Doppler Imaging, Applanation Tonometry and Wave Intensity Analysis which have 
potential advantages in the assessment of the left ventricle and aorta and their 
interaction in Marfan Syndrome.  I also investigated three drugs a beta blocker, an 
angiotensin converting enzyme inhibitor and a calcium channel blocker to look at their 
impact on some of the parameters measured by these three novel tools in a double-
blinded, randomised cross-over trial. 
I conclude that these three novel tools would be useful adjuncts in monitoring Marfan 
Syndrome and their response to treatment.  I also found that beta blockers may still 
have a role to play in delaying and preventing aortic complications when given together 
with an angiotensin converting enzyme inhibitor, calcium channel blocker or 
angiotensin receptor blocker.  There are, however, other issues that need addressing 
to improve the management of the cardiovascular complications of Marfan Syndrome.  
This includes a multi-team approach to this multi-system disease and improvements in 
the standard of research. 
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CHAPTER 1.1 
A REVIEW OF MARFAN SYNDROME 
 
History 
Marfan Syndrome was first described in 1896 by Professor Antoine Bernard-Jean 
Marfan (1858-1942), a French paediatrician working in Paris1.  At the Medical Society 
of Paris meeting that year he presented the case of a 5 year old girl who had 
disproportionately long arms.   
In 1902, Mery and Babonneix studied the same girl again, this time with the advantage 
of new technology in the form of radiography.  They discovered her dorsal spine was 
malaligned and her thorax was asymmetrical.  They called the condition 
hyperchondroplasia2.  In later studies further anomalies were documented, including 
arachnodactyly (long digits) and dislocation of the ocular lens.   
In 1912, Salle3 described mitral valve abnormalities and heart dilatation in an infant with 
heart failure but it was not until 1943 that the typical cardiac abnormalities (aortic 
dilatation and dissection) were linked to the Marfan phenotype.    
Cardiovascular disease accounts for more than 90% of premature deaths in patients 
with Marfan Syndrome4.  In the 1950s, studies of a relatively large number of patients 
and their families delineated the natural history of Marfan Syndrome , particularly the 
cardiovascular complications.  McKusick5,in 1955, said “What the suspensory ligament 
of the lens has in common with the media of the aorta is obscure.  If known, the basic 
history of the syndrome might be understood.”  It was at this time that the first Marfan 
clinic was set up at his institution, The Johns Hopkins Hospital in Baltimore.   
Before the era of open heart surgery, the majority of patients with Marfan Syndrome 
died prematurely of aortic rupture often by their third decade6.  Even after open heart 
surgery became established, surgical management was reserved for patients who had 
suffered acute dissection or rupture.  Results were therefore poor.   
Over the last ten years there have been important advances in the understanding of 
the development of Marfan Syndrome and this has led to the investigation of new 
therapeutic targets to prevent or delay aortic dilatation.  Prior to this, beta blockers 
have been the mainstay of medical treatment. 
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Incidence and aetiology 
Marfan Syndrome is an autosomal dominant disorder of connective tissue that has both 
high penetrance and variable severity.  The incidence of Marfan Syndrome is around 2-
3 per 10,000 individuals7.  In 25%, there is no family history, which suggests the 
condition has presented de novo.  There are currently (1st September 2011) 601 
identified genetic mutations of which 80% were novel8.  
Marfan Syndrome is caused by an abnormality of fibrillin, a 350kD glycoprotein, which 
is the main structural component of microfibrils.  Microfibrils provide a supporting 
scaffold for the deposition of elastin throughout the body. Fibrillin is present in many 
other tissues including lung, dura mater, skin, tendon, the ciliary zonules of the lens, 
myocardium, heart valves and periosteum.  Abnormalities in these fibrillin-containing 
tissues are found in most patients with Marfan Syndrome.   
In 1991, mutations in the fibrillin-1 gene (15q21.3) were found to cause Marfan 
Syndrome9.  For many years this was thought to be the only cause of the Marfan 
phenotype.  In 2005, however, it was reported that mutations in transforming growth 
factor-beta (TGF-beta) receptors 1+2 on chromosome three caused a similar but more 
severe vascular phenotype to that seen in Marfan Syndrome –named the Loeys-Dietz 
syndrome10.  This is associated with aggressive aortic vascular disease and can be 
distinguished from Marfan Syndrome by the presence of hypertelorism, low set ears 
and a bifid uvula or cleft palate.  In comparison to Marfan Syndrome, there is a much 
higher risk of dissection at a young age, at smaller vessel dimensions and in non-aortic 
vessels.   
TGF-beta cytokines play a major role in tissue development and cellular regulation11.  
There is a regulatory relationship between extracellular microfibrils and TGF-beta 
signalling so that an abnormality in either can lead to a common final pathway which 
causes the development of the Marfan phenotype.  This will be discussed in detail in 
the next chapter. 
 
Clinical features 
Multiple organ systems are affected including the skeleton, eyes, heart, lungs and 
blood vessels.  Marfan Syndrome is diagnosed in our studies using the Ghent nosology 
(Table 1) which combines clinical and genetic factors12.  The diagnosis is confirmed if a 
patient has major criteria in two or more organ systems and minor criterion in a third 
system or if mutation positive one major and one minor criterion.  
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Table 1- Ghent Diagnostic Criteria for Marfan Syndrome
12
 
 
Category Major criteria Minor criteria 
Family history  independent 
diagnosis in parent, 
child or sibling 
 
Genetics  mutation FBN1  
Cardiovascular  aortic root dilatation 
 dissection of 
ascending aorta 
 mitral valve prolapse 
 calcification of the mitral 
annulus (<40yrs) 
 dilatation of the pulmonary 
artery 
 dilatation/dissection of 
descending aorta(50yrs) 
Ocular  
 ectopia lentis 
2 needed:  
 flat cornea 
 elongated globe 
 myopia        
Skeletal 4 needed:   
 pectus excavatum 
needing surgery 
 pectus carinatum 
 pes planus 
2-3 major, or 1 major and 2 minor 
signs:  
 moderate pectus 
excavatum 
 high narrowly arched 
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 wrist and thumb 
sign 
 scoliosis>20º or 
spondylolisthesis 
 armspan-height 
ratio>1.05 
 protrusio 
acetabulae (X-ray, 
MRI) 
 diminished 
extension 
elbows<170º 
palate 
 typical face 
 joint hypermobility 
Pulmonary   spontaneous 
pneumothorax 
 apical bulla 
Skin   Striae 
 recurrent or incisional 
herniae 
Central Nervous 
System 
 lumbosacral dural 
ectasia (CT or MRI) 
 
Note:  lumbosacral dural ectasia and protrusion acetabulae are diagnosed using Magnetic resonance imaging or CT scan. 
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Diagnostic Criteria 
In 1986, an international panel of experts set out the so-called Berlin nosology13 to 
diagnose Marfan Syndrome. Following the identification of the fibrillin 1 gene, the Berlin 
nosology was changed to the Ghent nosology due to over-diagnosis.  Recently, and 
since I started the MD, the Ghent nosology have been revised in 201014.  Even though 
the original Ghent nosology confirmed Marfan Syndrome in over 95% of patients, there 
were concerns over the lack of validation of some of the diagnostic criteria; the 
application of some criteria to the paediatric population; and the availability and 
expense of MRI scanning for lumbosacral dural ectasia and protrusion acetabulae.  
The current revised diagnostic criteria rely much more heavily on the cardiovascular 
and ocular systems.  It is thought that the new guidelines may delay a definitive 
diagnosis of Marfan Syndrome but will reduce the risk of premature or misdiagnosis14.  
The difficulty in diagnosing Marfan Syndrome is an important one.  Matching phenotype 
and genotype is a problem especially in a genetic disease that has over 600 genetic 
mutations.  There can also be considerable variation in clinical features even within 
families with the same mutation.  As with a number of genetic diseases there seems to 
be a spectrum of disease and people are often diagnosed as Marfanoid without 
meeting the full Ghent criteria for Marfan Syndrome.   
Marfan Syndrome may be suspected in foetal life and can be diagnosed on antenatal 
ultrasound15, but the diagnosis is often not made until late childhood or adult life.  In the 
young child it can be difficult to make a definitive diagnosis.  Children often have an 
evolving phenotype and may need to be followed for several years before the diagnosis 
can be confirmed or refuted16.  All these possible cases should be regularly assessed 
by echocardiography, optometry and skeletal survey as the child grows.  A full family 
history and assessment of other family members also gives clues to the diagnosis.  
The American Academy of Paediatrics have produced detailed recommendations for 
the follow up of children with Marfan Syndrome which takes this difficulty into 
account17.     
 
Differential Diagnosis 
“Neonatal” Marfan Syndrome is a severe form of Marfan Syndrome often associated 
with a deletion in the exon 24-32 region of the Fibrillin 1 gene.  This rare condition 
differs from the more usual infantile Marfan Syndrome in the severity of the cardiac and 
pulmonary manifestations18.  Infants with the “neonatal” form often have severe mitral 
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and tricuspid regurgitation in addition to aortic root dilatation.  Similarly, the usual 
arachnodactyly and tall stature may be accompanied by ectopia lentis, very loose skin 
“as if two sizes too big,” emphysema and joint contractures.  The cardiovascular 
features often require surgical intervention in infancy and this may be complicated by 
scoliosis and pulmonary hypertension. The long term prognosis is very poor –usually 
due to progressive valve dysfunction or lung abnormalities18,19.   
Other Marfan-like syndromes do exist and there can be considerable overlap with the 
Sphrintzen-Goldberg syndrome, Loeys-Dietz syndrome and the vascular form of Ehlers 
Danlos syndrome14,20.  This emphasises the importance of appropriate diagnosis using 
the Revised Ghent criteria which takes these other syndromes into consideration.   
 
Cardiovascular abnormalities  
At 30 years of age, men with Marfan Syndrome have an annual mortality of 2%, and 
women 1%21.  According to actuarial life tables, these figures represent a 20-40 fold 
increased risk compared with a UK population of the same age22.  The mean age at 
death in affected individuals is 44 years for men and 47 years for women21, and about 
70% die from acute cardiovascular complications, mainly aortic dissection23.  The in-
hospital mortality of Marfan patients with dissection (21%) and the rate of complications 
are similar to those observed in older patients in whom the aetiology of dissection is 
arterial hypertension24.  The most important target for improving survival in patients 
with Marfan Syndrome, therefore, is to prevent or delay aortic dissection. 
Virtually all adults with Marfan Syndrome have an abnormal cardiovascular system.  
The most common cardiovascular abnormalities are dilatation of the aorta and mitral 
regurgitation (Table 2).   
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Table 2: Cardiovascular Manifestations of Marfan syndrome 
 
Lesion/ Feature Frequency Complications Comments 
Aortic root 
dilatation 
60-80% Aortic dissection Dissection rare 
< 10yrs old 
Pulmonary artery 
dilatation 
76%  Dissection rare Diagnostic 
feature < 40yrs 
old 
Mitral regurgitation/ 
prolapse/annular 
calcification  
52-68% Arrhythmias 
Endocarditis 
Ventricular 
dysfunction 
Regurgitation 
may be 
intermittent 
Descending aorta 
dilatation 
 Aortic dissection Rare in 
childhood 
Endothelial 
dysfunction 
/abnormal aorta 
elasticity 
80-100%  Increased 
vascular stiffness  
May contribute 
to dissection 
risk 
Tricuspid valve 
prolapse 
4%  
36% in infantile 
type 
May progress 
requiring repair 
Severe disease 
uncommon 
except in 
infantile type 
Left ventricular 
dysfunction 
Up to 100% 
Severity varies. 
Diastolic. May be 
progressive to 
systolic 
dysfunction. 
May occur 
despite normal 
valves 
Arrhythmias Up to 20-30% May cause 
sudden death 
Associated with 
ventricular  
dilatation;  
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Coronary artery 
aneurysm 
< 1%  Only described in 
adults 
 
Atrial septal defect 4% May need 
surgical repair 
More common 
than in normal 
population 
 
Most children with Marfan Syndrome have aortic root dilatation.  The reported 
frequency of other valve abnormalities depends to some extent on the rigour of the 
method of assessment.  Moreover, some abnormalities (for example, mitral 
regurgitation and prolapse) can be intermittent and vary from mild to severe at different 
times in the same patient.  Patients with valvular complications are at increased risk of 
infective endocarditis.  Recommendations for antibiotic prophylaxis have changed and 
rely on local policy but good dental hygiene and early treatment of skin sepsis remain 
vital.   
Cardiac arrhythmias are an under-recognised cause of morbidity and mortality.  A link 
between Marfan Syndrome and Wolff Parkinson White syndrome has been postulated 
and atrial fibrillation has been reported in children and adults25,26.  Minor ECG 
abnormalities may be present in up to 50% of children with Marfan Syndrome27.  In 
addition, ventricular arrhythmias may occur and can lead to sudden death28-30.  This is 
not surprising given the extensive fibrillin network which extends throughout the 
myocardium31.  For the same reason, paradoxical septal motion is common.  There is 
also an important subgroup who have significant left ventricular dysfunction which is 
unrelated to valve regurgitation32,33. 
 
Cardiovascular Assessment of Marfan syndrome 
Echocardiography is the mainstay of assessment of people with Marfan Syndrome.  A 
protocol for cardiovascular assessment is shown in Table 3.   
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Table 3: Protocol for cardiovascular assessment of Marfan syndrome 
Clinical assessment  Comment 
Weight /height Allows calculation of body surface area for aortic root 
nomogram 
Auscultation Ejection click is common if aortic root dilated  
Midsystolic click may be present in valve prolapse.  
Murmurs associated with valve regurgitation.  
Blood pressure If on beta blocker, calcium antagonist  or ACE 
inhibitor/receptor blocker  
Electrocardiogram 
 
12 lead ECG at each visit  
Consider ambulatory or event monitor if palpitations 
Echocardiogram Full study every 12 months.  
Measure LV dimensions and function, pulmonary valve 
diameter, aortic root diameter.   
Plot aortic root against body surface area nomogram. 
 
Detailed echocardiographic assessment should include a full study of left ventricular 
function, aortic root dimensions and intracardiac valves. Structural lesions should be 
excluded – in particular, atrial septal defect.  Each echocardiography department 
should have a standardised protocol for measurement of the aortic root to allow 
reproducible sequential measurements which can be plotted against body surface 
area34 (Figure 1).   
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Figure 1     Echocardiographic Measurement of Aortic Root34 
LV
LA
1
2
3
4
 
 
The aortic root should be measured at the annulus (1), sinus of Valsalva (2), 
sinotubular junction (3) and ascending aorta (4).  Measurements should be made in 
diastole at right angles to the aortic valve closure line using the leading edge 
technique.  These should be plotted against normal values.  Normal values are 
available for aortic root dimensions34.  These nomograms have been criticised as they 
do not reflect the normal aortic root dimensions in tall, slim people in whom Marfan 
Syndrome has been excluded.  Rozendaal suggested that an adjusted nomogram 
derived from tall, non-Marfan people should be used to take this into account35.  The 
same group devised a discrimination score which showed that the rate of aortic root 
growth in children and adolescents with Marfan Syndrome differs from the normal 
population with a sensitivity and specificity of 84% and 73%36.   
Perhaps the most important factor is the need for each echocardiography unit to 
develop a standardised measurement technique which enables reproducible 
measurements to be recorded sequentially in comparison to somatic growth.  This 
allows discrimination between normal aortic growth and progressive dilatation and 
enables the appropriate institution of treatment  
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The pattern of root dilatation should also be noted as diffuse dilatation with loss of the 
sinotubular junction is associated with an increased risk of dissection37.  In some 
Marfan patients it is not possible to fully assess the aorta due to a poor acoustic 
window.  This may be exacerbated by significant scoliosis.  In this situation, MRI 
scanning should be used.  This has the benefit of allowing an assessment of the 
lumbar dura.  Dural ectasia is present 40% of children and over 90% of adults with 
Marfan Syndrome38,39.  
The frequency of cardiovascular assessment will depend on the age of the patient, the 
underlying cardiovascular abnormalities and medication.  In general, most patients 
should be assessed every 6-12 months17.  This may need to be more frequent if 
commencing medication or if there is a rapid growth phase.   
 
Treatment of the cardiovascular manifestations of Marfan Syndrome 
General advice 
Most authorities advise patients with Marfan Syndrome to avoid isometric exercise and 
competitive or contact sports7,40.  This is based on the small risk of aortic dissection on 
exercise7,41,42.  Unfortunately, this advice can occasionally lead to complete avoidance 
of recreational exercise.  Regular exercise has many psychosocial and general health 
benefits43.  Moreover, although studies have not been performed in Marfan Syndrome,  
regular exercise is known to attenuate poor vascular compliance in conditions such as 
diabetes and hypertension44,45.  Consequently, patients with Marfan Syndrome should 
be encouraged to remain active and a specific aerobic exercise prescription may be 
beneficial.  Similarly, adherence to a healthy “Mediterranean diet” and avoidance of 
obesity and cigarette smoking should be recommended as this may prevent 
exacerbation of the increased vascular stiffness which occurs in the Marfan aorta46-48. 
Due to its autosomal dominant inheritance, relatives are also at risk from Marfan 
Syndrome and should be offered medical assessment.  Genetic counselling for would-
be parents explaining the 50% risk to their child and the potential complications during 
pregnancy, especially increasing aortic root dilatation, should also be discussed.   
The diagnosis of Marfan Syndrome itself, with its increased mortality and morbidity also 
raises psychosocial issues and the early involvement of clinical psychologists and 
support groups such as The Marfan Association UK can help in many cases. 
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Risk Stratification 
Risk stratification in children is difficult. In adults, excessive aortic root dilatation 
(>1.7mm/year), increased aortic stiffness, aortic root diameter > 55mm49,50 and 
dilatation at the aortic sinotubular junction37 are significant risk factors for dissection.  A 
family history of aortic dissection is one of the most important risk factors. The absence 
of lens dislocation has been reported as a risk factor for aortic dissection although this 
may simply reflect delay in diagnosis and treatment49. 
Cardiac Surgery 
Few children with Marfan Syndrome require cardiac surgery before reaching teenage 
years. In the neonatal form, surgery may be necessary to repair or replace the mitral or 
tricuspid valves and to replace the aortic root51.  Outside of infancy, tricuspid valve 
surgery is rarely necessary and mitral valve repair or replacement is uncommon in 
childhood. Tsang reported only 7 children referred over a 7 year period to a large 
cardiac surgical centre51.  Of these, 3 had the infantile form; 2 required mitral valve 
replacements (aged 2 and 7 years- one of whom also underwent tricuspid valve repair) 
and one aortic root replacement (aged 2 years).  The 4 older children all required aortic 
root surgery (aged 15, 17 and 18 years).     
The traditional form of elective aortic root replacement is the composite (Bentall) 
graft52.  This involves the resection of the aneurysmal portion of the ascending aorta 
and replacement with a prosthetic valve incorporated in a dacron tube.  More recent 
alternatives include using a valve-sparing procedure or novel exostent technique.   
The valve sparing procedure involves resecting the ascending aorta and replacing it 
with a sculpted dacron tube which sits above the native aortic valve53,54.  This has the 
major advantage of avoiding the need for anticoagulation.  Although the aortic valve 
leaflets are abnormal in Marfan patients, the data in adults suggest that survival is 
similar to the composite graft and valve related complications are lower55.  Preliminary 
results in children suggest that the valve-sparing technique has excellent short term 
results but this is dependant on the precise valve-sparing method used56.   
The exostent is a new concept which involves creating a 3 dimensional model of the 
dilated aorta and producing a computer-designed stent which is placed on the outside 
of the dilated root57.  This avoids the need for bypass surgery but prevents any form of 
growth and therefore, could not be used in a young child.  Long-term data are awaited.   
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The final option is the use of a human donor aorta (homograft).  This has the 
advantage of avoiding anticoagulation but is complicated by the shortage of homografts 
and the poor longevity of the graft in young patients58,59.   
Perhaps the most important decision is the timing of aortic root surgery. The ideal time 
to replace the root is “one or two months before it dissects” 60.  Although aortic 
dissection is rare in childhood, the success of elective replacement (> 95% survival) is 
much lower than if emergency surgery is needed.  In adults, it is usually recommended 
that the root is replaced when the sinus of Valsalva measures 5cm although this figure 
is reduced if there are additional risk factors such as a strong family history of 
dissection7,61.  In older children, most authors recommend root replacement at 5cm, 
when enlargement is greater than 1cm per year or if there is progressive aortic 
regurgitation62.  
The surgical risk is not to be underestimated and therefore, delaying the need for 
surgery is of primary importance to the clinician.  Medical treatment in the form of beta 
blockade is most commonly used.  Second-line therapy involves Angiotensin 
Converting Enzyme inhibitors (ACEi), Calcium Channel Blockers (CCB) or Angiotensin 
Receptor Blocker (ARB) therapy.  The medical treatments that are currently used and 
some novel possibilities will be discussed in detail in the following chapter.
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CHAPTER 1.2 
CURRENT AND NOVEL MEDICAL TREATMENTS IN MARFAN SYNDROME. 
 
Pathophysiology 
The main aim of treatment in Marfan Syndrome is to delay aortic root dilatation and 
therefore reduce the risk of aortic dissection and delay surgery for as long as possible.  
As our understanding of the pathophysiology of Marfan Syndrome increases, novel 
areas of potential medical therapy become apparent.   
Fibrillin-1 contains calcium-binding sites that are important in stabilising the microfibril 
against proteolytic degradation by serine proteases such as matrix metalloproteinases 
(MMPs) and calpains.  Hence, abnormal fibrillin-1 is either not secreted or forms 
abnormal microfibrils which in turn lead to decreased elastin and abnormal elastic 
properties of the aortic wall.  In 1991, Hirata63 found decreased distensibility, increased 
stiffness index and increased pulse wave velocity in the ascending and abdominal 
aortas of Marfan subjects.  The Marfan aorta also has abnormal endothelial function 
with elevated levels of the endothelial cell products factor VIII antigen and 
thrombomodulin64 and impaired flow-mediated vasodilatation65.   
Over time as a consequence of central aortic pressure and waves acting on the stiff 
aortic wall and these abnormalities in the extracellular matrix itself, the aortic diameter 
enlarges eventually resulting in intramural haemorrhage (from ruptured vaso 
vasorum)and aortic dissection or rupture. 
 
TGF- β 
There is recent data, murine and human, on the effects of targeting TGF- receptors 
and this plays an important role in the pathogenesis of Marfan Syndrome.   
TGF-β1 is a central player in the development of fibrosis in chronic inflammatory 
conditions.  Fibroblasts and smooth muscle cells respond to TGF-β1 by expansion of 
the extracellular matrix with increased collagen synthesis and deposition paralleled by 
downregulation of matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9) and 
upregulation of their tissue inhibitors (TIMP).  TGF-β1 also mediates the effects of 
angiotensin II (AII) on extracellular matrix remodelling and vascular fibrosis.   
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Activation of TGF-β1 is via several signal transduction pathways.  Fibrillin-1 also 
contributes to the regulated activation of TGF-β1 and in Marfan Syndrome, fibrillin-1 
deficiency causes enhanced signalling of TGF-β1.  In 2003, Neptune66 reported that 
fibrillin-1 regulates the activation of TGF-β1 in the developing lung and that enhanced 
signalling in the fibrillin-1-deficient state contributes directly to apoptosis in the lung.   
In 2004, Ng67 hypothesised that TGF-β1 may contribute to the multisystem 
pathogenesis of Marfan Syndrome and his group have recently demonstrated 
activation of TGF-β1 in prolapsed mitral valves in fibrillin-1-deficient mice.  Moreover, 
they showed that TGF-β1 antagonism in vivo caused “phenotypic rescue” of the mitral 
valves.  In 2006, Habashi68 demonstrated increased aortic TGF-β signalling in a mouse 
model of Marfan Syndrome.   
The actions and interactions of abnormal fibrillin, TGF-β1activity, angiotensin II and the 
proteases MMPs and calpains, all have a role to play in the pathological process in the 
Marfan aorta and in the development of Marfan Syndrome.  These proteins provide 
possible therapeutic targets for medical intervention.  
 
Clinical studies of medical treatment for Marfan Syndrome 
Until recently, only three classes of drugs had been investigated in the prevention of 
aortic dissection and rupture in Marfan Syndrome - beta blockers, angiotensin 
converting enzyme inhibitors and calcium channel blockers, and most of these studies 
had been of beta blockers alone.  At the start of my thesis, there had been no 
prospective, randomised, double-blind study yet reported.  Table 1 summarises all the 
published clinical studies of medical treatment for Marfan Syndrome in humans.   
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Table 1 - Summary Table of Published Evidence in The Medical Treatment of Marfan Syndrome in Human 
Subjects 
 
AUTHOR DESIGN INCLUSION 
CRITERIA 
AGE GENDER DURATION INTERVENTIONAL 
TREATMENT 
OUTCOME 
BL Halpern 
1971
69 
Prospective 
Acute trial  
Non-randomised 
Non-blinded 
N/K N/K N=2 
M:F N/K 
Acute study Propranolol 
5mg iv  
Propranolol dP/dT, HR 
pre-ejection period.  Authors 
noted problems with side 
effects and qds regime 
L Ose 
1977
70 
Retrospective 
Non-randomised 
Non-blinded 
MF pts; Aortic 
dilatation  AR  
5-59yrs 
Mean 30.4 
14.8yrs 
 
N=25 
M=16, F=9 
1-7yrs range, 
mean 31.8yrs 
Propranolol 
titrated to keep HR<70 at all 
times. 120-160mg/day(adult); 
40-80mg/day(children) 
20% had acute aortic 
dissection and died despite Rx.  
Other pts had ↑ aortic root 
dilatation.  No side effects 
noted 
CM Reed  
1992
71 
Prospective 
Non-randomised 
Non-blinded 
MF assessed by 
geneticist 
10-18yrs Mean 
14.7yrs 
N=9 
M=5, F=4 
≥6 weeks Oral atenolol titrated to 
2mg/kg/day in 2 divided doses 
Significant decrease in HR, 
peak aortic velocity, LV 
ejection force and force/BSA 
after treatment.  No change in 
afterload or bp 
CM Reed  
1993
72 
Retrospective 
Non-randomised 
Non-blinded 
MF assessed by 
geneticist 
6-22yrs Mean 
14±3yrs 
N=22 
M=14, F=8 
Mean 3.9± 1.4yrs Atenolol titrated clinically up to 
2mg/kg/day 
No change in pulse pressure, 
aortic stiffness or distensibility 
with atenolol in this young 
popn 
AC Tahernia 
1993
73
 
Prospective 
Non-randomised 
Blinded 
MF by 1979 
criteria 
5-14yrs Mean 
9.3yrs 
N=6 
M=4, F=2 
2-5yrs Propranolol <1mg/kg in 2 
divided doses given to the 3 
pts with aortic dilatation 
No stats but in the 3 pts on 
propranolol who already had at 
least moderate aortic root 
dilatation there was no 
progression by echo.  There 
was progression in the control 
group.  No deaths/surgery 
occurred.  No side effects 
noted. 
J Shores  
1994
74 
Prospective 
Randomised   
Pts and investigators 
unblinded.  Echo 
done blinded. 
MF (Berlin); 
12-50yrs; 
On no current 
treatment; mild-
moderate aortic 
root dilatation 
Mean  
15.4 yrs 
propranolol 
14.5 yrs control 
N=70 
M=39, F=31 
32 Propranolol 
38 Controls 
9.3 yrs in controls, 
10.7 yrs in 
treatment group 
Propranolol titrated to keep 
HR<100bpm during exercise. 
Mean 212±68mg/day 
Slower rate of aortic root 
dilatation in treatment group 
but heterogeneous response. 
Fewer clinical end points 
(AR,aortic dissection,c-v 
surgery, CCF, death) in 
treatment group (5 vs 9).  
Includes 2 deaths (no 
treatment group) but no aortic 
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dissection on autopsy. 
22 adverse effects in 30 pts – 
1 dose reduction 
MA Salim  
1994
75 
Prospective  
Non-randomised 
Non-blinded 
MF (Berlin); 
<21 yrs old 
10.4± 3.4yrs 
14.1± 3.4yrs 
treatment 
10.2± 4.6yrs 
controls 
N=113 
M=76, F=37 
100 on treatment 
13 control 
2.1-8.2yrs 
 
Propranolol or atenolol vs no 
treatment.  Titrated according 
to protocols 
The greatest rate of aortic root 
dilatation was in the no 
treatment group.  5 treated pts 
had asc aortic grafts despite 
larger doses of treatment 
DI Silverman 
1993
76
 
Retrospective 
Non-randomised 
Non-blinded 
No control group 
MF (Berlin) Mean 37±17yrs N=417 
M=213, F=204 
191 (46%) 
received beta-
blocker 
5.5±2.1yrs Propranolol, atenolol, 
metoprolol, nadolol or more 
than 1 over time 
Retrospective analysis of MF 
pts from clinic databases. 
191/417 were given a beta-
blocker.  There were 8 deaths 
(4.1%) and 58 
operations(30.4%) in that 
group.  Median cumulative 
survival was slightly higher 
(72vs70yrs) and mean age at 
c-v surgery was higher 
(33vs29yrs) in those who had 
taken beta blockers. No data 
on side effects 
ME Legget 
1996
77
 
Retrospective 
Non-randomised 
Non-blinded 
No control group 
MF Mean 21yrs 
Range 1-54yrs 
N=83 
30 (36%) received 
beta blockers ≥1yr 
<1-16yrs  
Mean 4yrs 
Unknown Aortic ratios and the change in 
ratio between initial and final 
echos did not differ between 
groups. Number of deaths, 
aortic root replacement for 
dissection or surgery for 
ascending aortic aneurysm did 
not differ between the groups. 
A Haouzi  
1997
78 
Acute trial 
Prospective 
Non-randomised 
Non- blinded 
 
MF(Berlin) 32± 10yrs MF  
35± 5yrs controls 
 
13 MF pts  
10 normal controls  
60 mins Pts scanned before and 60 
mins after metoprolol 1mg/kg 
stat 
100% of controls had lower 
stiffness indices after 
metoprolol cf only 62% MF pts. 
Non-responders had more 
dilated ascending aortas. 
M Groenink  
1998
79 
Prospective 
Non-randomised 
Non-blinded 
MF (Berlin) 21-41yrs N=12 
M=4, F=8 
6 MF pts (Berlin)  
6 normal controls 
2 weeks- 
6.7 months 
200mg metoprolol once daily 
or 100mg atenolol once daily 
for at least 2 weeks 
↑aortic distensibilty in asc aorta 
and ↓pulse wave velocity in MF 
group after treatment 
diagnosed by MRI 
R Rossi-Foulkes 
1999
80 
Prospective 
Non-randomised 
Non-blinded 
MF (Ghent); 
paediatric pts; 
F<17yrs old 
M<19yrs old 
Range 0.5-17.8 
yrs old  
Mean 9.4± 
5.3yrs 
N=44 
M=28, F=25 
26 MF pts  
20 on BB  
6 on CCB, 5/6 on 
verapamil 
18 MF pts on no 
Mean 44± 24 
months.   
Calcium channel blocker 
(verapamil in 5/6) and beta 
blocker.  Titrated to max 
tolerated ↓in HR and bp 
Slower aortic root growth in 
medicated pts.  20% in 
treatment group developed 
major c-v complications (AR; 
severe MR and aortic 
dilatation; progressive aortic 
dilatation; aortic dissection; 
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treatment.   descending aortic aneurysm).  
Too few on CCB to see any 
difference between BB and 
CCB 
AS Rios  
1999
81 
Prospective 
Non-randomised 
Non-blinded 
MF pts; 
No 
Symptoms; 
18-45 yrs 
31±14.2yrs N=23 
M=11, F=12 
4±2.2 yrs Atenolol max dose to achieve 
HR 50-60bpm, SBP >89mmHg 
or side effects 
Mean dose 43.5± 21.6mg/day 
Heterogeneous response to 
atenolol.  Stiffness index and 
distensibility didn’t change in 
35%.  Responders more likely 
if aortic root diameter<40mm 
GJ Nollen 
2004
82
 
Prospective 
Non-randomised 
Non-blinded 
MF (Ghent) 
22/32 MF patients 
had aortic root 
replacement 
MF- 33yrs 
sd 11yrs 
Normals mean 
29yrs sd 5yrs 
25 MF pts on BB 
7 MF pts no BB 
(M=25;F=7) 
10 normal controls 
(M=7;F=3) 
Acute study Unknown BB No significant difference in 
transition point-ie. the pressure 
at which the pressure-area 
relation deviates from its 
elastic (linear) to the collagen 
(exponential) course. This was 
measured at the descending 
aorta at the level of the 
pulmonary bifurcation by MRI 
and Finometer non-invasive bp 
monitor.  There was also no 
difference in diameter of 
descending aorta, distensibilty 
or mean bp between MF 
groups 
AT Yetman  
2005
83 
Prospective 
Non-randomised 
Blinded 
echocardiographer 
MF (Ghent) Mean age 12.0 
±7.6yrs  
ß-blocker 
14.6 
±7.7yrs enalapril   
N=58 
M=28, F=30 
32 MF pts on 
ACEi,  
24 MF pts on 
atenolol  
2 MF pts on 
propranolol 
3±0.2 years Median doses: Atenolol 25mg 
twice daily, propranolol 1mg/kg 
thrice daily, enalapril 5mg 
twice daily. 
Enalapril improved aortic 
distensibility, reduced aortic 
stiffness, and was associated 
with a smaller ↑in aortic root 
diameter and fewer clinical end 
points cf BB. 
There were 7 root 
replacements in BB group and 
2 in ACEi group.  There was 1 
death -due to ventricular 
arrhythmia in the BB group. 
8 pts were on enalapril due to 
ses from  ß-blocker 
M Ladouceur 
2007
84
 
Retrospective 
Non-randomised 
Non-blinded 
MF (Ghent) <12yrs 
Mean age 
6.1±3.2yrs in BB 
group 7.4±5.2yrs 
in control group 
N=155 
M=82, F=73 
77 MF pts on BB 
78 MF pts never 
had BB 
Mean 4.5±3.7yrs Atenolol >70% 
Nadolol 17% 
Propranolol 6% 
BB decreased the rate of aortic 
dilatation at the Sinuses by 
mean of 1.6mm/yr (p<0.05) by 
echo. Trend (ns) toward lower 
cardiac mortality, reduced 
need for preventive aortic 
surgery and less dissection in 
BB group. 
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2/77 stopped taking BB 
although pts on CCBs/ACEis 
already excluded from study. 
ESS Tierney 
2007
85
 
Retrospective 
Non-randomised 
Blinded 
echocardiographer 
MF (Ghent) Mean 9.2±4yrs 
in BB group. 
Mean 8.8±4.8yrs 
in the control 
group 
N=63 
29 on BB 
34 controls 
Mean FU: 76 
months BB;  
81 months control 
Atenolol mean dose 
0.92mg/kg/day 
No significant difference in the 
aortic root 
measurement/death/surgerybe
tween the BB and control 
groups. 
10/29 BB group had ses. 
AA Ahimastos 
2007
86
 
Prospective 
Randomised 
Double-blinded 
Placebo-controlled 
MF (Ghent) Mean 34yrs in 
ACEi group 
Mean 31yrs in 
placebo group 
N=17 
10 on ACEi 
7 on placebo 
24 week FU Perindopril 8mg/day Patients given ACEi or placebo 
in addition to normal BB.  ACEi 
group had reduced aortic 
stiffness, aortic root diameter, 
TGF-β, MMP-2 and MMP-3 
levels.  No ses/major 
events/deaths in either group 
BS Brooke
87
 
2008 
Retrospective 
Non-randomised 
Observational 
Blinded 
echocardiographer 
 
MF (Ghent) ARB median age 
6.6yrs; range 1-
16yrs. 
BB median age 
12yrs; range 
4months-19yrs. 
N=18 on ARB 
N=65 on BB 
Median FU 26.1 
months 
Losartan in 17pts 
Irbesartan in 1pt. 
The mean rate of change in 
aortic diameter decreased 
significantly from 3.54mm 
during previous medical 
therapy to 0.46mm/yr during 
ARB therapy.  No ses noted in 
ARB group. 
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Beta-Blockers 
1950-1980 
In the 1950s, it was discovered that giving reserpine to a strain of turkeys susceptible 
to aortic rupture prevented the birds’ untimely death88.  In 1965, Wheat89 reported 
increased survival of patients with dissecting aneurysm when treated with 
antihypertensive drugs.  These studies led to the use of Propranolol and Reserpine in 
Marfan patients seen at The Johns Hopkins University, Baltimore.  It was from this 
institution in 1971, that Halpern69 described their use of Propranolol to slow aortic root 
dilatation and dissection in six adults with Marfan Syndrome.  It was postulated that the 
negative inotropic and chronotropic effects of the beta blocker could be used to 
decrease the progression of aortic dilatation and therefore prevent acute aortic 
dissection.  Side effects were experienced by one third of this small group of patients 
who were given Propranolol four times daily because of its short half-life.  The authors 
also described the administration of intravenous Propranolol 5mg to two Marfan 
patients to prolong the pre-ejection period defined as the time from the Q wave on the 
ECG to aortic valve opening.  Six years later, however, one of the original authors 
wrote again with Ose70, describing 25 patients with Marfan Syndrome and aortic 
dilatation with or without aortic regurgitation.  All had been given Propranolol (120-
160mg) for one to seven years and 20% died of acute aortic rupture.  In this paper 
published in 1977, it was suggested that Propranolol had no beneficial effect on the 
increasing dilatation of the aorta. 
 
1980-2000 
A reduction in vascular complications in Marfan Syndrome was not confirmed until 
1994 when, in a landmark paper, Shores74 reported a significant reduction in the rate of 
aortic dilatation with Propranolol compared to no treatment.  Seventy adults and 
children with Marfan Syndrome diagnosed by the older Berlin nosology and with mild-
to-moderate aortic dilatation were treated in an open-label study.  Aortic diameters 
were measured by a blinded echocardiographer.  The rate of aortic dilatation was 
significantly lower in the treatment group compared to the control group.  On average, 
the rate of enlargement of the aorta in patients on treatment was less than a third the 
rate of patients on no treatment (p<0.001).  Clinical end-points were reached in 16% of 
patients in the treatment group and 24% of patients in the control group.  Only two 
patients died during the study, both in the control group; post-mortem examination 
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revealed neither aortic dissection nor any obvious cause of death.  22 episodes of side 
effects were seen in the 30 treated patients, one requiring a decrease in dose.  The 
theoretical reason suggested for the beneficial effect of beta blockers on Marfan aortas 
was the decrease in the rate of change in central arterial pressure (dP/dt).  
Subsequently, beta blockers have been shown not to reduce central arterial pressure 
or stiffness90 and other available drugs may decrease central pressure and stiffness 
more91-93.  The conclusions of Shores et al were supported by Salim75 in a retrospective 
study of beta-blocker treatment in 100 Marfan patients compared to no treatment in 13 
Marfan patients.  However, in this study, 5% of the treated group went on to have 
ascending aortic grafts. 
A trial worth reporting because of the patient size and therefore its influence in meta-
analyses is that by Silverman, 199376.  They retrospectively looked at the clinic data of 
417 patients diagnosed with Marfan Syndrome by the older Berlin nosology.  The trial 
looked at survival rates and compared them to a paper by Murdoch et al in 197294.  On 
looking back over the data they found that 191 patients (102 men and 89 women-total 
46% of the patients reviewed) had taken at least one beta blocker (14 took propranolol; 
100 took atenolol; 5 took metorolol; 50 took nadolol; 22 took more than one in 
succession).  The mean duration of treatment was 5.5±2.1yrs.  They remarked that the 
median cumulative probability of survival for the beta blocker patients was 72 yrs 
compared to 70 yrs for the rest (p=0.01) and mean age at surgery was 33±11yrs for the 
beta blocker group compared to 29±10yrs for the others (p=0.24).  Aetiology of the 8 
deaths in the treated group was not reported.  The limitations in such a study are clear.  
It is, therefore, most noted for the skew it would put on a meta-analysis due to the large 
patient numbers.    
Other mechanisms may be in action.  Since conduit arteries including the aorta have 
adrenergic innervation95, it has been suggested that beta blockers may also have direct 
effects on the elastic properties of the aorta.  In 1997 Haouzi78 showed that in 10 
controls, oral Metoprolol decreased aortic stiffness acutely (beta index from 4.8 to 3.6) 
and increased distensibility (3.5 to 4.9 x10-6 cm2.dyne-1).  It was also effective in eight 
of 13 Marfan patients (62%) (beta index 13.4 to 7.5; distensibility 1.3 to 2.5 x10-6 
cm2.dyne-1) but in five subjects (38%) these indices deteriorated.   
Other investigators also observed variable haemodynamic responses to beta 
blockade72,79.  Haouzi78 reported that the Marfan subjects who benefited most from beta 
blockade were those whose aortas were less dilated (346 vs 386 mm).  In 1989 Yin96 
gave intra-venous Propranolol to Marfan subjects during diagnostic cardiac 
catheterisation, and found that it increased the magnitude of aortic wave reflection, 
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reduced arterial compliance and did not decrease the maximum acceleration of blood 
into the ascending aorta.  Other authors have reported that beta-blockade increases 
peripheral vascular resistance, which in turn may increase central aortic pressure and 
wall stress81. 
GJ Nollen82 looked at 32 Marfan patients and 10 normal controls with MRI and a 
Finometer-a finger arterial non-invasive blood pressure monitor that is used to 
reconstruct aortic pressure.  They describe the pressure-area curve derived from MRI 
(in the descending aorta at the site of the pulmonary bifurcation) and Finometer which 
changes from a linear to an exponential relationship.  They suggest that this transition 
point corresponds to a change in load-bearing from the linear –elastin fibres, to the 
exponential-elastin and collagen fibres.  There was no transition point in the 10 normal 
controls but there was in six of the 32 Marfan subjects.  There was no significant 
difference in this relationship between the beta blocker and other Marfan group.  
Unfortunately, 22 of the 32 Marfan subjects had already had aortic root replacement 
and so their central haemodynamics and response to beta blockers will be different 
because of this97. 
 
2000- 2011 
A more recent trial looked at the effect of beta blockers on ascending aortic dilatation in 
children less than 12 years old84.  They looked back retrospectively at their young 
Marfan clinic patients and analysed their echos.  77 children took a beta blocker before 
the age of 12 years- greater than 70% took atenolol; 17% nadolol and 6%propranolol.  
They were compared to a group of 78 who had never taken beta blockers.  5 children 
were excluded as they were taking verapamil (3) or an unnamed ACEi (2).  The 
baseline characteristics were similar apart from the control group had a lower ratio of 
supra-aortic ridge to Sinus of Valsalva diameter.  This is important as we know that 
localised aortic dilatation at the sinuses has a better prognosis and dilates slower than 
generalised dilatation involving loss of the sinotubular junction100.  This wasn’t 
commented on in the paper.  The results showed that the rate of aortic root dilatation 
was 1.05mm/year in the beta blocker group compared to 1.15mm/year in the control 
group after 4.5±3.7 years (p=0.0001).  This means a total difference between groups of 
4.5mm over the study period.  Four children died during the period –one of respiratory 
distress and three sudden deaths due to atrial or ventricular arrhythmias.  Three of the 
four were in the control group.  Five of the control group had aortic surgery compared 
to two in the control group.  Two of the beta blocker group had to stop treatment due to 
side effects which weren’t specified. 
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Typical of the confusion in the data, the latest trial Tierney et al85 tell us that beta 
blockers do not alter aortic root measurements in paediatric Marfan patients.  They 
retrospectively reviewed the echo studies with blinded operators of 29 Marfan patients 
taking beta blockers and 34 untreated.  The average dose of atenolol was 
0.92mg/kg/day and the length of follow-up was 76 and 81 months in the respective 
groups.  After this time, there was no significant difference in the aortic root diameters 
of the two groups.  They had one death in the untreated group, a 10 year old who died 
perioperatively during aortic valve replacement.  Two patients underwent elective aortic 
root replacement in the untreated group and one patient underwent surgery for aortic 
root dissection in the beta blocker group.  Ten of the twenty-nine patients in the beta 
blocker group had side effects (34%) including exercise intolerance, fatigue, 
brochospasm and depression.  Interestingly, seven of the thirty-four untreated group 
(21%) also reported symptoms during the study including fatigue, brochospasm, 
migraines or headache and depression.  Seven treated patients (24%) were non-
compliant at one or more clinic visit showing another difficulty faced in looking after this 
young population. 
 
Meta-Analysis of Beta Blocker Trials 2007 
The only meta-analysis performed, was by DR Gersony et al98, emphasising the 
differences between and paucity of good trials on the efficacy of beta blockers in 
Marfan Syndrome.  They came to the conclusion that there was no evidence that beta 
blockers have clinical benefit in Marfan patients.  They analysed six studies73-77 and 
used the endpoints of aortic dissection or rupture, cardiovascular surgery or death.  As 
described earlier the Silverman study76 had a large impact due to the 417 patients in 
the trial.  This was much larger than the next largest trial –Salim, 199475 whilst the 
smallest trial only had 6 patients -Tahernia,199373.     
 
Variability In Trial Design and Results 
It seems that there are trials confirming reduction in the rate of aortic growth with beta 
blockers although there are others describing varying response to treatment but no 
study showing a reduction in major endpoints such as aortic dissection and death.   
A quick look at the table above reveals the differences between the trials in this area 
with regard to patient selection, age of patient, type of study, randomisation, blinding, 
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length of study, type and dose of beta blocker used, measures used, scanning method 
(MRI or echo) and the complete lack of a prospective, randomised, double-blind trial.     
Concurrent vasodilators might counteract any rise in systemic vascular resistance71,96 
but most patients receive a beta blocker such as atenolol alone, although evidence for 
its efficacy is limited.   
 
Side Effects of Beta Blockers 
Compliance may also be a problem in predominantly young patients who require 
lifelong treatment - beta blockers have a significant side-effect profile. All beta blockers 
are less commonly given to paediatric hypertensive patients because of their adverse 
events99.  This includes bronchospasm, fatigue, depression and behavioural problems 
impacting on school and socially.  Marfan patients with the increasingly common 
asthma will not be given beta blockers and so will need an alternative.  This all has 
serious implications for the young Marfan population. 
 
Despite the varying conclusions of the trial data, the paucity of good trials and the side 
effect profile, beta blockers are still recommended in children with Marfan Syndrome by 
the American Academy of Pediatrics101.  They remain today the first choice in the 
prevention of aortic dilatation, dissection and rupture in the Marfan population.  I 
researched possible alternatives to beta blockers, firstly reviewing other medications 
that have any trial data and secondly, some medications that aren’t used but may have 
potential benefits and would warrant further investigation. 
 
Calcium channel blockers 
Calcium channel blockers are sometimes prescribed for patients with Marfan 
Syndrome when beta blockers are contraindicated, for example in asthma, or if 
intolerable side effects are encountered but their use has been evaluated in only one 
small study.  Rossi-Foulkes80 reported a slower rate of enlargement of the aorta in 26 
patients receiving treatment, compared with placebo (+0.9 vs 1.8 mm/yr, p<0.02), but 
20 patients received -blockers and only six a calcium channel blocker (including 
Verapamil in five).  No comparisons between the drugs were reported because the 
numbers were too small. 
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Since Verapamil is negatively inotropic and chronotropic and also causes generalised 
arterial and arteriolar dilatation, there are theoretical grounds for expecting benefit in 
Marfan syndrome, but they have not been tested adequately.  Verapamil’s slow release 
formulation has a half-life of 5-12 hours and so can be given as a once daily 
preparation to improve compliance.  Calcium antagonists reduce central arterial 
pressure and stiffness90.  A dihydropyridine calcium antagonist such as Nifedipine or 
Amlodipine might have similar effects on conduit arterial function, but might be less 
useful because of the relative lack of effects on cardiac inotropic state.  Amazingly, 
there are no other trials human or otherwise looking at Calcium channel blockers 
despite them often being used if beta blockers are contraindicated. 
 
Angiotensin converting enzyme inhibitors 
Angiotensin converting enzyme (ACE) inhibitors reduce central arterial pressure and 
conduit arterial stiffness90.  Preliminary evidence suggests that they may be useful in 
Marfan syndrome83.  In hypertension studies it has been suggested that Perindopril 
may reduce large arterial stiffness by a mechanism that is independent of its direct 
effect on lowering blood pressure102.  Perindopril is swiftly broken down to its active 
metabolite perindoprilat which has a half-life of 3-10 hours and therefore, can be given 
once daily. 
ACE inhibitors have other effects that might also be clinically useful in patients with 
Marfan syndrome.  Cystic medial degeneration of the aorta is observed in Marfan 
Syndrome as well as in aortic dilatation, aneurysm and dissection related to 
atherosclerosis and ageing103, perhaps caused by accelerated apoptosis of vascular 
smooth muscle cells (VSMC).  Activation of the angiotensin II type 2 receptor (AT11R) 
and reduction in the expression of angiotensin II type 1 receptor (AT1R) plays an 
important role in promoting apoptosis of VSMCs and cystic medial degeneration in 
Marfan Syndrome103.  Therefore, an ACE inhibitor but not an Angiotensin II type 1 
receptor (AT1R) blocker can prevent cystic medial degeneration, apoptosis of VSMCs, 
and aortic dissection in rats fed β-aminopropionitrile monofumarate, which induces 
dissection by inhibiting the cross-linking of collagen fibres104.  However, the authors did 
note that ACEIs not only block the Renin Angiotensin System pathway but also inhibit 
the breakdown of bradykinin and activate nitric oxide synthase which is a possible 
cause of their benefit. 
A recent prospective, blinded, non-randomised trial83 compared Enalapril and either 
Atenolol or Propranolol (Propranolol was given in children <12.5kg) in 57 subjects, 
Page | 26  
 
mean age of 14.6 and 12 years respectively.  They were followed prospectively for a 
mean of three years.  An increased aortic distensibility (3.0 ±0.3 vs 1.9±0.4cm²dynes 
־¹; p<0.02) and a reduced aortic stiffness index (8.0±2.9 vs 18.4±3.8; p<0.05) were 
seen in the Enalapril group compared to the beta-blocker group and this resulted in a 
smaller increase in aortic root diameter (0.1±1.0 vs 5.8±5.2mm; p<0.001).  Nine 
subjects underwent aortic root replacement during the study, two in the Enalapril group 
(6%) and seven while on beta blockers (28%).  A total of twelve patients who had taken 
beta blockers took enalapril due to side effects whilst no-one in the enalapril group 
reported serious side effects.  The authors gave three possible mechanisms for the 
beneficial effect of the ACE inhibitor.  The first is inhibition of VSMC apoptosis as 
described above; the second is bradykinin-mediated improvement in aortic elastic tone; 
and the third is blocking hyperhomocysteinaemia which increases vascular stiffness.  
ACE inhibitors also reduce matrix metalloproteinase activity105. 
A recent randomised, double-blind, placebo-controlled, Australian trial by Ahimastos, 
200786 showed that in patients already taking beta blockers there was reduced aortic 
stiffness, aortic root diameter, TGF-β, MMP-2 and MMP-3 levels when also given 
perindopril compared to placebo.  10 patients (average age 34 years) took 8mg/day 
perindopril compared to 7 patients (average age 31 years p=0.47) taking placebo in 
addition to their normal beta blocker for a total of 24 weeks.  There were no side 
effects, major events or deaths in either group.  The authors suggest that the effects 
seen in the perindopril group likely occurred by reducing signalling through both AT1 
and AT2 receptors and that the reduction in TGF-β, MMP-2 and MMP-3 are probably 
secondary to reduced AT1 receptor signalling.  Reduction in AT2R signalling may 
provide additional benefit through protection from cystic medial degeneration as 
described previously.  This suggests that ACEis should provide the Marfan aortic root 
more protection than AT1R antagonists alone. 
 
Angiotensin II type-1 receptor blockers (AT1R Blockers) 
Angiotensin II stimulates collagen formation, triggers matrix remodelling and vascular 
hypertrophy, depresses nitric oxide-dependent signalling, increases oxidant stress, and 
reduces elastin synthesis106.  It also stimulates cytokines and growth factors that 
contribute to an increased inflammatory response.  These all contribute to arterial 
stiffness. 
AT1R blockers are often used for conditions such as hypertension that require ACE 
inhibitors, when the latter cannot be used because of bradykinin-mediated side effects.  
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It may be helpful to decrease blood pressure in Marfan Syndrome by any mechanism 
but unlike the ACE inhibitors, the AT1R blockers do not inhibit VSMC apoptosis and 
therefore may not reduce cystic medial degeneration, the histological abnormality seen 
in aortic dissection.  However, there is evidence that the AT1R blocker Irbesartan 
decreases MMP activity105. 
 
TGF-β receptor antagonism and AT1R blockers 
The potential role of TGF-β receptor antagonism by AT1R blockers has caused the 
most excitement in this area.  This antagonism has been shown to attenuate 
hypertension and the decline of renal function in uraemic rats107.  Losartan has also 
been shown to reverse interstitial fibrosis and the expression of collagen and TGF-1 in 
a mouse model of hypertrophic cardiomyopathy108.  The mechanism by which AT1R 
blockade antagonises TGF-β signalling is uncertain.  However, activation of AT1 
receptors increases the expression of TGF-β ligands and receptors and induces the 
activation of thrombospondin, a powerful TGF-β activator.   
 
Habashi’s Mouse Model 
A paper published in April 200668 has caused a huge amount of excitement and 
provoked a flurry of new research by researchers looking at the medical treatment of 
Marfan Syndrome.  Habashi demonstrated that TGF-β antagonism by the AT1R 
blocker Losartan prevented aortic aneurysm and also partially reversed impaired 
alveolar septation in a mouse model of Marfan Syndrome.  The authors gave Losartan, 
Propranolol or placebo to pregnant mice which had the commonest mutation causing 
Marfan Syndrome.  The doses were titrated to achieve comparable haemodynamic 
effects.  The pups continued to be treated up to ten months of age.  Fragmentation of 
aortic elastic fibres was seen in both placebo and Propranolol-treated mice but not in 
the Losartan group.  Also, the aortic wall architecture was normal in the Losartan group 
relative to the placebo group and Propranolol had no effect.  Aortic wall thickness and 
aortic diameter were similar in the placebo and Propranolol groups (p=0.19) but 
undistinguishable between the wild-type and Losartan-treated mice (p=0.24).  The 
authors went on to give the same drugs to seven week-old mice to see if Losartan 
could have similar effects after the establishment of aortic aneurysms.  They found that 
Losartan prevented elastic fibre fragmentation and blunted TGF-β signalling in the 
aortic media and that the Losartan mice had the same aortic root growth rate as the 
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wild-type mice (p=0.55).  The Propranolol group had a slower rate of aortic root growth 
than did the placebo mice (p<0.001) but this was still greater than the wild-type and 
Losartan group (p<0.02).  Propranolol had no effect on the aortic wall thickness 
(p=0.17) or elastic fibre architecture (p=0.47) compared to placebo and their effect 
seemed to be limited to slowing aortic root growth.  Thus Losartan but not Propranolol 
achieved full correction of the phenotypic abnormalities in the aortic wall in the mouse 
model of Marfan Syndrome.   
This single experimental study may revolutionise treatment in Marfan Syndrome.  It has 
precipitated the commencement of a large-scale prospective trial comparing beta 
blockers to Losartan in humans with Marfan Syndrome109. 
 
Further AT1R Blocker Studies 
Recently, BS Brooke 200887, looked at 18 Marfan children who had been followed 
during a median 26.1 months (range 12 to 47 months) of therapy with ARBs after other 
medical therapy (beta blocker alone (12pts) or in combination with an ACEi (4pts) or 
CCB (2pts))had failed to prevent progressive aortic root dilatation.  All patients had 
severe aortic root enlargement.  The ARB was losartan (1.4mg/kg/day) in 17 patients 
and irbesartan (2mg/kg/day) in 1 patient.  Treatment with the ARB significantly slowed 
the progress of aortic root diameter from 3.54mm per year during previous medical 
therapy to 0.46mm per year during ARB treatment (p<0.001).  The degree of response, 
however, was variable.  They compared the ARB figures with a group of similar 
patients who had milder aortic root disease and took beta blockers alone.  The mean 
rates of change in aortic root diameter in the beta blocker group (1.71mm/yr) were 
significantly higher than the more severely affected ARB group (p<0.001).  The more 
distal segments of the ascending aorta past the sinotubular junction were unaffected by 
the ARB therapy.  No side effects were encountered.  
Recently, HHC Yang et al110 used a mouse Marfan model to look at losartan versus 
doxycycline versus the combination of both with respect to aortic root diameter.  At 4 
months of age when the mice thoracic aortic aneurysms had established they gave the 
three groups (n=15/group) of mice the above combination of drugs.  At nine months the 
aortic diameter in the untreated Marfan mice was increased by 40% compared to 
control.  Losartan or doxycycline reduced aortic diameter by 10-16% versus untreated 
Marfan aortas.  Losartan and doxycycline combined completely prevented thoracic 
aortic aneurysm and improved elastic fibre organisation.  They also reduced MMP-2 
and 9 and TGF-β.  Aortic contractile and relaxation functions were also normalised.  
Page | 29  
 
This result shows that the combination of the losartan to reduce TGF-β activity with the 
doxycycline to reduce MMP activity works synergistically in reducing the rate of aortic 
root dilatation in the mouse model and would therefore be interesting to trial in human 
Marfan syndrome. 
There seems, therefore, to be two theories with contradictory beliefs of the 
effectiveness of general ACE inhibition compared to selective angiotensin 1 receptor 
antagonism.  Reducing AT2R decreases VSMC apoptosis and therefore cystic medial 
degeneration but this receptor induces anti-inflammatory and antiproliferative effects 
beneficial in aortic-wall homeostasis; whereas reducing AT1R reduces TGF-β activity. 
 
Experimental studies of alternative drugs 
Aldosterone receptor antagonists 
Aldosterone-responsive mineralocorticoid receptors are also present in the heart and 
large arteries and aldosterone is produced in the vascular wall.  Aldosterone 
upregulates and increases the sensitivity of angiotensin type 1 receptors, and therefore 
mediates and exacerbates angiotensin II-induced cardiovascular damage.  Thus, 
aldosterone receptor antagonists may be a useful adjunct to therapy, although whether 
their effects would be greater or even equal to those of ACE inhibitors or AT1R 
blockers is unknown. 
 
Nitrates 
Organic nitrates are another important class of drug which are only now being 
evaluated in Marfan Syndrome111.  These drugs are metabolised with the release of 
nitric oxide which activates guanylate cyclase and increases the formation of cGMP.  
cGMP activates protein kinase G and leads to a cascade of effects in smooth muscle.  
These effects culminate in dephosphorylation of myosin light chains and sequestration 
of intracellular calcium ions, causing muscle relaxation.  Organic nitrates lead to 
venodilation and also have marked effects on large muscular arteries.  This reduces 
pulse wave reflection from arterial branches and therefore, reduces central aortic 
pressure.  With larger doses, resistance arteries and arterioles dilate and arterial 
pressure falls.   
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Nitric oxide also has other effects.  It inhibits vascular smooth muscle cell proliferation, 
inhibits platelet adhesion and aggregation and inhibits monocyte adhesion and 
migration.  Consequently, it may slow aortic dilatation and dissection.  There are 
currently two trials in progress looking at the difference in arterial stiffness of Marfan 
subjects when given a nitrate or an AT1R blocker or placebo111. 
 
Matrix metalloproteinase (MMP) activity 
MMPs are large endopeptidases that degrade matrix proteins such as collagen and 
elastin.  MMPs and their endogenous tissue inhibitors (TIMPs) are regulated by three 
different mechanisms112.  Firstly, gene expression is tightly controlled at the 
transcriptional level (for MMPs and TIMPs).  Secondly, plasmin and urokinase 
plasminogen activator (uPA) control the activation and degradation of the MMPs from 
inactive proenzymes.  Thirdly, the endogenous TIMPs actively inhibit the proteolytic 
activity of MMPs. 
In Marfan Syndrome, the concentration of MMPs and TIMPs may be implicated in the 
cardiovascular and valvular lesions.  Immunohistological analysis of the aortic roots in 
seven patients with Marfan Syndrome revealed extensive cystic medial necrosis, loss 
of elastic fibres, collagen and smooth muscle cells and this was seen primarily in 
central regions113.  Normal aortic tissue expresses modest amounts of MMP-1,-2 and –
9 in endothelial cells and macrophages, weak quantities of MMPs in smooth muscle 
cells and virtually none in elastic fibres.  Expression of TIMP-1 and –2 is weak in 
corresponding cell types in the normal aorta.  Increased expression of MMP-2 and –9 
which degrade basement membrane collagen and partly digest elastin was also 
demonstrated in abdominal aortic aneurysms of Marfan Syndrome patients compared 
with controls114.  Affected aortic valves exhibit moderate immunoreactivity of MMPs and 
weakly reactive TIMPs in regions containing fibroblasts and myofibrils.  Increased 
expression of MMP-1, -2, -3 and –9, without corresponding elevation in TIMPs –1 and 
–2, provides topographic evidence that abnormal remodelling might play a role in 
connective tissue diseases such as Marfan Syndrome.  If an MMP/TIMP imbalance 
plays an aetiological role in tissue destruction, then future interventions may include 
those targeted at the extracellular matrix in Marfan syndrome. 
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MMP Inhibitors - Doxycycline and Tetracycline 
Pharmacological agents such as Tetracycline and Doxycycline are nonselective 
inhibitors of MMP activity in vitro, which have been shown to suppress experimental 
abdominal aortic aneurysms in rodents.  In small, uncontrolled clinical trials, pre-
treatment with Doxycycline, twice daily doses for seven days, reduced MMP-2 and –9 
expression in aortic tissues of patients with abdominal aortic aneurysms compared with 
untreated controls114,115. 
Doxycycline has been shown to delay aneurysm rupture (132 vs 79 days, p<0.01)in a 
mouse model of Marfan Syndrome, reduce aortic wall elastic fibre degradation and 
lower MMP-2 and -9 levels compared to untreated Marfan mice116.  Doxycycline and 
derivatives seem to antagonise the activation of MMP-9 expression in tissue 
monocytes/macrophages and to retard proMMP-2 processing115. 
It has also been recently shown that long-term doxycycline is more effective than 
atenolol in preventing thoracic aortic aneurysm in a mouse model of Marfan 
Syndrome117.  This group gave a group of Marfan mice atenolol, doxycycline or left 
them untreated.  At six and nine months the aortic root measurements of the atenolol 
group were significantly better than the untreated group but the doxycycline group were 
significantly better than the atenolol group and were no different from the normal 
controls.  Doxycycline also improved elastic fibre integrity, normalised aortic stiffness, 
suppressed the upregulation of TGF-β and reduced MMP-2 and -9.  Intraperitoneal 
injection of neutralising antibodies against MMP-2 and -9 yielded similar results to that 
of doxycycline.   
The same group studied the additional benefit of doxycycline to losartan in preventing 
thoracic aortic aneurysm in the same mouse model as described earlier110.  However, 
direct evidence of efficiency in man is still awaited.  Enalapril and Irbesartan have both 
been found to decrease MMP-9 protein and MMP-9 activity in patients with coronary 
artery disease and arterial hypertension six to eight weeks after coronary 
angioplasty105. 
 
Advanced Glycation End Product Crosslink Inhibitors/Breakers/AGE receptor 
Blockers 
Long-lived structural proteins such as collagen and elastin undergo continual non-
enzymatic cross-linking with reducing sugars during life.   This initial reaction is fast, 
reversible and dependent on the concentration of available sugars.  Lowering the sugar 
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concentration reverses the reaction.  Further rearrangement forms a more stable 
glycated protein.  These proteins accumulate over time and can form cross-linked 
proteins called advanced glycation end-products or AGEs.    
It is these heterogeneous AGE complexes that can irreversibly cross-link collagen and 
elastin increasing cardiovascular risk.  This process occurs with ageing but is 
accelerated in diabetes, end-stage renal failure and hypertension.  AGE cross-links 
have been implicated in age-related structural and physiological changes in the 
cardiovascular system, such as increased vascular and myocardial stiffness, 
endothelial dysfunction, altered vascular injury responses and atherosclerotic plaque 
formation118. 
Many of these changes were thought to be irreversible, but studies of novel therapeutic 
agents that inhibit AGE cross-link formation (Aminoguanidine, Pyridoxamine, OPB-
9195), break existing cross-links (DPTC, ALT-711, LR-90), or block receptors for AGEs 
(RAGE), support reversibility and therefore suggest potential clinical benefit. 
For example, a study in aged, healthy monkeys119 found a significant decrease in pulse 
wave velocity, augmentation index, and a sustained decrease in aortic stiffness 
compared to pre-treatment values.   
In 2001, Kass120 carried out a phase two clinical trial in the US on 93 patients aged 
over 50 years with stiffened vasculature.  The patients who received ALT-711 had a 
statistically lower arterial pulse pressure and an increase in large artery compliance 
compared to placebo.  The drug was well tolerated and the numbers of patients 
reporting side-effects was the same as placebo. 
Although never tested in Marfan subjects, this new class of drugs may be of benefit in 
preventing or reversing aortic stiffness in Marfan Syndrome. 
 
Drugs to decrease homocysteinaemia 
In Marfan Syndrome, homocysteinaemia has been suggested to be a risk factor for 
aortic dissection.  In 2003, Giusti121 divided 107 Marfan patients into three groups 
based on the severity of their cardiovascular manifestations.  Total homocysteine levels 
were significantly higher in the group with most manifestations and the highest in those 
with aortic dissection.  It has been postulated that hyperhomocysteinaemia induces a 
marked remodelling of the extracellular matrix of the arterial wall by induction of 
elastolysis through the activation of metalloproteinases.  Moreover, homocysteine 
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cumulatively damages long-lived proteins and fibrillin is especially susceptible to 
irreversible homocysteinylation which impedes the formation of microfibrils.  More 
research is needed to elucidate whether increased homocysteine levels are a cause or 
a consequence of cardiovascular manifestations in Marfan Syndrome. 
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Conclusions 
The unravelling of the complex interactions between elastin, fibrillin, aldosterone, TGF-
β and the MMPs has only just started and has been benefited greatly by recent mouse 
models of Marfan Syndrome.  The therapeutic benefits of drugs that interact with these 
factors (fig 1) has also just begun and needs to be investigated in the human 
population.  In 2011, the medical treatment of Marfan patients with increased aortic 
diameters is given based on one non-randomised, unblinded trial published 12 years 
ago74.  There are now at least thirteen studies being planned to look at the medical 
treatment with drugs such as irbesartan, losartan, nebivolol and nitrates being 
investigated122. 
When we started planning this MD in 2004, we wanted to investigate what parameters 
of vascular and ventricular function should be used to monitor patients with Marfan 
Syndrome and using what diagnostic tools.  This will be discussed further in Chapter 2.  
We also wanted to investigate different drugs on these parameters to see if it would be 
appropriate to recommend the initiation of large, randomised controlled trials using 
alternative drug therapies.  This will be discussed in Chapter 3.4.   
When we started the trial, the stand-out drugs to investigate were the current normal 
practice beta-blocker atenolol; the calcium channel blocker verapamil; and the ACEi 
perindopril.  The more recent studies of Losartan as a TGF-β antagonist and 
doxycycline as an MMP antagonist and the potential benefits of nitrates were published 
after our trial was commenced but have become the focus of ongoing research 
worldwide.   
This is a syndrome that has benefitted from recent progress in mouse modelling and 
the discovery of potential drug benefits but due to the lack of research previously, my 
MD hypotheses remained unanswered. 
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CHAPTER 1.3 
TOOLS AND PARAMETERS: TISSUE DOPPLER IMAGING 
Current Transthoracic Echocardiography (TTE) Assessment of Marfan Syndrome 
Transthoracic echocardiography is an easily-available, non-invasive test that has few 
contraindications and is well-tolerated by patients.  It is able to look at the left ventricle, 
heart valves and aortic root in detail and is therefore the predominant investigation 
currently used to assess for the cardiac and aortic manifestations of Marfan Syndrome.  
It is also an expanding speciality with the introduction of new software packages into 
newer machines.  In this chapter I will look firstly at the current echocardiographic 
parameters measured in the evaluation of Marfan Syndrome; then review the most 
relevant newer parameters; and throughout I will describe the general 
echocardiographic methodology used in our trials. 
Current Assessment 
As described in Chapter 1.1, the current method of investigating the myocardial and 
arterial abnormalities in Marfan Syndrome is by sequential scanning by transthoracic 
echocardiography (TTE).  A routine first scan would be done and in addition to the 
minimum dataset (British Society of Echocardiography Education Committee123) it 
would be used to look specifically for abnormalities more commonly seen in Marfan 
Syndrome. 
Left ventricular systolic and diastolic function can be affected and therefore should be 
assessed.  The mitral annulus can become calcified and the mitral valve should be 
assessed for prolapse and regurgitation.  The pulmonary artery diameter should be 
measured to assess for dilatation.  The tricuspid valve should be assessed for 
prolapse.  There is an increased incidence of atrial septal defects (4%) and so this 
should be looked for also.   
Aortic root measurements are made according to set guidelines by MJ Roman124 
(figure 1).  Four measurements at the aortic annulus(1), sinus of Valsalva(2), 
sinotubular junction(3) and ascending aorta 2cm above the sinotubular junction(4).  
The measurements are taken during diastole placing the calliper from leading edge to 
leading edge at right angles to valve closure.   
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The measurements gained by echo are then plotted against body surface area and 
inserted onto a nomogram so a comparison can be made over time and compared to 
the general Marfan population. 
The rest of the ascending aorta, arch and descending aorta can also become dilated 
and dissect or rupture and so should be assessed. 
 
Figure 1: Echocardiographic Measurement of the Aortic Root124 
LV
LA
1
2
3
4
 
TTEs are performed annually but timing varies according to the subject’s risk factors for 
dissection: 
 Aortic diameter > 5.5cm125,126 
 Aortic dilatation extending beyond Sinus of Valsalva127 
 Rapid rate of aortic dilatation (> 5% /year or 2mm / yr)125,126 
 Family history of dissection125,126 
 Cigarette Smoking 125,126 
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Pregnant women are at a five times higher risk of dissection (1% increased mortality 
and rises with increased aortic diameter128) due to hormonal changes on the arterial 
wall and an increased circulating volume.  Therefore, women are scanned monthly 
during pregnancy.   
In addition to TTE, 5 yearly MRI or CT scans are performed.  Cross-sectional imaging 
has the advantages of looking for dural ectasia which is present in over 90% of Marfan 
adults129 and is more accurate if the patient has poor echocardiography windows due to 
their musculoskeletal abnormalities.  However, their limited availability means TTE is 
the workhorse of surveillance.  Surgery is considered if the aortic root diameter reaches 
5cm but earlier if rapid dilatation or if there is a strong family history of dissection.  An 
aortic root diameter of 4cm is used for pregnant women or for women considering 
pregnancy prophylactically130,131. 
Problems with TTE Parameters Currently Used 
There is inevitably variation in aortic diameter measurements between TTE operators 
and between departments.  Also, an arbitary number of 5cm will inevitably be too late 
for some Marfan subjects and too early for others.  This risks some subjects still 
dissecting (the mortality rate is 5 times higher for emergency compared to elective 
surgery132) while others will go through the trauma of open thoracotomy before the 
need to.   
Aortic measurements can be difficult to measure even using the Roman four 
measurements for standardisation.  The measurements can also be difficult to assess.  
The nomograms have been criticised as they do not reflect the normal aortic root 
dimensions in tall, slim people in whom Marfan Syndrome has been excluded133.  Not 
all Marfan patients are morphologically typical.  Assessment becomes even more 
difficult in a younger population differentiating between normal somatic growth.  This 
leads to the question whether there are other parameters that we could measure to 
predict dissection.   
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Novel Assessments in Transthoracic Echocardiography 
Tissue Doppler Imaging (TDI)    
This is a modified colour Doppler technique that is used to measure myocardial wall 
movement.  Doppler echocardiography relies on detection of the shift in frequency of 
ultrasound signals reflected from moving objects.  Conventional Doppler techniques 
assess the velocity of blood flow by measuring high velocity, low amplitude signals 
from small, fast moving blood cells.  Tissue Doppler imaging quantifies the low velocity, 
high amplitude signals seen with myocardial tissue motion.  Pulsed TDI can be used to 
measure long-axis ventricular motion in all six left ventricular walls as the endocardial 
fibres are most parallel to the ultrasound beam in apical views.  The apex of the heart 
remains relatively stationary throughout the cardiac cycle so that mitral annular motion 
is a good measure of overall longitudinal left ventricular contraction and relaxation134.  
These longitudinal myocardial velocities can be measured by placing the sample 
volume in the ventricular myocardium adjacent to the mitral annulus (figure 2).  
Regional myocardial velocities can also be assessed by placing the sample volume in 
the mid-part of each third of each left ventricular wall and again can be applied to all six 
ventricular walls.  A myocardial velocity trace is reproduced to give peak systolic 
velocities for each segment. 
Figure 2: Tissue Doppler Imaging of the Left Ventricle at the Medial and 
Lateral Mitral Annulus 
LV
LA
MV
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The cardiac cycle is seen in figure 3 by using Pulsed TDI at the mitral annulus and can 
be split into five components.  Firstly, the narrow upward and downward waves 
immediately after the QRS complex represent movement during isovolumic 
contraction (IVC).  Secondly, the large upward wave is the peak systolic velocity, Sm, 
as the annulus moves towards the apex.  Thirdly, there is a narrow downward then 
upward wave representing movement during isovolumic relaxation (IVR) (not seen in 
a normal right ventricle).  The fourth element is Em (m for myocardium, also known as 
Ea for annulus or EI) which represents the early diastolic myocardial relaxation as the 
left ventricle moves away from the apex.  Lastly, Am (m for myocardium, also known 
as Aa for annulus) is the myocardial velocity associated with atrial contraction.   
Figure 3: Pulsed Tissue Doppler at the Mitral Annulus     
 
 
Pulsed TDI has high temporal resolution (typically 300 samples/sec) but has no spatial 
resolution within the sample volume and therefore, cannot be used in multiple 
myocardial segments simultaneously.  With Colour TDI, a colour-coded representation 
of myocardial velocities is superimposed on gray scale images to indicate the direction 
and mean velocity of myocardial motion.  Colour TDI has increased spatial resolution 
and can evaluate multiple segments in a single view. 
 
 
IVC Sm
IVR
Em
Am
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Current Applications of TDI 
Assessment of Left Ventricular Systolic Function 
Sm, the peak systolic velocity when measured at the lateral mitral annulus is a 
measure of longitudinal systolic function.  It has been correlated with LV ejection 
fraction135 and peak dp/dt136.  Regional reductions in Sm are correlated with regional 
wall motion abnormalities and TDI is often used as part of dobutamine stress 
echocardiography as peak Sm increases with dobutamine and exercise and decreases 
with ischaemia137,138.  The lowest systolic velocities arise from the anterior septum 
(mean 7.5 cm/s) and the highest from the right ventricle (mean 15.2 cm/s).  Diastolic 
velocities and hence E/A ratios follow a similar pattern.  Additionally, the systolic and 
diastolic velocities decrease from the basal segment to the apex of the same 
myocardial wall.  This is a consequence of the anatomical arrangement of the 
myocardial fibres: subendocardial and subepicardial fibres are mostly parallel to the 
long axis of the left ventricle and the midwall fibres are orientated circumferentially and 
hence the degree of longitudinal shortening will decrease towards the apex139. 
TDI has also given rise to new measures of regional and global cardiac function - 
Strain and Strain rate.   
Strain (ε) is a measure of tissue deformation.   
ε = L – Lo 
     Lo 
With L being the length of the object after deformation and Lo its original length. 
As the ventricle contracts, the muscle shortens in longitudinal and circumferential 
dimensions (negative strain) and thickens or lengthens in the radial direction (positive 
strain).  Strain is measured as a percentage (%).  Strain is affected by pre-load and 
increasing pre-load increases strain and increasing after-load decreases strain.  Also, 
the LV cavity size matters and in small left ventricles radial strain is increased and 
longitudinal strain is reduced140.   
Strain rate (SR) is a measure of the velocity of the tissue deformation 
SR = V2-V1 
         d 
where V1 and V2 are velocities of myocardial deformation at two points separated by a 
distance d.  The units of SR are per sec.  Unlike strain, strain rate is thought to be less 
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related to pre- and after-load139.  When measuring strain and strain rate by TDI, the 
data can be displayed by colour, with different colours representing different values, or 
graphically against time/cardiac cycle (Figures 4 and 5). 
 
Figure 4: TVI Strain including Timings with sample volume at the Mid 
Septum of the Left Ventricle 
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Figure 5: TVI Strain Rate including Timings with sample volume at the Mid 
Septum of the Left Ventricle 
Systole
Early 
filling
Late 
filling
IVRT
IVCT
 
 
Correct acquisition firstly involves optimisation of the 2D image to avoid reverberation 
artefact.  Then we narrow the sector width to improve spatial resolution and ensuring 
adequate frame rate (≥100 frames/sec).  The sample volume is placed on an 
appropriate area of myocardium which stays on the myocardium throughout the cardiac 
cycle.  The graphical representation of strain or strain rate can then be shown.   
The next step is to define the timing of the waveform by inserting aortic valve opening, 
aortic valve closing and mitral valve opening.  Once the timings are in place isovolumic 
contraction, systole, isovolumic relaxation and diastole can be seen.  The graph can 
then be analysed.  The normal resting values for longitudinal SR are 1.0-1.4/sec 
with standard deviation of 0.5-0.6/sec.  Normal longitudinal systolic strain varies 
from 15-25% with normal radial strain ranging from 50-70% and standard deviations 
of 5-7%141. 
This technique has been validated firstly with sonomicrometry142 and also with MRI143.  
The sensitivity of SR has made it a useful addition in the evaluation of subclinical heart 
disease and has been used in Amyloidosis144 and Friedrich’s ataxia145 and in 
distinguishing between nonobstructive Hypertrophic cardiomyopathy and hypertensive 
Page | 44  
 
left ventricular hypertrophy146,147 and in the response to treatment in Fabry disease148.  
This sensitivity would be an advantage in detecting early left ventricular diastolic and 
systolic dysfunction in the Marfan population secondary to abnormal elastin in the 
myocardium. 
Assessment of Diastolic Function  
TDI is also currently used as part of the transthoracic echocardiography examination of 
LV diastolic function and left atrial filling pressure (British Society of Echocardiography 
minimum dataset123).  Measurements of pulse-wave mitral inflow E and TDI lateral 
mitral annulus Em are used to estimate left atrial pressure.  If E/Em >10 (measured at 
the lateral mitral annulus) or >15 (medial mitral annulus) then pulmonary capillary 
wedge pressure is >15mmHg with 92% sensitivity and 80%specificity149.  The pattern 
of the Em and Am waves guide assessment of LV diastolic dysfunction (figure 8). 
 
Figure 6: Patterns of Diastolic Dysfunction149  
 
 
  Reproduced from Sohn et al. J Am Coll Cardiol 1997;30:474-480. 
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Isovolumic Acceleration (IVA) 
Many of the TDI indices of myocardial contractility are affected by both preload and 
afterload.  Isovolumic acceleration (IVA), that is, myocardial acceleration during 
isovolumic contraction (figure 7) has been shown to be a sensitive measurement of left 
and right ventricular myocardial contractile function that seems unaffected by preload 
and afterload within a physiological range and in an animal model150,151.  
Figure 7 shows a TDI velocity trace at the medial mitral annulus. The trace shows 
isovolumic contraction (IVC) and the slope of this equates to isovolumic acceleration.  
Then follows peak systole (Sm), isovolumic relaxation (IVR), early diasolic filling (Em) 
and atrial contraction (Am) as previously described.  
 
Figure 7: TDI Isovolumic Acceleration (IVA). 
 
Sm
IVR
Em
Am
Slope=IVA
IVC
 
 
Since I started the MD, Isovolumic acceleration has been further investigated by 
Margulescu and colleagues152.  They found that it was a useful tool to discriminate 
between poor and normal left ventricular function especially when measured from the 
medial mitral annulus.  However, they reported difficulty with low reproducibility 
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especially in the low left ventricular function group with inter- and intraobserver 
variabilities of 28 and 30%.   
 
TDI In The Aortic Wall  
Harada and colleagues153 studied wall motion velocities in the abdominal aorta using 
TDI in 12 Marfan patients and 30 age-matched controls.  In each subject they used a 
transabdominal short axis view and, by M-Mode, measured aortic diastolic (onset of the 
ECG R wave) and systolic (point of maximal anterior motion of the aortic wall) 
diameters.  These diameters were corrected for body surface area.  They calculated 
the change in diameter of the abdominal aorta by (Ds-Dd)/Dd.  They also calculated 
the β stiffness index by ln(Ps/Pd)/(Ds-Dd)/Dd where Ps and Pd are the systolic and 
diastolic blood pressures.  They also measured aortic wall motion velocity by TDI 
pulsed Doppler with a 1mm sample volume placed on the anterior wall of the 
abdominal aorta.  A peak systolic velocity (S) and peak diastolic velocity (D) were 
measured from this.   
They found that the Marfan patients had significantly greater aortic stiffness index, β 
and significantly reduced Peak S and D (p<0.01).  They also had low interobserver 
variability between their two observers’ measurements (r=0.94 and 0.95). 
This study interested me greatly and I wanted to reproduce its findings in our Marfan 
population and also to measure the same parameters but at the aortic arch where there 
is more elastin and where dissection and rupture is more likely to occur.  Difficulty in 
acquiring adequate aortic root views by TTE meant that I could not test this technique 
more proximally. 
  
Conclusions 
Transthoracic echocardiography is the current tool of choice in the assessment of the 
cardiovascular abnormalities in Marfan Syndrome.  It enables analysis and monitoring 
of both the ventricular and aortic parameters that predict aortic dissection and rupture.  
However, I have described some difficulties in this assessment and described some 
novel parameters that could potentially aid the TTE assessment.  These new TTE 
parameters: TDI peak systolic velocity, E/EI, strain, strain rate, isovolumic acceleration 
and aortic wall velocities would be useful theoretical adjuncts in assessing left 
ventricular systolic and diastolic function and aortic properties in Marfan Syndrome.  
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CHAPTER 1.4 
TOOLS AND PARAMETERS:  APPLANATION TONOMETRY  
 
In Marfan Syndrome the aim of preventing aortic dissection and rupture is by reducing 
the pressure in the proximal aorta.  Traditionally, we have measured brachial blood 
pressure with a sphygmomanometer and cuff and assumed this accurately reflects the 
pressure “faced” by the left ventricle at each heart beat.  This has been, in part, due to 
the need for invasive measurement of central aortic pressure and so this has been 
reserved for research alone.  However, measuring central aortic pressure which is 
directly opposed to the left ventricle gives a more accurate reflection of the arterial load 
faced155.  Moreover, the shape and character of the pulse wave and not just the systolic 
and diastolic values adds information to the interaction between heart and arterial 
system155.  However, whereas it is simple to measure blood pressure in a limb with a 
cuff, it has remained, until recently, a challenge to accurately measure ascending aortic 
pressure. 
 
Windkessel Effect 
The Windkessel effect has been described as the distension of the large elastic arteries 
when the blood pressure rises during systole and recoil when the blood pressure falls 
in diastole.  As the rate of blood entering the large elastic arteries is greater than the 
rate leaving due to peripheral vascular resistance there is a net storage of blood during 
systole which discharges during diastole.  This effect helps in the dampening of blood 
pressure (pulse pressure) and aids organ perfusion during diastole when left ventricular 
ejection ceases.  Windkessel is literally German for air chamber but implies an elastic 
reservoir.  The concept has largely been overtaken by modern interpretations of arterial 
pressure and waveforms in terms of wave propagation and reflection which I will 
discuss both in this and the next chapter. 
 
The Effect Of Aortic Stiffness 
In studies of hypertension where, similar to Marfan Syndrome, there is also an increase 
in arterial stiffness, this stiffness accelerates the speed at which the left ventricular 
ejection pressure wave travels through the arterial system.  This pressure wave acts as 
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a periodically oscillating wave travelling from the heart to the peripheral arteries.  It is 
also known that throughout this journey there are changes in the arterial bed- bends, 
curves, arterial branches and differences in arterial properties -which cause wave 
reflection back to the heart.  As the speed of the left ventricular pressure wave 
increases, the earlier the reflected wave returns to the left ventricle.  When the 
reflected wave arrives not during diastole but in systole it augments the late systolic 
pressure (afterload) on the left ventricle.  This increases central pulse pressure, 
increases left ventricular load and also because the wave is arriving less in diastole, 
reduces coronary artery perfusion155 (figure 1).  It is, therefore, vital to be able to create 
and understand the central aortic pressure waveform to get an accurate picture of left 
ventricular-arterial coupling.  This has been an important factor in the latest European 
Society of Hypertension guidelines for the management of hypertension156.  They 
emphasise that systolic blood pressure and pulse pressure vary between the aorta and 
the brachial artery; that drug therapy that is successful at reducing peripheral blood 
pressure may not have the same beneficial effect centrally156; and that central blood 
pressure relates to cardiovascular events157. 
 
Figure 1: The Differences In Left Ventricular-Arterial Coupling Between 
Hypertensive and Normal Populations. 
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In a young normal population the pressure waveform at the ascending aorta is smaller 
in amplitude than at the periphery (figure 2).  This is due to wave reflections 
encountered from all the branches on travelling through the arterial system.  This is 
called Pulse Pressure Amplification: 
Pulse Pressure Amplification=  Peripheral Pulse Pressure 
     Central Pulse Pressure 
In an elderly or a hypertensive population the difference in amplitude is less.  This is 
because wave reflections from the arterial tree return before aortic valve closure, 
augmenting the aortic pressure wave.  The normal pulse pressure amplification if age 
<20 years old is 1.7; for those age >80 years old is 1.2 and there is a gender difference 
with amplification higher in men.  Amplification is also increased in tall people and if the 
heart rate increases.  It is decreased with age, increasing aortic stiffness, increased 
peripheral reflections, shorter people (due to increased reflections), hypertensives, 
diabetics, hypercholesterolaemia, smokers and people with cardiovascular disease.   
 
Figure 2:  The Pulse Pressure Waveform158 
 
Reproduced from McDonald’s Blood Flow in Arteries, 1998, 4th Edition. Arnold. London. 
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Figure 3: Pulse pressure wave at the radial artery and the aorta  
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The amplitude of the pressure wave (figure 3) is the Pulse Pressure (PP).  The 
augmented part of the pressure waveform is named the Augmentation pressure (AP).  
It begins at the site of the first inflection point (IP) which signifies the arrival of the 
reflected wave.  Augmentation index is calculated as: 
Aix = Augmentation pressure (AP) 
Pulse Pressure (PP) 
Tr is the time (seconds) from the start of the forward pulse pressure wave to the arrival 
of the backward reflected wave from the periphery.  
 
Detection of Peripheral Blood Pressure Waveforms 
In the past invasive measurements had to be made for detecting pulse pressure 
amplification, central aortic pressures and the pressure waveform by recording both 
peripheral and central blood pressures.  However, this has obvious limitations.  The 
peripheral pulse can now be detected by extremely sensitive pressure sensors that can 
be used at the tip of hand-held pencil probes.  These sensors accurately measure 
intravascular pressure when the probe is pressed on the skin over an artery and the 
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artery is slightly compressed against a firm structure such as bone.  This principle is 
known as Applanation Tonometry159,160  
 
Generalised Transfer Function (GTF) 
The aortic waveform can then be reconstructed from the non-invasive radial waveform 
acquired by applanation tonometry by means of a “generalised transfer function.” 
The characteristics of the transfer function are determined by arterial diameter, arterial 
wall elasticity, arterial wall thickness, number of arterial side branches and the 
condition of the vascular beds.  Despite brachial vasculature being different between 
individuals it was found that the main components of the transfer function did not vary 
significantly in normal adults with age or in normal conditions or in conditions of 
vasodilatation following nitrate administration. 
The use of the generalised transfer function was validated by a study by Chen159 who 
used an invasive measurement of the aortic pressure and radial pressure in 20 patients 
at steady state and during haemodynamic changes incurred by the Valsalva; 
abdominal compression; nitrate administration and vena cava obstruction.  The 
average of the individual transfer functions was used to determine the generalised 
transfer function.  However, the generalised transfer function itself has never been 
released into the public for close scrutiny. 
 
Reproducibility 
The main element affecting reproducibility is the ability to obtain an accurate radial 
pulse waveform as all parameters are derived from this.  This is determined by the 
stability of the subject’s physiological status and operator skill. 
Siebenhofer et al160 studied 33 healthy subjects of mean age 33 years and showed: 
SphygmoCor Parameter    Inter-operator variability 
Derived Systolic pressure     0.1±1.7mmHg 
Derived Diastolic pressure     0.1±0.7mmHg 
Augmentation Index      0.4±6.4%  
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Limitations 
The major limitation is if the radial pulse is altered by obstruction of any part of the 
brachial system.  If this is the case then the radial pulse cannot be used to derive the 
aortic pressure waveform.  However, this is uncommon and further studies have shown 
good correlations between the derived and measured central aortic systolic pressure 
and Augmentation index158,161,162. 
Recent large trials have shown the independent role of central blood pressure as a 
predictor of cardiovascular events163,164.  The CAFE trial157 was a large, prospective, 
randomised, open, blinded end-point study recruiting over 2000 hypertensive patients.  
It showed that the traditional antihypertensive therapy of atenolol ± thaizide-based 
regimes lower central blood pressure significantly less than the newer contemporary 
amlodipine ± perindopril-based regimes despite similar effects on brachial blood 
pressure.  It also showed that central pulse pressure, augmentation and height of the 
aortic pulse wave up to the first inflection point were significantly associated with a 
composite end-point of cardiovascular and renal outcomes.   
ASCOT164, of which CAFE was a substudy, showed significant reductions in total 
coronary events, cardiovascular death and stroke with its amlodipine ± perindopril-
based regime compared to the atenolol ± thiazide-based group.  These results were in 
a hypertension population but are of course important in the context of our Marfan 
patients who have been predominantly taking beta blockers to reduce their central 
aortic pressures but are being checked in clinic by brachial blood pressure 
measurements.  
 
Pulse Wave Velocity 
The velocity that the pulse wave travels can also be measured between two anatomical 
sites and has become a widely validated and accepted measure of arterial stiffness165-
169.  The underlying principle is that with age and with hypertension the aorta becomes 
stiffer and the pulse wave therefore travels faster.  Therefore, in our Marfan population 
we would expect an increased pulse wave velocity also.  It is measured using a 
Doppler probe to detect the onset of flow in an artery.  Doppler pulses are then 
recorded sequentially at two different arterial sites and compared using the R-wave of 
the ECG (fig 4).   
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Figure 4: Carotid-Femoral Pulse Wave Velocity 
 
 
Pulse Wave Velocity = Length between Measurement Sites (mm) 
     Time Delay between onset of R waves (ms) 
Commonly used sites are carotid-femoral and carotid-radial.  In our Marfan population I 
will measure both but as the carotid-femoral path contains more aorta, this would be 
theoretically better.  A 4MHz Doppler probe is used to solve the potential problem of 
obese or muscular necks.  Carotid-femoral pulse wave velocity is the current “gold 
standard” measurement of large artery stiffness169.  It is a simple, non-invasive 
measurement which determines the speed of the pulse wave travelling along the aortic 
and aorto-iliac arterial pathway. 
It has also been published that in a group of 241 patients with end-stage renal failure, 
increased aortic stiffness as measured by aortic pulse wave velocity, is a strong 
independent predictor of all-cause and cardiovascular mortality170.   
 
Applanation Tonometry, Pulse Wave Velocity and Marfan Syndrome 
There have been a few studies looking at these parameters in patients with Marfan 
Syndrome.  Yin, 1989171 showed an increased magnitude of wave reflection (calculated 
by the ratio of backward to forward components of the aortic pressure wave) measured 
invasively by micromanometer at the time of cardiac catheterisation in nine patients as 
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workup to aortic root replacement.  The wave reflection was normalised by 
vasodilatation with intravenous nitroprusside and further increased by intravenous 
propranolol.   
Mortensen, 2009172 has recently looked at Applanation tonometry in Marfan Syndrome.  
He found an independent association in 50 medically treated adults with Marfan 
Syndrome who hadn’t previously had cardiovascular surgery, between aortic root 
diameter progression and Augmentation index (p=0.02) and lower pulse wave velocity 
(p=0.03).   
Jondeau, 1999173 measured carotid pulse pressure by applanation tonometry as a 
surrogate for central aortic pressure in a group of twenty patients with Marfan 
Syndrome.  Their group found that carotid pulse pressure was a major determinant of 
ascending aorta diameter, whereas brachial pulse pressure was not.  They also found 
that arterial distensibility, as measured non-invasively by ultrasound, was 38% lower in 
the Marfan abdominal aorta compared to the “normal” control group whereas there was 
no significant difference in distensibility between groups at the common femoral artery, 
common carotid artery or the radial artery.   Interestingly, 6 of the 20 Marfan group 
were taking long-term beta blockers which were only stopped the day before the study.   
Kiotsekoglou A, 2009174 however, found that when they measured common carotid 
arteries in 32 Marfan subjects and 29 controls by ultrasound the intima-media thickness 
did not change but compliance and distensibilty were significantly reduced in the 
Marfan group (p<0.05) although 13 of the 32 Marfan subjects were taking atenolol.   
There have been MRI trials which have shown increased aortic pulse wave velocity in 
Marfan patients measured from the ascending to the abdominal aorta175,176 but we don’t 
know whether the subjects were taking medication at the time of the study.  This is 
important information missing as we know that ACEIs reduce aortic stiffness as 
assessed by echocardiography compared to beta blockers in Marfan Syndrome and 
that this is associated with a smaller increase in root diameter and fewer clinical end 
points.177  Also in a small study looking at the addition of perindopril to normal beta 
blocker therapy in 17 Marfan patients, they showed reduced aortic pulse wave 
velocities in the perindopril group.178  
Thus, there have already been a small number of trials looking at the central aortic 
pressure wave by Applanation tonometry and aortic stiffness by pulse wave velocity 
and their applicability in Marfan Syndrome.  These studies have demonstrated that 
these parameters can be measured by the Applanation tonometry tool.  The 2007 
European Society of Cardiology hypertension guidelines also give a warm approval for 
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Applanation tonometry but caveat that “The prognostic role of central as opposed to 
peripheral blood pressure needs to be confirmed in more large-scale observational and 
interventional studies,” I imagine meaning beyond ASCOT and CAFE.  Nevertheless, 
the measurement of central aortic pressures, Augmentation index, Pulse Pressure 
Amplification and Carotid-Femoral Pulse Wave Velocity will become more widely used 
in the hypertension literature and impact on clinical end points that would also be 
beneficial in Marfan Syndrome, a disease so profoundly affected by ascending aortic 
stiffness.     
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CHAPTER 1.5 
TOOLS AND PARAMETERS:  WAVE INTENSITY ANALYSIS 
 
Background 
In transthoracic echocardiography and applanation tonometry we are investigating two 
distinct anatomical areas, either the left ventricle or the aorta.  It is also vital to 
understand and investigate the interaction between the two.   
A tool recently developed to address left ventricular-arterial coupling was 
conceptualised by Kim Parker and Chris Jones in 1990179 by adapting a mathematical 
model used in flow mechanics.  Parker described aortic blood flow as “an infinitesimal 
number of wavefronts that propagate along the aorta causing changes in pressure and 
velocity as they pass.”  These wavefronts either increase the pressure in the aorta 
(compression waves) or decrease it (expansion waves) and either travel forward 
from the heart or backwards from the systemic periphery.  Pressure and flow change 
together in forward wavefronts but in opposite ways in backward, reflected waves.  This 
gives rise to four possibilities: 
Forward compression wave (FCW) – increases pressure, increase velocity 
Forward expansion wave (FEW) – decreases pressure, decreases velocity 
Backward compression wave (BCW) – increases pressure, decreases velocity 
Backward expansion wave (BEW) – decreases pressure, increases velocity. 
Using this concept of infinitesimal discrete wavefronts as the basic elements and by 
using their mathematical model the aortic wave can be further analysed.  The flow in 
elastic arteries propagates downstream and upstream with velocity: 
Flow Velocity = U ± c where U is the velocity of the blood and c is the wave speed.   
c, the wave speed is determined by c=(1/ρ·D) where D is the distensibility of the aorta 
and ρ is the density of the blood. 
In a transient wavefront the change in pressure across the wavefront (dP) is related to 
the change in velocity: 
dP = ± ρ· c· dU 
Page | 57  
 
Where the + sign refers to forward direction and the – sign refers to the backward 
direction.  
The wave intensity = dP .dU,  is the product of instantaneous changes in velocity and 
pressure.  It is positive for forward waves and negative for backward waves (figure 1).  
This approach is now generally known as Wave Intensity Analysis (WIA).180 
 
Figure 1: Aortic Pressure, Velocity and Net Wave Intensity 
 
 
Measuring Pressure and Velocity 
WIA has an advantage in that it can be used in the time domain allowing us 
interpretation of temporal events in the cardiac cycle.  In this way, WIA can be 
calculated from simultaneous measurements of pressure by measuring the diameter of 
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the blood vessel (common carotid artery is used as the most proximal, easily 
accessible artery) and velocity by measuring flow181.   
Diameter has been shown to relate linearly to pressure over the physiological range (r2 
>0.97) and can be calibrated by measuring the brachial blood pressure.  Flow can be 
measured using pulse wave doppler positioned in the lumen of the common carotid 
artery.  
 
Separated Waves 
Initially, it was only possible to calculate the net Wave Intensity (fig 1).  Parker, Fraser, 
Rakebrandt and colleagues worked closely with the Japanese company Aloka (Hitachi-
Aloka, Tokyo, Japan) who adapted their ultrasound machine to enable the acquisition 
of the patient data required.  Additionally, new software182 was developed which 
enabled separation of the net WI into the four individual forward and backward-moving 
waves.  The timing, duration, peak amplitude and net energy of the separated waves 
can now be measured. 
Local wave speed can also be measured from the slope of the pressure-velocity loop in 
early systole when forward wave travel is predominant183.  Augmentation index, 
Peterson’s pressure-strain elastic modulus (epsilon) and the β stiffness index (beta) 
can also be calculated184.   
 
Implications of Measuring Separated Waves 
The amplitude of the forward compression wave is an index for left ventricular 
contractile function (+dp/dt).185  The net negative wave intensity in midsystole arises 
from reflections (backward compression waves) and increases central aortic pressure 
and decreases forward flow.  The expansion wave that starts in late systole before 
aortic valve closure marks the onset of left ventricular relaxation and is equivalent to a 
forwards-travelling suction wave that decelerates flow and reduces pressure, leading to 
aortic valve closure.186   
By measuring the forward compression wave and the backward compression wave it 
would give us an insight into the interaction between left ventricle, aorta and peripheral 
vasculature in our Marfan population that no other tool can do.  Additionally, it allows 
the measurement of Augmentation index and indices of vascular stiffness – local 
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wavespeed, Peterson’s pressure-strain elastic modulus (epsilon) and the β stiffness 
index (beta). 
 
Evidence for WIA 
WIA has been confirmed in experimental and clinical studies187-189 and has been used 
to differentiate between myocardial and vascular effects of antihypertensive 
treatment.190  Swampillai, 2006191, investigated a group of healthy volunteers and found 
caffeine consumption was associated with an increase in the forward compression 
wave and local wave speed without changes in pressure-strain elastic modulus (Ɛ) and 
(β) stiffness index; whereas cigarette smoking resulted in only an acute increase in 
local arterial stiffness indices.  This suggests a prevalent myocardial inotropic effect of 
caffeine as opposed to the mostly vascular action of smoking and WIA was useful in 
distinguishing these factors.   
 
Disadvantages of WIA 
Wave Intensity signals are intrinsically noisy and there is considerable biological 
variability in net wave intensity. 
The common carotid artery is used to measure the flow and diameter, where reflections 
are influenced by cerebral vasomotor tone as well as local arterial properties192.  In our 
Marfan population the common carotid artery has less elastin compared to the Aorta 
and this may influence results.  In the wider population, the clinical utility of WIA has 
not yet been established.193  The use of WIA has never been reported in Marfan 
Syndrome.  
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CHAPTER 1.6 
HYPOTHESES: 
 
 
My thesis has been designed to investigate firstly, the parameters that could most 
usefully be measured in monitoring the myocardial and arterial dysfunction in patients 
with Marfan Syndrome.  Secondly, I wanted to investigate the tools that could be best 
utilised to measure these parameters.  Lastly, I wanted to investigate the effects of 
three different medical treatments on these parameters using the different tools. 
 
 
 
Hypothesis 1: New parameters of myocardial and arterial function would 
be useful adjuncts in monitoring the vascular and 
myocardial manifestations of Marfan Syndrome 
 
 
 
Hypothesis 2: Tissue Doppler Imaging, Applanation Tonometry and 
Wave Intensity Analysis would be useful tools in 
monitoring the vascular and myocardial manifestations of 
Marfan Syndrome 
 
 
 
Hypothesis 3: ACEI and CCB reduce central aortic haemodynamics 
more than Beta Blockers in Marfan Syndrome 
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CHAPTER 2.1 
PATIENTS, TRIAL APPROVAL PAPERWORK AND METHODS 
Marfan Patients 
We approached 55 Marfan patients from the South Wales and South West regions via 
databases from the two main tertiary congenital heart centres:  The Congenital Heart 
Disease Centre, University Hospital of Wales, Cardiff; and the Bristol Congenital Heart 
Centre, Bristol.  Local expertise was gained and aided recruitment – Dr Dirk Wilson in 
Cardiff and Dr Graham Stuart in Bristol.  We also sought help from the local genetics 
department in Cardiff – Dr Sally Davies and all Cardiology Consultants in South Wales 
were written to in order to aid recruitment of Marfan patients who were being followed-
up in their clinics.  The patients were written to and asked to contact me if they were 
interested in participating in our trial.  They then attended the Wales Heart Research 
Institute, Cardiff or the Bristol Congenital Heart Centre, Bristol for confirmation of their 
diagnosis by the Ghent criteria and initial assessment to see if they met the inclusion or 
exclusion criteria.  They were all given verbal and written information about the trial.  
We recruited patients from Cornwall to West Wales. 
Inclusion criteria:  were subjects aged 16-60 years, who were either on no treatment, or 
were taking a β-blocker or other monotherapy only.  Patients with previous aortic 
dissection or aortic surgery, severe heart valve regurgitation or aortic diameter at the 
sinotubular junction ≥ 5.0 cm were excluded.  In addition, for the medical treatment 
study, patients who had contraindications to specific drug treatment (such as asthma), 
and women who were pregnant, at risk of pregnancy or breast-feeding, were excluded. 
22 patients attended the Wales Heart research Institute for assessment.  One subject 
did not have Marfan Syndrome.  2 Marfan patients were breast-feeding or trying to get 
pregnant.  1 patient attended this session but did not attend consequently.  The latter 3 
all had initial studies only.   
In the medical treatment study, 18 patients started the trial and 14 completed it.  1 
subject thought they were having side effects from the medication but when we broke 
their drug code they had in fact been taking the blinded version of their normal 
medication.  1 patient got a University place away from home and could not attend due 
to distance.  1 patient attended for 2 sessions only, because her lesbian partner was 
undergoing a renal transplant.  1 patient got into trouble with the law and could only 
attend 3 sessions. 
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Trial Approval Paperwork 
Full written consent was obtained from all subjects.  We had full MREC (Multiple 
Research Ethics Committee) approval after completing the paperwork and attending an 
interview at the Royal Free Hospital in London.194   
I received honorary contracts from the two hospitals in Cardiff and Bristol.  We 
completed R and D (Research and Development) paperwork and were given local 
permission from both Cardiff and Bristol to perform a trial on their sites.   
Further paperwork was sent to the MHRA ( Medicines and Healthcare products 
Regulatory Agency) and we got their approval to conduct a trial involving medication.  
We purchased the trial medication from a local supplier in Cardiff but the drugs had to 
be firstly manufactured and then packaged in exactly the same capsules for blinding.  
We contacted both pharmacies and Biochemistry laboratories at Cardiff and Bristol to 
enable correct dispensing of the drugs and to check renal function after 
commencement of the ACEI, perindopril.   
I attended a Good Clinical Practice in Research Training day in Cardiff and filled in the 
paperwork to access medical records for research.  A sponsorship form was completed 
and Cardiff University agreed to sponsor our study.   
During this time new Standard Operating Procedures for Research Ethics Committees 
came into place (March 2004)194.   
R+D: 05/CAD/3320 
EudraCT 2005-000749-13 
Cardiff University Sponsorship SPON CU101 
Data protection number RD 05198 
MREC  05/Q0501/41 
Heart Research UK Ref: RG2535/07/09 
 
We eventually, achieved full approval and could commence the trial. 
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Baseline Studies 
At baseline, essential anthropometric data such as height, weight, age, and disease 
severity were recorded.  Beta blockade or other monotherapy was withdrawn over a 
period of two weeks in subjects already on treatment, and then all subjects had a two-
week period off all treatment, during which they received a placebo single-blind.   
Blood pressure was measured from the brachial artery with an appropriately sized cuff 
in the supine position following quiet rest for 10 minutes using a validated semi-
automated oscillometric device (Dinamap, General Electric, Connecticut, US).  
 
Transthoracic Echocardiography Methods 
Transthoracic echocardiography was performed using commercially available 
equipment (Vivid 7, General Electric, Connecticut, US). A minimum dataset was initially 
recorded in each patient, according to the recommendations of the British Society of 
Echocardiography.  At each acquisition, the image was optimised to obtain the highest 
frame rates and best quality tissue doppler data.   
Aortic root diameter was measured according to Roman at end-diastole in the 
parasternal long-axis view, at 4 levels: annulus, sinuses of Valsalva, sino-tubular 
junction, and ascending aorta 2 cm above the sino-tubular junction.   
Left ventricular global, longitudinal and radial function were measured using 
conventional (Simpson’s biplane method and annular plane systolic excursion) and 
tissue Doppler indices at each left ventricular wall in parasternal long axis, parasternal 
short axis, apical 4 chamber, apical 2 chamber and apical long-axis views.  Left-
ventricular stroke volume was calculated by both Doppler and Simpson techniques.  
Left ventricular contractile function was estimated from isovolumic acceleration and 
peak systolic mitral annular velocities as described in Chapter 1.3.  Diastolic filling 
pressure was estimated using the E/e’ ratio.   
The amplitude and timing of expansion in the aortic arch and abdominal aorta were 
measured using pulsed tissue Doppler, as previously published by Harada.  When we 
deviated from the above methods, for example in Chapter 3.1.1, it is fully explained in 
the text. 
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Applanation Tonometry Methods 
In our Applanation Tonometry studies, we initially invited the subjects to rest supine for 
10 mins in a quiet room.  Blood pressure in the brachial artery was measured as 
described above. 
Pressure waveforms in the radial artery were recorded by applanation tonometry with a 
Millar tonometer (SPC-301) and calibrated to the brachial blood pressure.  The 
waveforms were analysed with commercial software (SphygmoCor version 7, AtCor, 
New South Wales, Australia) to obtain an averaged radial arterial waveform, and to 
derive a corresponding central aortic pressure waveform using the generalised transfer 
function.  Augmentation index, defined as the ratio of augmentation pressure to central 
pulse pressure expressed as a percentage, was calculated from three or more 
consecutive radial recordings, and an average of the two readings with the lowest 
standard deviations was used in the analysis.  Pulse pressure amplification was 
measured as brachial pulse pressure/central aortic pulse pressure. 
Carotid-to-radial and carotid-to-femoral pulse wave velocities were obtained, as an 
index of aortic stiffness.  The carotid, radial and femoral arteries were applanated using 
the Millar tonometer, and sequential recordings of pressure waveforms were compared 
using pulse wave analysis.  The surface distances between the sampling points were 
measured and the transit time was calculated using the SphygmoCor software.  Data 
were collected by two trained researchers (myself and fellow researcher Dr Damien 
Kenny, Bristol) and the means of the two measurements with the lowest standard 
deviations were used in the analysis. 
 
Wave Intensity Methods 
Our subjects were studied reclined on a couch following a 10 minute rest in a dark, 
quiet room.  Left brachial blood pressure was measured before each scan as described 
above.  A 3 lead electrocardiogram was monitored throughout. 
The right common carotid artery was exposed and scanned using a 7.5MHz linear 
array probe incorporating a 5MHz Doppler transducer.  This was connected to an Aloka 
SSD-5500 ultrasound machine (Hitachi-Aloka, Tokyo, Japan)195 (figure 1). 
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Figure 1: Ultrasound Measurement of Common Carotid Artery Diameter and Flow 
to Calculate Net Wave Intensity 
Doppler beamEcho-tracking
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As seen in fig 1. A longitudinal view of the right common carotid artery was acquired 
and the probe positioned so the anterior and posterior wall intima were clearly seen.  A 
single scan line was aligned perpendicularly to the vessel walls at a site 2cm proximal 
to the carotid bulb.  The anterior and posterior intima-media borders were tracked using 
high-resolution online wall tracking with a sampling rate of 1kHz196.  Arterial pressure 
waveforms were obtained automatically in real time by calibrating peak and trough 
values with systolic and diastolic blood pressure measured by sphymomanometry.196   
A pulse wave Doppler beam was aligned to the artery walls to measure velocity from a 
colour flow Doppler box covering the lumen.  Velocity was calculated from the mean of 
the colour Doppler data.  Arterial diameter and velocity were recorded continuously for 
20 secs.  After acquisition, 20 beats were selected with noisy waveforms rejected.  
These beats were signal-averaged to give single waveforms of diameter and velocity 
(fig 2).   
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Figure 2: Wave Intensity Analysis Real Time Measurement  
REAL TIME MEASUREMENT
Anterior wall
Posterior wall
Diameter-change
Blood Velocity
Wave Intensity
ECG
 
The MATLAB program was used to calculate net Wave Intensity and then to separate 
the waves into their four components and to calculate the local wavespeed, Peterson’s 
pressure-strain elastic modulus (epsilon) and the β stiffness index (beta). 
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CHAPTER 3.1.1 
REPRODUCIBILITY OF TISSUE DOPPLER IMAGING – THE M4 STUDY 
 
Introduction 
Regional left ventricular function can now be quantified precisely by tissue Doppler 
(myocardial velocity imaging), giving numerous specific measurements of motion and 
deformation that can be used to diagnose disease even at a preclinical stage.  Many 
echocardiography departments use more than one brand of echocardiography 
machine.  Unfortunately, however, manufacturers process the signals in different ways 
and so it is uncertain if measurements can be compared between machines.  In 
addition, if the technique is to be standardised, the same patient having studies on 
different machines by different operators, should give comparable results.   
Studies so far have been extremely variable.  In one previous study197 they showed 
that two commercially available speckle-tracking software appear to be comparable 
when quantifying left ventricular function in a healthy population of 28 people.  
However, a multicentre study198 also looking at strain by speckle-tracking showed 
considerable variation that could only partly (16% of variance) be explained by patient 
factors.  It is important to note that both these two studies were of a healthy population.  
A study in 2006199, reported 20 healthy participants having a coefficient of variation of 
up to 19% in the measurement of tissue velocity, strain and strain rate but no 
significant difference between the two systems trialled.  A further study in the US also 
shows variation200.  They tested three common commercial US systems with a Doppler 
string phantom.  In measuring pulsed and continuous-wave Doppler velocities one of 
the systems consistently overestimated velocity by 5% whereas the other two were 
similar and accurate. 
Variation between systems has also been looked at briefly in magnetic resonance 
imaging.201  In this study, Kornaat and colleagues looked at two surrogate markers for 
osteoarthritis between two 3.0T MRI systems from different manufacturers.  In this 
small trial of five healthy volunteers they found no differences in these markers 
between the two scanners. 
With such variation in the literature, I, therefore, wanted to look at these potentially 
important differences in a more real-life situation.  We arranged four of the most-used 
types of echocardiography machines in a healthy and unhealthy population using 
several echocardiographers from our department.  We took a wide range of 
measurements including tissue Doppler, real-time and off-line measurements.  
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I, therefore, set out a list of objectives: 
 
 To compare reproducibility of tissue Doppler measurements obtained on the same 
patients, between different machines and operators 
 To compare real-time and processed measurements 
 To compare the reproducibility of tissue Doppler measurements with the 
reproducibility of standard echocardiographic measurements (M-mode, 2D, blood 
pool doppler) 
 
Methods 
4 of the latest model, high-tech machines were obtained for 2 weeks from GE, Toshiba, 
Acuson and Aloka.  60 patients each attended for one morning or one afternoon with a 
wide range of diagnoses and ages varying from normal to severe heart failure.  Each 
patient had 4 consecutive echocardiographic studies performed on each machine 
independently by a separate operator, in random order (each starting with a different 
system but then consecutively all the others, in a circuit).  Each operator made 
measurements for that system following a common protocol.   
 
I specifically looked at:  
 What was the intermachine/operator reproducibility of myocardial velocity? 
 What was the intermachine/operator reproducibility of myocardial strain? 
 What was the intermachine/operator reproducibility of myocardial strain rate? 
 Was there a difference in the reproducibility of systolic, early diastolic (E), and 
late diastolic (A) indices? 
 Was reproducibility affected by frame rate? 
 Was reproducibility affected by image quality? 
 Was there a systematic difference between machines/operators or is it random? 
 Were velocities consistently more reproducible between systems, than strain 
and strain rate? 
 What were the implications for drawing conclusions from repeated 
measurements? 
 
Protocol 
Anthropometric data were collected:  age, gender, height, weight, body mass index, 
diagnosis.  The times for analyses were recorded and image quality was also graded 
by the operators on a scale of 1 to 5.  The image was optimised to get the best frame 
rate and therefore best quality tissue Doppler data.  
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In the Parasternal long-axis (PLAX) view, the measurements obtained were for radial 
(short-axis) function of the left ventricle in the basal posterior (BP) segment: 
Sm velocity in systole 
Em velocity in early diastole 
Am velocity during atrial contraction 
and the derived parameters 
SRs strain rate in systole 
S strain in systole 
 
In the Apical imaging planes we used: Apical 4-chamber view (A4C) – for septal and 
lateral walls; Apical 2-chamber view (A2C) – for inferior and anterior walls; Apical long-
axis view (APLAX) – for posterior and anteroseptal walls. 
The three apical views were acquired at 60 degree intervals by rotating the transducer 
positioned over the apex of the heart.  All these views were used to measure long-axis 
function of the left ventricle (movement/contraction along the plane from the base of the 
heart to the apex).  
5 parameters were measured in the basal segment of each wall (same parameters as 
for the short-axis measurements from the parasternal window) and the frame rate was 
documented for each imaging plane/pair of walls. 
 
Myocardial segments 
The study protocol included a focussed image just of the septum, to give higher frame 
rates in order to optimise signal quality (Septum with high FPS).  From these images, 
the same 5 parameters were measured at three levels corresponding to the basal, 
mid, and apical segments.  
 
Right ventricle 
We included only one set of measurements from the right ventricle, in order to simplify 
acquisition and analysis and because the right ventricle is rarely affected in Marfan 
Syndrome.  These parameters were velocities of the lateral tricuspid annulus (LTA) at 
the base of the right ventricular free wall as this is used clinically.  Deformation indices 
are never measured at the annulus and so they were not recorded. 
 
Real-time vs off-line measurements 
Deformation indices (i.e. strain and strain rate) can only be measured “off-line”, that is 
by processing of digitally stored velocity data. 
Velocity, however, can be measured in 2 ways – either in “real-time” from a pulsed 
Doppler measurement, or by processing digitally stored data to obtain “off-line” 
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measurements at the same site.  There is an important systematic difference between 
these measurements since the pulsed, real-time technique gives peak velocities and 
the processed off-line technique gives mean velocities; thus the “off-line” 
measurements would be expected to be about 25% lower. 
To assess this, velocities were measured at the medial mitral annulus (MMA) and 
lateral mitral annulus (LMA) by both techniques. 
 
Timing of myocardial motion 
Accurate measurements of the timing of heart muscle movement is now important for 
studying dyssynchrony in the normal and diseased heart (for example, to identify 
patients who might benefit from resynchronisation therapy with a biventricular 
pacemaker).  There have been no reported comparisons of timings between machines. 
We measured timings of only one parameter – that is, time from the onset of the QRS 
complex on the ECG to the time of peak systolic velocity of mitral annular motion (Time 
to peak).  This was done at two sites (medial and lateral mitral annulus) and using 2 
methods (real-time, off-line). 
 
Estimated left atrial filling pressure 
A combination of one blood-pool Doppler measurement (velocity of flow across the 
mitral valve in early diastole) and one tissue Doppler measurement (mitral annular 
velocity during early diastole, Em, using real-time measurements) is now widely used 
to estimate left atrial pressure non-invasively.  We therefore made recordings to allow 
us to assess the intermachine variability of this derived haemodynamic index. 
We recorded velocities of blood flow through the mitral valve in early diastole (E) and 
during atrial filling (A); in clinical practice these are often combined in the E/A ratio 
which is an indicator of myocardial relaxation.  
 
I was involved in the setting up of this study.  The echocardiographic data were 
recorded independently by four other clinical research fellows.  I then compiled the data 
base summarising all the results.  I calculated the derived measurements and 
undertook the initial analyses.  I prepared the database for further statistical analysis 
which was performed by Tomas Andersson, Karolinska University, Stockholm. 
 
Results 
The baseline characteristics of the study group are seen in Table 1 with a wide range 
of age and size with a 62% male preponderance.  20% are a normal population and the 
remaining subjects had a range of cardiac and non-cardiac disease mirroring a normal 
hospital outpatient echocardiography list.  The GE machine was given the highest 
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image quality average (4.3 out of 5) and the Toshiba system the lowest image quality 
average (3.3 out of 5) by the echocardiographers although it must be noted the GE 
system is the machine the scanners were more experienced in using and this is a very 
subjective measure.   
 
Table 1: Baseline Characteristics of the Study Group (n=60 patients) 
 
Characteristic Value 
Age (yrs) 
-mean 
-range 
 
52.6 
19-88 
Height (cms) 
-average 
-range 
 
168 
146-190 
Weight (kgs) 
-average 
-range 
 
77 
51-122 
BMI 
-average 
-range 
 
27.4 
20.6-39.7 
Male gender n⁰ (%) 37/60 (62%) 
Image quality average (rated 1-5 
by echocardiographer) 
-Machine A (GE) 
-Machine B (Acuson) 
-Machine C (Toshiba) 
-Machine D (Aloka) 
 
 
4.3 
3.4 
3.3 
3.8 
Diagnosis n⁰ (%) 
-Normal 
-Heart Valve disease 
-Heart Failure 
-Coronary artery disease 
-Cardiomyopathy 
-Non-cardiac disease 
-Hypertension 
-Atrial fibrillation 
 
12 (20%) 
11 (18%) 
9 (15%) 
9 (15%) 
8 (13%) 
8 (13%) 
5 (8%) 
4 (7%) 
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Table 2 shows the correlations of tissue Doppler measurements at the basal septum of 
the left ventricle in an apical 4 chamber view.  This shows good correlations between 
machines for peak systolic (r=0.64), early (r=0.73) and late (0.54) diastolic velocities 
but a disappointing correlation for strain rate (0.18) and strain (0.19).  It is also noted 
that there wasn’t a specific machine combination where the correlations were 
particularly good or poor.  For example, when measuring peak systolic velocity, early 
and late diastolic filling the worst correlations were with machine A vs B; for strain rate 
it was machine C vs D; and for strain it was machine A vs D.  
 
Table 2: Correlations and R² Of Tissue Doppler Measurements at The Basal 
Septum on Apical 4 Chamber View  
 
 A vs B A vs C A vs D B vs C B vs D C vs D Mean R of all 6 
combinations 
SmBS 0.54 
0.29 
0.68 
0.46 
0.63 
0.4 
0.69 
0.48 
0.59 
0.35 
0.70 
0.49 
0.64 
EmBS 0.58 
0.34 
0.69 
0.48 
0.65 
0.43 
0.81 
0.66 
0.81 
0.66 
0.81 
0.66 
0.73 
AmBS 0.47 
0.22 
0.59 
0.35 
0.54 
0.29 
0.56 
0.31 
0.52 
0.27 
0.57 
0.32 
0.54 
SR 0.23 
0.05 
0.28 
0.08 
0.05 
0.00 
0.23 
0.05 
0.25 
0.06 
0.01 
0.00 
0.18 
Ss 0.15 
0.02 
0.35 
0.12 
0.02 
0.00 
0.14 
0.02 
0.23 
0.05 
0.22 
0.05 
0.19 
  
Table 3 shows the correlations for all 6 left ventricular walls, the lateral tricuspid 
annulus and the basal septum at high frame rate.  These figures show a mean 
correlation between machines of r=0.56 for all 8 walls and a range of correlations of 
r=0.44 at the left ventricular basal posterior wall to r=0.64 at the left ventricular basal 
septum at normal frame rate.  Interestingly, the high frame rate seemed to have no 
impact on the peak systolic velocities with a correlation of r=0.62 compared to a 
correlation of r=0.64 when a lower frame rate was used at the same site –left 
ventricular basal septum.  
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Table 3: Correlations and R² Of Peak Systolic Velocities at the Six LV Walls, at 
High Frame Rate and The RV FreeWall 
 
 A vs B A vs C A vs D B vs C B vs D C vs D Mean R of all 
6 
combination 
SmBP 0.39 
0.15 
0.49 
0.24 
0.49 
0.24 
0.50 
0.25 
0.34 
0.12 
0.44 
0.19 
0.44 
SmBS 0.54 
0.29 
0.68 
0.46 
0.63 
0.4 
0.69 
0.48 
0.59 
0.35 
0.70 
0.49 
0.64 
SmBS 
high 
frame 
rate 
0.52 
0.27 
0.74 
0.55 
0.58 
0.34 
0.65 
0.42 
0.55 
0.30 
0.69 
0.48 
0.62 
 
SmBL 0.49 
0.24 
0.58 
0.34 
0.43 
0.18 
0.56 
0.31 
0.33 
0.11 
0.80 
0.64 
0.53 
SmBI 0.45 
0.20 
0.66 
0.44 
0.61 
0.37 
0.63 
0.40 
0.71 
0.50 
0.74 
0.55 
0.63 
SmBA 0.33 
0.11 
0.51 
0.26 
0.45 
0.20 
0.51 
0.26 
0.60 
0.36 
0.71 
0.50 
0.52 
SmAS 0.52 
0.27 
0.56 
0.31 
0.61 
0.37 
0.26 
0.07 
0.61 
0.37 
0.70 
0.49 
0.54 
Sm 
LTA 
0.46 
0.21 
0.67 
0.45 
0.53 
0.28 
0.70 
0.49 
0.47 
0.22 
0.53 
0.28 
0.56 
 
We also looked at real-time and processed measurements.  Table 4 compares early 
diastolic filling at LMA and MMA showing a large difference in reproducibility between 
machines at the LMA (r=0.80) compared to the MMA (r=0.52).  Time to peak systolic 
velocities were measured in real-time and processed and the correlations were lower 
when processed times were used (r=0.41 and 0.49) compared to real-time (r=0.52 and 
0.55) and this was true whether it was measured at the lateral or medial mitral annulus.  
However, the correlations were again lower for MMA (r=0.41 and 0.52) compared to 
LMA (r=0.49 and 0.55). 
The best correlations between the machines were seen with normal pulsed Doppler 
early and late diastolic filling at mitral inflow.  The correlation for early diastolic filling 
was r=0.89 and late diastolic filling was r=0.81. 
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Table 4: Correlations and R² At Mitral Inflow and the Mitral Annulus 
 
 A vs B A vs C A vs D B vs C B vs D C vs D Mean R 
of all 6  
E 0.92 0.89 0.93 0.85 0.86 0.87 0.89 
A 0.81 0.85 0.79 0.86 0.75 0.79 0.81 
Em at LMA 0.81 
0.66 
0.84 
0.71 
0.85 
0.72 
0.79 
0.62 
0.76 
0.58 
0.76 
0.58 
0.80 
Em at MMA 0.85 
0.72 
0.73 
0.53 
0.21 
0.04 
0.76 
0.58 
0.32 
0.10 
0.25 
0.06 
0.52 
0.27 
Time to 
peak Sm 
real-time 
LMA 
0.71 
0.50 
0.64 
0.41 
0.65 
0.42 
0.60 
0.36 
0.37 
0.14 
0.35 
0.12 
0.55 
Time to 
peak Sm 
processed 
LMA 
0.37 
0.14 
0.60 
0.36 
0.63 
0.40 
0.44 
0.19 
0.35 
0.12 
0.57 
0.32 
0.49 
Time to 
peak Sm 
real-time 
MMA 
0.52 
0.27 
0.71 
0.50 
0.62 
0.38 
0.54 
0.29 
0.31 
0.10 
0.40 
0.16 
0.52 
Time to 
peak Sm 
processed 
MMA 
0.30 
0.09 
0.63 
0.40 
0.47 
0.22 
0.32 
0.10 
0.32 
0.10 
0.40 
0.16 
0.41 
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Table 5: Bland-Altman Mean differences between the Four Machines for the six 
main parameters. 
 
 A vs B A vs C A vs D B vs C B vs D C vs D Mean of 
all 6  
E (m/s) 0.0±0.1 0.1±0.1 0.0±0.2 0.1±0.1 0.0±0.2 -0.1±0.2 0.0 
SmBS 
(cm/s) 
0.6±1.5 1.6±1.2 1.7±1.4 0.8±1.4 1.1±1.7 0.1±1.4 1.0 
SmBS 
HFR 
(cm/s) 
0.1±1.6 1.6±1.1 2.4±1.6 1.5±1.4 2.0±1.8 0.6±1.4 1.4 
SsBS (%) -5±25 -1±19 0±29 5±21 6±26 0±22 1 
SRsBS  
(.s-1) 
-0.8±1.8 -0.1±2.4 -0.3±2.6 1.0±2.5 0.9±2.4 0.1±2.8 0.1 
Time to 
peak Sm 
processed 
LMA (ms) 
5±66 -12±49 -3±46 -15±64 0.2±62 11±47 -2 
 
Table 5 illustrates the mean differences in measurements between the different 
machine combinations for six specific parameters.  It shows very little difference 
between machines with respect to early diastolic mitral blood flow Doppler (E).  
However, there are large mean differences and standard deviations in the other 
parameters especially systolic strain (SsBS) and strain rate (SRsBS).  The timing 
parameter shows larger mean differences for the combinations A vs C, B vs C and C 
vs D compared to A vs B, A vs D and B vs D.  However, the standard deviations are 
about the same for all six combinations. 
 
Figure 1 shows a good correlation r=0.92 between the GE and Acuson machines for 
early diastolic filling (E).   
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Figure 1: Scatterplot of Early diastolic filling (E) as measured by the GE Vivid 7 
and the Acuson (r=0.92). 
0.25 0.50 0.75 1.00 1.25 1.50 1.75
AcusonE
0.50
1.00
1.50
2.00
V
7E
 
Figure 2 illustrates the layout for the next 2 figures.  Figures 3 and 4 highlight the 
variability in correlations and mean differences between two parameters – the first in 
figure 3 shows little intermachine variation, the second in figure 4 showing huge 
intermachine variation. 
 
Figure 2:  
A B C D
A
B
C
D
Aloka "A” / Toshiba "B” / GE V7 "C” / Acuson "D"
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Figure 3: Correlations and Mean Differences for early diastolic mitral blood flow 
doppler (E) between Machines  
Mitral E velocity, pulsed Doppler
0.87 0.93 0.85
0.89 0.85
0.1 ± 0.1 0.92
0.0 ± 0.2 - 0.1 ± 0.2
0.0 ± 0.1
0.1 ± 0.1
0.0 ± 0.2
Correlations    0.89
Mean differences (m/s)
0.0
 
 
Figure 4: Correlations and Mean Differences for systolic strain at the basal 
septum (SsBS) between Machines  
Ss basal septum A4C
0.15 0.35 0.02
0.14 0.23
5 ± 21 0.22
0 ± 22
- 5  25
- 1 ± 19
0 ± 29
Correlations     0.19
Mean differences (%)
1
6 ± 26
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Discussion 
Firstly, it must be noted that having different fellows performing the echocardiography 
is a confounding variable in this study and may alter the impact of the machines 
themselves on the measured variables.  This would benefit from a more complex 
statistical review.  However, in this study, there were considerable and potentially 
clinically significant variations in myocardial velocities and deformation recorded on 
different echocardiographic machines by different operators, in the same patients 
under similar physiological conditions.   
It is worth explaining that this study is not looking at the accuracy of the four individual 
machines per se but emphasises the differences between them.  However, I have 
shown a large variation in correlations amongst machines in the tissue Doppler 
parameters especially pronounced with strain and strain rate.  The correlations for 
strain (r=0.19) and strain rate (r=0.18) were so low that it must be raised whether these 
parameters are reliable enough to be used in echocardiography labs with different 
manufactured machines.  Correlations of peak systolic velocities of between 0.44 and 
0.64 are however better but the lack of difference with a higher frame rate was a 
surprise (r=0.62 HFR compared to 0.64).  This may be because our 
echocardiographers were very experienced in a research setting and optimized the 
echo parameters as routine and therefore, the high frame rate had less of an impact.   
Tissue Doppler measurement of early diastolic filling at the LMA (r=0.80) was much 
better than at the MMA (r=0.52) and maybe adds weight to measuring this parameter, 
to calculate left atrial filling pressure, routinely at the lateral mitral annulus or by 
averaging the two.  Current British Society Of Echocardiography guidelines suggest 
using either sites. 
There was also a notable difference between specific machines especially when 
generally the correlations were lower.  However, we did not find evidence to show that 
2 particular machines were always very different compared to other combinations.   
It was reassuring to see high correlations between machines for pulsed Doppler E and 
A measurements of early and late diastolic filling at mitral inflow.  These parameters 
are measurements of left ventricular relaxation and are found in all guidelines and are 
taken at every basic echocardiography exam. 
The causes of these differences need to be understood and overcome by standard 
acquisition, tracking and signal averaging if the diagnostic potential of Tissue Doppler 
is to be optimised.  At present, it seems sensible to at least sequentially scan the same 
Marfan patient with the same machine and ideally by the same operator.  It also seems 
sensible to purchase one type of echocardiography machine for each department 
although cost, new software updates and different personal preferences amongst 
Consultants makes this practically difficult.
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CHAPTER 3.1.2 
Tissue Doppler Imaging In A Normal, A Subclinical Hypothyroid, A Type 2 
Diabetic And A Marfan Population 
 
Introduction 
In Chapter 1.3, we identified two novel parameters of left ventricular myocardial 
function that had good theoretical reasons for being useful adjuncts in our assessment 
of the cardiovascular abnormalities seen in Marfan Syndrome, - isovolumic 
acceleration (IVA)and peak systolic velocity (Sm).   
IVA, that is, myocardial acceleration during isovolumic contraction at the base of each 
of the six left ventricular walls has been described in chapter 1.3 as a sensitive 
measurement of left202-204 and right205 ventricular myocardial contractile function that 
seems unaffected by preload and afterload at least within physiological range.  IVA 
correlates closely with invasively derived haemodynamic indices of contractility such as 
dp/dt and end-systolic elastance.202  IVA can also be measured in each left ventricular 
wall and regionally.   
Peak systolic velocity when measured at the lateral mitral annulus is a measure of 
longitudinal systolic function.  It has been correlated with LV ejection fraction206 and 
peak dp/dt207.  Regional reductions in Sm are correlated with regional wall motion 
abnormalities and TDI is often used as part of dobutamine stress echocardiography as 
peak Sm increases with dobutamine and exercise and decreases with ischaemia.208,209   
The most commonly used index of left ventricular function, the Ejection Fraction (EF), 
is affected by volume and is a marker of global left ventricular function.   
I, therefore, wanted to investigate these two new parameters in terms of their 
reproducibility and the variation at the six different left ventricular walls and their ability 
to expose subclinical deterioration in left ventricular function.  Members of our research 
group had already performed echocardiography on a subclinical hypothyroid and type 2 
diabetic population.  As both populations would be expected to have subclinical left 
ventricular systolic dysfunction I analysed the data acquired and compared it to a 
normal population group and my Marfan population. 
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Hypothesis 1:  IVA and Peak systolic mitral annular velocity will detect subclinical left 
ventricular impairment in our 3 abnormal populations. 
Hypothesis 2:  IVA and Peak systolic mitral annular velocity will detect regional 
differences in left ventricular impairment. 
Hypothesis 3:  Peak systolic mitral annular velocity will have lower variability compared 
to IVA. 
 
Methods 
Subjects 
A total of 85 volunteers were examined at our institution.  They consisted of 20 normal 
volunteers, 21 female subclinical hypothyroid patients (SCH), 23 type 2 diabetic 
patients (T2DM) and 21 Marfan patients (MF).  All volunteers were given written 
information and gave informed consent.  The baseline characteristics are recorded in 
Table 1 and the thyroid function of the subclinical hypothyroid group in Table 2.   
 
Transthoracic Echocardiography Acquisition 
All volunteers underwent transthoracic echocardiography using a GE Vivid 7 machine 
(General Electric, Connecticut, US) equipped with a 2.5MHz probe.  Optimised Tissue 
Doppler images were attained using a frame rate of >100s-1 and the loops were stored 
for post-processing.  Two different echocardiographers were used for the diabetic, 
subclinical hypothyroid and normal groups and I was the echocardiographer for the 
Marfan group.   
Longitudinal IVA and peak systolic velocity (Sm) were measured at the septal, lateral, 
inferior, anterior, basal-posterior and anteroseptal walls from the apical 4-chamber, 
apical 2-chamber and apical long-axis views.  Ejection fraction (as the most commonly 
used index of left ventricular function) was measured by the Simpson’s biplane method.  
IVA was measured by placing the cursor at the base of the left ventricular wall 
immediately (0.5cm) below the insertion of the mitral valve leaflet as described by 
Vogel and colleagues.202  A three beat loop was recorded but a single beat loop was 
selected to increase the size of the image for accuracy and the slope was measured at 
isovolumic acceleration.  This was done in 2 of the 3 beat loops recorded and an 
average taken.  IVA was measured as the slope from the first positive deflection after 
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the onset of systole, as ascertained from the surface ECG, during isovolumic 
acceleration from zero to peak velocity.   
The peak systolic velocities (Sm) were also measured using Tissue Doppler Imaging 
and recorded using maximal frame rates at the base of each of the six left ventricular 
walls  
Statistics 
I analysed all the echo data from all four groups to calculate the peak systoloic 
velocities and the IVA.  I produced the database and performed the statistical analysis 
using SPSS Version 18.  The data was checked for Normality by inspecting histograms 
and Q-Q Plots.  The means of IVA and Sm at each wall were calculated with the 
standard deviations.  The differences between the four populations were calculated 
using a One Way Anova with Tamhane’s T2 posthoc calculation.  This gave a mean 
difference, standard error and a significance level.  A p value <0.05 was considered 
statistically significant.  The correlation between the independent predictors of the key 
cardiac variables and the variables themselves was performed using Pearson’s 
Correlation Coefficient.  Reproducibility is expressed as the Coefficients of Variation 
(CV).  Each variable was acquired once by the operator but measured twice by me in 
all subjects after a time period of 24 hours and compared to the same measurement 
calculated by another fellow.  CV was measured by Standard Deviation (SD)/mean x 
100.  The SD is the standard deviation of the measurement error associated with a 
single measurement calculated as the SD of residuals (measurement 1-measurement 
2) divided by √2    
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Table 1: Baseline Characteristics of the Four Different Populations 
 Normal  
Population 
Subclinical 
Hypothyroid 
Patients 
Type 2 
Diabetic 
patients 
Marfan 
Patients 
Number 20 21 23 21 
Age (yrs) 25.7 ±2.9 49.2 ±3.8 64.1 ±8.5 30.4 ±12 
Male/Female 50%/50% 0%/100% 70%/30% 43%/57% 
Smokers 0% 5.3% 20% 7% 
BMI (kg/m2) 24.1 ±5.4 29.9 ±6.7 31.6 ±8.9 22.9 ±4 
Data are mean ±SD. 
Table 2: Baseline Thyroid function In the Subclinical Hypothyroid Patients 
(SCH) 
 
 Subclinical Hypothyroid Patients 
TSH (mIU/litre) 0.5-5.0 normal 8.8  (range 5.7-21.6) 
Free T4 (ng/dl) 0.8-1.8 normal 1.0 ±0.1 
Free T3 (ng/dl) 0.2-0.5 normal 0.38 ±0.03 
Thyroid Peroxidase Antibody +ve 89% 
Data are mean ±SD. 
 
Results (Tables 3+4) 
Ejection Fraction: 
Although both the SCH and Marfan population had mean ejection fractions measured 
that are below the cut-off of normal, that is 55%, there was no significant difference 
between the groups.  However, the standard deviation for the three abnormal groups 
was much higher than the normal group indicating the abnormal groups did contain 
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subjects with below normal ejection fractions.  The heart rates were the same for all 
groups.  It is noted that the Marfan group stopped taking their medication, mostly beta 
blockers, two weeks prior to testing. 
 
Peak Systolic Mitral Annular Velocities (Sm): 
The peak systolic mitral annular velocities were significantly lower in both the T2DM 
group and the SCH group compared to the normal group in all six left ventricular walls 
(P>0.05).  The velocities were also significantly lower in the MF group at the anterior 
and anteroseptal walls.  The velocities were also lower in the MF group at the 
remaining septal (18%), lateral (16%), inferior (10%) and basal-posterior walls (12%) 
but did not reach statistical significance. 
Intraobserver variability for peak systolic mitral annular velocity was 15% and 
interobserver variability was 20%.  
 
Isovolumic Acceleration: 
There was no statistically significant variation in longitudinal IVA between the six left 
ventricular walls.  IVA was significantly different between the normal population and the 
SCH and the normal population and the T2DM group in both the septum (by 38% for 
both comparisons) and anterior walls (31% and 44% respectively, p<0.05).  There was 
no statistical difference in IVA between the normal and Marfan population.  When we 
calculated the average of IVA in the six left ventricular walls, there was no statistical 
difference between the three groups.   
Intraobserver variability for IVA was 28% and interobserver variability was 30%. 
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Table 3: Comparison of Regional Peak Systolic Mitral Annular Velocities Between the Four Groups 
 Mean Sm ± Standard Deviation (cm/s) Mean Differences ± Standard Error Significance Level 
 Normal (A) SCH (B) T2DM (C) MF (D) A vs B A vs C Avs D A vs B A vs C A vs D 
Septum 6.6 ± 1.1 5.2 ± 0.7 4.9 ± 1.4 5.4 ± 1.8 1.3 ± 0.3 1.7 ± 0.4 1.2 ± 0.5 P<0.001* P<0.001* P=0.1 
Lateral 8.0 ± 1.3 5.7 ± 1.5 4.8 ± 2.1 6.6 ± 2.8 2.3 ± 0.4 3.2 ± 0.5 1.3 ± 0.7 P<0.001* P<0.001* P=0.32 
Inferior 6.9 ± 1.1 6.0 ± 1.0 5.7 ± 1.7 6.2 ± 1.2 1.0 ± 0.3 1.3 ± 0.4 0.7 ± 0.4 P<0.05* P<0.05* P=0.28 
Anterior 7.3 ± 1.5 5.3 ± 1.5 4.4 ± 1.4 5.4 ± 2.0 2.0 ± 0.5 3.0 ± 0.5 1.9 ± 0.6 P<0.001* P<0.001* P<0.01* 
Basal-
posterior 
7.4 ± 1.6 6.1 ± 1.0 5.3 ± 1.6 6.5 ± 1.8 1.3 ± 0.4 2.2 ± 0.5 0.9 ± 0.5 P<0.05* P<0.001* P=0.4 
Anteroseptal 6.6 ± 1.3 4.4 ± 1.1  3.9 ± 1.6 4.3 ± 1.3 2.2 ± 0.4 2.7 ± 0.4 2.2 ± 0.4 P<0.001* P<0.001* P<0.001* 
HR (bpm) 65 ± 14 67 ± 10 66 ± 12 65 ± 11 -2 ± 4 -1 ± 4 0.2 ± 4 P=1.0 P=1.0 P=1.0 
EF (%) 60 ± 5 54 ± 9 56 ± 11 53 ± 13 5 ± 2 4 ± 3 6 ± 3 P=0.2 P=0.6 P=0.2 
Frame Rate 175 ± 20 165 ± 25 161 ± 26 170 ± 22 9 ± 6 10 ± 5 5 ± 3 P=0.5 P=0.3 P=0.9 
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Table 4: Comparison of Regional Isovolumic Acceleration Between the Four Groups 
 
 Mean IVA ± Standard Deviation (m/s
2) Mean Differences ± Standard Error Significance Level 
 Normal (A) SCH (B) T2DM (C) MF (D) A vs B A vs C Avs D A vs B A vs C A vs D 
Septum 1.6 ± 0.7 1.0 ± 0.5 1.0 ± 0.5 1.2 ± 0.7 0.5 ± 0.2 0.6 ± 0.2 0.4 ± 0.2 P<0.05* P<0.05* P=0.3 
Lateral 1.3 ± 0.6 1.2 ± 0.5 0.9 ± 0.8 1.1 ± 0.6 0.2 ± 0.2 0.4 ± 0.2 0.3 ± 0.2 P=0.93 P=0.39 P=0.54 
Inferior 1.3 ± 0.5 1.1 ± 0.3 1.0 ± 0.6 1.1 ± 0.4 0.2 ± 0.1 0.3 ± 1.8 0.2 ±0.2 P=0.65 P=0.51 P=0.68 
Anterior 1.6 ± 0.6 1.1 ± 0.6 0.9 ± 0.6 1.3 ± 1.0 0.6 ± 0.2 0.8 ± 0.2 0.4 ± 0.3 P<0.05* P<0.005* P=0.6 
Basal-
posterior 
0.9 ± 0.6 1.2 ± 0.5 1.1 ± 0.9 1.2 ± 0.6 -0.3 ± 0.2 -0.2 ± 0.2 -0.3 ± 0.2 P=0.66 P=0.97 P=0.56 
Anteroseptal 1.1 ± 0.5 0.9 ± 0.4 0.8 ± 0.4 0.8 ± 0.9 0.1 ± 0.1 0.3 ± 0.1  0.3 ± 0.2 P=0.97 P=0.37 P=0.77 
6 Wall Av. 1.4 ± 0.5 1.1 ± 0.4 1.0 ± 0.5 1.1 ± 0.4 0.3 ± 0.1 0.4 ± 0.2 0.2 ± 0.1 P=0.2 P=0.09 P=0.7 
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Table 5: Correlation between Age and BMI and the Regional Peak Systolic 
Mitral Annular Velocities For all Groups  
 
 Age BMI Septum Lateral Inferior Anterior Baso-
posterior 
Antero-
septal 
Age  1.0 0.8 -0.31 -0.50 -0.32 -0.43 -0.43 -0.24 
BMI  0.8 1.0 0.11 0.24 0.12 0.25 0.28 0.11 
 
Table 6: Correlation between Age and BMI and the Regional Isovolumic 
Acceleration For all Groups 
 
 Septum Lateral Inferior Anterior Baso-
posterior 
Antero-
septal 
6 wall 
average 
Age -0.02 -0.15 -0.07 -0.28 -0.08 -0.08 -0.17 
BMI 0.11 <0.01 <0.01 0.16 0.05 0.11 0.13 
 
Table 5 shows the correlations between the two key independent predictors age and BMI 
was 0.8.  Therefore, as expected, a strong correlation that as age increases so does BMI.  
Tables 5 and 6 show there were much lower correlation values for both regional peak 
systolic mitral annular velocities and regional isovolumic acceleration with age and BMI.  
The highest correlation was -0.5 between age and lateral wall peak systolic mitral annular 
velocity.  The six wall IVA average had very low correlations with age (-0.17) and BMI 
(0.13).  
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Discussion  
During tissue Doppler imaging, high frame rates were achieved for each population and 
therefore, the results should be accurate.  Peak systolic mitral annular velocities detected 
abnormaIities in all walls in the T2DM and SCH groups compared to the normal 
population.  Abnormalities were also detected in the anterior and anteroseptal walls in the 
MF group.  The ejection fractions measured suggest that all three abnormal groups had 
subjects with below normal left ventricular systolic function.  The reason for their reduction 
in left ventricular function is difficult to speculate on due to the different ages in the four 
groups which was confounded with their underlying diagnosis.  The mean ages were 26 
years in the normal group; 49 years in the SCH; 64 years in the T2DM; and 30 years in the 
MF groups.  The reason the MF group only had significantly different peak systolic mitral 
annular velocities in only two of the six walls may be due to their relative youth.  Also, 
there was a difference in the sex of the groups due to the medical disorders they had with 
100% female sex in the subclinical hypothyroid group and significantly more men in the 
diabetic group.  It must be noted that performing correlations with age and BMI against the 
key cardiac variables in the four groups combined (tables 5 and 6) did not reveal any 
significant correlations  However, the patient characteristics revealed important differences 
and if repeated the groups should be better matched. 
 
The only statistical differences in IVA measurements between the normal control group 
and the other three abnormal groups were seen at the anterior wall in the T2DM and SCH 
groups and at the septum in the T2DM group.  This is a marked difference from the peak 
systolic mitral annular velocities.  It may be partly explained by difficulties encountered 
during measurement.  Acquisition of the trace required for IVA at each site was not difficult 
but the actual measurement itself was difficult and prone to error.  Choosing the correct 
slope was subject to considerable intraobserver (28%) and interobserver (30%) variability 
and scores poorly compared to the variability with the peak systolic velocitiy (15 and 20%). 
 
My results are similar to that found in a recent paper210 looking at IVA in three groups -a 
normal population, a type 2 diabetic population and a heart failure population.  The mean 
LVEFs in these three groups were 60%, 56% and 32% respectively.  They concluded that 
IVA may be used as a research tool but the clinical applicability is hampered by low 
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reproducibility, especially in patients with impaired left ventricular function in whom it would 
be most useful.  We did not look at heart failure subjects in our study but at three groups 
where abnormal left ventricular function would be more subtle which would be more 
applicable to our Marfan population.  However, my IVA variability was similar if not worse 
than this recent paper.  Their mean intraobserver variability was 12%(normal group), 
18%(T2DM group) and 30%(HF group) compared to our mean intraobserver variability of 
15%(normal group) and 28%(abnormal groups).  Their mean interobserver variability was 
23%(normal group), 21%(T2DM group) and 28%(HF group) compared to our mean 
interobserver variability of 25% (normal group) and 30% (abnormal groups).    
Peak systolic velocity at the mitral annulus however did exhibit significant differences 
between the normal control group and the three abnormal populations in all six ventricular 
walls.  The velocities were markedly lower in the SCH and T2DM groups and to a lesser 
degree in the MF group perhaps reflecting less left ventricular pathology in this group.  The 
peak systolic velocities were far easier to acquire and measure and the intraobserver (5% 
for the normal group and 8% for the abnormal group) and interobserver (10% for both 
groups) variabilities were much lower compared to that seen with IVA.   
This study suggests that Tissue Doppler Imaging in the form of peak systolic mitral annular 
velocity may play a real role in evaluating Marfan patients’ left ventricular function and 
indeed pick up subtle and subclinical changes not yet reflected in symptoms or even in 
measured or visually interpreted ejection fraction.  IVA cannot be recommended as such 
and remains a research tool only at the present time.   
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CHAPTER 3.1.3 
TDI IN THE MARFAN AORTA STUDY 
Introduction 
As described in Chapter 1.3 and in the paper by Harada 2004211, Tissue Doppler Imaging 
can also be applied to the abdominal aorta in Marfan patients to assess aortic wall 
stiffness (fig.1). 
Figure 1: Pulsed-Wave TDI of the Abdominal Aorta 
 
It is not certain that the abdominal aorta is always involved in the Marfan Syndrome 
phenotype reflected by the fact that dilatation or dissection of the descending aorta under 
the age of 50 years is only included as a minor criterion in the Ghent Diagnostic 
nosology212 and not included at all in the scoring of systemic features in the Revised Ghent 
criteria.213  Utilising TDI to investigate not only the abdominal aorta but also the ascending 
aorta and arch in Marfan Syndrome may add further information to the clinician beyond the 
normal practice of serially measuring aortic diameters. 
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Methods 
I investigated 21 Marfan patients diagnosed by the Ghent criteria212 and recruited from two 
tertiary congenital heart centres (Bristol Congenital Heart Centre, Bristol and Congenital 
Heart Disease Centre, University Hospital of Wales, Cardiff).  Full written consent was 
obtained from the subjects and I had full MREC and local R and D approval as described 
in Chapter 2.1.  Subjects with previous aortic dissection or surgery, severe valvular 
regurgitation or an aortic diameter ≥5.0cm were excluded.  The subjects were told to 
abstain from their usual medication over a period of two weeks prior to the trial.   
On arrival, I measured their weight and height.  They then reclined on a comfortable couch 
and rested for 10 minutes.  The blood pressure was recorded from the right arm using an 
electric cuff device (Dinamap).  I used a GE Vivid 7 echo machine and measurements 
taken.  I measured Peak S and D and β-index as described above by Harada et al and in 
Chapter 1.3.  I also measured the time to peak systole (from the R wave on the ECG to the 
Peak S on Pulsed-wave TDI) with the sample volume placed over 3 sites: the aortic arch 
wall, the abdominal aorta wall and in the blood flow itself.  The data acquisition, post-
processing, database set-up and statistical analyses were performed by myself. 
 
Hypothesis:  Time to peak systole in the aortic arch will be shorter as the stiffness index 
increases in a Marfan population. 
Statistics 
The data was analysed using SPSS version 18.0.  Correlations between the stiffness 
index and the timings were calculated using the Pearson and Spearman correlation 
coefficients.  Intraobserver Reproducibilty was measured by Coefficient of Variation.  I 
acquired each variable twice per subject on the same date one measurement straight after 
the other.  The CV was then measured by calculating the Standard Deviation (SD)/mean x 
100.  The SD was calculated by (measurement 1 – measurement 2) divided by √2. 
 
Results 
Feasibility: in most subjects I was able to complete the measurements.  Finding the aortic 
arch in a suprasternal window is a difficult skill developed with practice.  When scanning 
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the abdominal aorta I used a set anatomical landmark, 2cm above the umbilicus, for probe 
placement.  This resulted in 100% success rate.  Analysis of the time to peak systole in the 
arch and abdominal flow was more difficult reflected in the low numbers in whom it was 
possible to get a reading (5 and 9 subjects respectively).  
The results are shown in Table 1.  The aortic arch and abdominal aorta were of normal 
dimensions in our group.  The mean abdominal aorta stiffness index (β) was 6.7.  Peak S 
and D in this adult Marfan population were 3.0 and 2.0.  Peak systole (S) in the abdominal 
aorta correlated with the time to peak systole in the abdominal aortic flow (r=-0.7, p<0.05) 
and with the peak diastole (D) in the abdominal aorta (r=-0.5, p<0.05).  There was no 
correlation between time to peak systole in the aortic arch and the stiffness index, β (r=0.3, 
p=0.15).    
Intraobserver Reproducibility was low for beta index, Peaks S and D (CV 19%) but higher 
for the timings reflecting the large choice of places to select as your area of sampling (CV 
35%). 
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Table1: Pulsed-Wave TDI Measurements at the Aortic Arch and Abdominal 
Aorta In A Marfan Population. 
 Marfan Group Mean ± Standard Deviation 
Age (years) 29.4 ±10.8 
Sex M=7, F=14 
BMI (kg/m2) 22.8 ±3.7 
Body Surface Area (m2) 2.0 ±0.3 
Arch diameter (cm) 2.1 ±0.8 
Beta Abdominal Aorta 6.7 ±4.3 
Peak S (cm/s) 3.0 ±0.01 
Peak D (cm/s) 2.0 ±0.01 
Time to peak systole in 
Arch Wall (ms) 
129 ±34 
Time to peak systole in 
Arch Flow (ms) 
173 ±39 
Time to peak systole in 
abdo aorta wall (ms) 
182 ±26 
Time to peak systole in 
abdo aortic flow (ms) 
221 ±51 
 
Discussion 
This is the first study to look at timings of wave travel through the Marfan Aorta by TDI.  It 
is difficult to compare my results as the only other published data on this is the Harada 
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paper which was in a paediatric Marfan population (mean age 11 ±4 years) compared to 
our adult Marfan population (mean age 29 ±11 years).  This study would have benefited 
from a normal age-matched control group.  However, this was a sub-study of my main 
pharmacological intervention study (Chapter 3.4.1) which was a crossover trial using the 
Marfan subjects themselves as their own controls.  If time had permitted, I would have 
recruited a further age-matched normal control population for these sub-studies.   
The results show that the mean beta stiffness index, measured in my population, of 6.7 
had a high standard deviation of 4.3 and may explain the lack of significant correlations.  
Harada’s group’s beta index was 3.6 ±0.5.  It must be remembered that this is the first 
study of these parameters and as experience of acquiring and measuring them increases I 
would expect the variability and standard deviations to reduce.   
Despite this, it is a relatively simple procedure to acquire the echocardiography windows.  
However, the large choice of where your sample volume should be placed, the size of the 
sample volume compared to the small diameter of the aortic wall and the noise associated 
also increases the reproducibility for the timings significantly compared to the beta index 
and Peaks S and D.   
The location of the abdominal aorta away from musculoskeletal pathology in the thorax is 
an advantage when scanning but the disease process does not always involve the 
abdominal aorta as described in the introduction.  Measurements at the aortic arch are 
more attractive as pathology here makes the diagnosis of Marfan Syndrome.  It is also the 
site closest to the aortic root and ascending aorta where the high cardiovascular risk of 
Marfan Syndrome derives from and of course, the timings would reflect wave travel 
through these conduits.   
Theoretically, you should see lower times from the Electrocardiogram R wave to peak 
systole as the aorta stiffens and wave travel becomes faster.  Subjects with Marfan 
Syndrome have at least annual transthoracic echocardiography and including these 
parameters should not add much to the acquisition time and only a little extra time to the 
post-processing.  The intraobserver reproducibility of 35% is high and so until further 
studies look at this and/or more experience of the technique is gained, these 
measurements must remain a research tool only for the present time.  
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CHAPTER 3.2.1 
APPLANATION TONOMETRY IN MARFAN SYNDROME 
Introduction 
The aim in Marfan Syndrome is to lower central aortic pressure, heart rate, dp/dt and 
central aortic stiffness.  Beta blockers, such as atenolol, lower central blood pressure less 
and peripheral pressure more compared to other newer antihypertensives such as ACEIs 
and CCBs.  Investigating parameters of central and peripheral blood pressure and 
comparing the two has obvious attractions in the assessment of Marfan patients as 
described in Chapter 1.4 and would be a useful method of assessing drug treatment 
effects.  Measurements made non-invasively from the wrist, neck and groin also provide 
an additional benefit if the tool is to be used regularly.  A recent paper from St George’s 
Hospital214 described central and peripheral haemodynamics in a Marfan population 
measured by Applanation Tonometry.  We wanted to measure the same parameters as 
this group did and compare the results to our Marfan population.   
Hypothesis:  Applanation Tonometry can be used as a tool in measuring central and 
peripheral haemodynamics in our Marfan population 
 
Methods 
I invited 21 patients from my recruited Marfan population (as described in Chapter 2.1) for 
investigation at the Wales Heart Research Institute and at the Congenital Heart Centre, 
Bristol.  They underwent baseline assessment and Applanation Tonometry as described in 
the methods section 2.1. 
Statistics 
Data were collected by a single trained observer (me).  I acquired at least 3 measurements 
and the mean of the two measurements with the lowest standard deviations were used in 
the data analysis.  The 2 measurements themselves were used for reproducibility as 
described below.  Statistical analysis was done using SPSS version 18.0.  The data were 
checked for Normality by inspecting histograms and Q-Q Plots.  The means and standard 
deviations were calculated and a p value <0.05 was considered statistically significant.  
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Intraobserver Reproducibility is expressed as the Coefficients of Variation (CV).  CV was 
measured by Standard Deviation (SD)/mean x 100.  The SD is the standard deviation of 
the measurement error associated with a single measurement calculated as the SD of 
residuals (measurement 1-measurement 2) divided by √2   The two measurements used 
for each variable were the two highlighted by the Sphygmocor software as those with the 
lowest standard deviations.  All acquisition, post-processing and statistics was performed 
by myself. 
 
Results 
The results are shown in Tables 1 and 2. 
Table 1: Peripheral Haemodynamics in a Marfan Population as Measured by 
Applanation Tonometry. 
 UHW MARFAN PATIENTS 
Mean ± standard deviation 
Age (years) 27.6 ±7.5 
Sex (Male/Female) 43%/57% 
BMI (kg/m2) 22.3 ±3.6 
Body Surface Area (m2) 2.0 ±0.3 
Heart Rate (bpm) 65.3 ±9.6 
Peripheral Systolic blood pressure 
(mmHg) 
118.7 ±15.7 
Peripheral Diastolic blood pressure 
(mmHg) 
74.6 ±7.6 
Mean arterial pressure (mmHg) 88.9 ±9.5 
Peripheral Pulse Pressure (mmHg) 44.1 ±13.0 
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Table 2: Central Haemodynamics in a Marfan Population as Measured by 
Applanation Tonometry. 
  
Central Systolic blood pressure 
(mmHg) 
105.9 ±12.4 
Central Diastolic blood pressure 
(mmHg) 
75.6 ±7.9 
Mean Arterial pressure (mmHg) 85.7 ±8.6 
Central Pulse Pressure (mmHg) 30.3 ±9.6 
Pulse Pressure Amplification 1.5 ±0.2 
Augmentation index (%) 9.0 ±8.3 
Carotid-Femoral Pulse Wave 
Velocity (m/s) 
6.4 ±1.4 
Carotid-Radial Pulse Wave 
Velocity (m/s) 
7.6 ±1.1 
 
Our intraobserver reproducibility using the Sphygmocor machine was excellent.  For 
central systolic blood pressure the CV was 1%, for Augmentation index it was 18% and for 
Pulse Wave Velocity it was 6%.   
 
Discussion 
The ease of use was apparent using the Sphygmocor system and Applanation Tonometry.  
Locating the peripheral pulses was actually easier than normal due to the tall, thin body 
habitus exhibited by most of our Marfan patients.  The learning time for acquiring the skills 
needed is short and the Sphygmocor programme which can be downloaded to your own 
laptop is simple and easy to understand.  It has an in-built quality control which advises 
you if you have poor arterial tracings and the programme includes an easy to manage 
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database.  It is also quick and a patient can have a whole study completed in 5-10 
minutes.  
 
Table 3: Peripheral Haemodynamics in the St George’s Hospital Marfan 
Population as Measured by Applanation Tonometry.  
 ST GEORGE’S HOSPITAL MARFAN PATIENTS 
Mean ± standard deviation 
Age (years) 30 ±11 
Sex (Male/Female) 65%/35% 
BMI (kg/m2) 21.2 
Body Surface Area (m2) 1.96 ±0.23 
Heart Rate (bpm) 52 ±12 
Peripheral Systolic blood 
pressure (mmHg) 
112.9 ±11.6 
Peripheral Diastolic blood 
pressure (mmHg) 
75.2 ±8.2 
Mean arterial pressure (mmHg) 87.7 ±8.7 
Peripheral Pulse Pressure 
(mmHg) 
37.7 ±7.9 
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Table 4: Central Haemodynamics in the St George’s Hospital Marfan 
Population as Measured by Applanation Tonometry. 
 
 ST GEORGE’S HOSPITAL MARFAN PATIENTS 
Mean ± standard deviation 
Central Systolic blood pressure 
(mmHg) 
100.9 ±11.2 
Central Diastolic blood pressure 
(mmHg) 
75.6 ±8.6 
Mean arterial pressure (mmHg) 86.4 ±8.6 
Central pulse pressure (mmHg) 25.4 ±8.7 
Pulse Pressure Amplification 1.48 
Augmentation Index (%) 12.4 ±13.3 
Carotid-Femoral Pulse Wave 
Velocity (m/s) 
7.0 ±1.7 
Carotid-Radial Pulse Wave 
Velocity (m/s) 
7.7 ±1.8 
 
As in the last chapter, this sub-study would have benefited from a normal, age-matched 
control group.  Again, due to the main study (Chapter 3.4.1) using the Marfan subjects as 
their own controls and lack of time, this was not possible.  However, it compares well with 
published data from a similar Marfan group at St George’s Hospital.  The University 
Hospital of Wales (UHW) and the St George’s Hospital (SGH) Marfan groups are similar.  
They are age-matched, with similar body mass indices and both groups were off 
medication for the purposes of the studies.  The St George’s published data are in tables 3 
and 4 for comparison.  
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The heart rate in the SGH group was 20% lower than our group despite neither groups 
reported to be on medication.  Both peripheral and central systolic blood pressures were 
also lower by 5% in the SGH group.  The SGH’s group have higher Augmentation index 
(by 27%) although the standard deviations are wide.  Their group also had higher pulse 
wave velocity (by 4%) with lower amplification (by 1%).   
The SGH’s group had lower heart rates and peripheral blood pressures but were of similar 
ages.  This suggests that if this was not a true effect then maybe their drug washout time 
was too short.  The SGH group had higher Augmentation index and pulse wave velocity 
with lower amplification suggesting stiffer aortas and therefore slightly more advanced 
aortic disease.  In fact, compared to a recently published normal reference range215 for 
carotid-femoral PWV, our subjects were not different from a normal population (mean 
PWV of 6.2m/s in their normal under 30 years old cohort).  However, the two groups were 
comparable and this is reassuring firstly that our population are typical of other Marfan 
patients and secondly, that our application of Applanation Tonometry and Pulse Wave 
Velocity is accurate and similar to published data.   
The reproducibility we calculated was also excellent – the figures I have used were taken 
the first time I used the system and would be even lower in experienced hands. 
   
In conclusion, Applanation Tonometry is an attractive additional method of evaluating and 
monitoring Marfan aortic properties.  It highlights differences in central and peripheral 
blood pressures and as such could be used to monitor change over time or evaluate 
effectiveness of drug treatment.  Additionally, my patients’ results are comparable to a 
Marfan cohort and their data published from South London.    
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CHAPTER 3.3.1 
WAVE INTENSITY ANALYSIS- A Comparative Study Between a Normal and Marfan 
Population. 
Introduction 
Wave Intensity Analysis is a research tool that has been used and investigated by our 
institution for the last ten years.  It has potential attractions in our Marfan population as it 
looks specifically at aortic wave travel, aortic stiffness indices and the interaction between 
the left ventricle and the aorta as described in Chapter 1.5.  We therefore, wanted to 
investigate this tool further.  We performed WIA on a normal population and our Marfan 
population and compared the results. 
 
Methods 
60 healthy volunteers had been recruited for another study at our institution and I had 
helped with the data acquisition.  In addition, I recruited our 21 Marfan subjects as 
described in Chapter 2.1.  All were invited to attend the Wales Heart Research Institute to 
participate in a WIA study.  The Marfan population consisted of 7 men and 14 women of 
average age 29.4 ±10.8 years (see Table 1).  The healthy volunteers had no history of 
cardiovascular disease, hypertension, diabetes or major illness and none was taking any 
medication.  They consisted of 37 men and 23 women of average age 47.7 ±13.7 years.  
On arrival they underwent baseline assessment as described in Chapter 2.1.  After resting 
for ten minutes WIA was performed on them as described in Chapter 2.1 by me.   
The data was analysed using SPSS version 18.0 (SPSS Inc, Chicago, IL, USA).  The data 
were checked for Normality by inspecting histograms and Q-Q Plots.  The means and 
standard deviations were calculated and the differences between the populations analysed 
by a Mann Whitney U-test as the indices were not normally distributed.  Statistical 
significance was taken as a p value ≤0.05.   
Intraobserver Reproducibility was expressed as the Coefficients of Variation (CV).  CV was 
measured by Standard Deviation (SD)/mean x 100.  The SD is the standard deviation of 
the measurement error associated with a single measurement calculated as the SD of 
Page | 101  
 
residuals (measurement 1-measurement 2) divided by √2   I acquired two measurements 
for each key variable for each subject one staright after the other to calculate this.  
The data acquisition, set-up of the database and all statistical calculations were performed 
by me.  The separation of the net WI into the four individual waves was done by a single 
operator using software he had designed specifically for this purpose as described in 
Chapter 1.5.  
Hypothesis:  Marfan patients will have higher stiffness indices and higher wave reflections 
as evidenced by the backward compression wave. 
 
Results 
The arterial haemodynamics in each population and the differences between the two are 
shown in Tables 1 and 2. 
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Table1: Arterial Haemodynamics and Local Stiffness Indices In a Normal and 
Marfan Population 
Parameter Units Normal 
Population 
Mean ±sd 
Marfan 
Population 
Mean ±sd 
Mann 
Whitney U-
Test 
 
Number  60 21  
Sex (M/F%)  62%/38% 33%/67% P<0.05* 
Age years 47.7 ±13.7 29.4 ±10.8 p<0.001* 
Heart Rate bpm 60.8 ±9.3 57.0 ±7.3 P=0.10 
Systolic blood 
pressure 
mmHg 121.0 ±15.0 117.9 ±17.4 P=0.37 
Diastolic blood 
pressure 
mmHg 75.1 ±9.8 71.2 ±9.3 P=0.09 
Mean arterial 
blood pressure 
mmHg 90.4 ±10.9 86.8 ±10.6 P=0.12 
Local wavespeed m/s 6.7 ±3.8 10.7 ±21.6 P=0.49 
Beta stiffness 
index 
 7.6 ±2.8 5.9 ±1.8 P<0.05* 
Epsilon (Elastic 
Modulus) 
kPa 99.4 ±43.5 73.5 ±28.0 P<0.05* 
Augmentation 
index 
% 9.2 ±13.7 8.9 ±15.2 P=0.67 
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Table 2: Separated Wave Amplitudes In a Normal and Marfan Population 
 
Parameter Units Normal 
Population 
Mean ±sd 
Marfan 
Population 
Mean ±sd 
Mann-
Whitney U-
test 
Forward 
Compression 
Wave Peak 
W/m2 8.6 ±4.9 8.0 ±6.1 P=0.67 
Forward 
Compression 
Wave Integral 
W/m2 375.0 ±193.2 306.7 ±294.5 P=0.13 
Backward 
Compression 
Wave Peak 
W/m2 -2.2 ±1.6 -3.5 ±3.0 P=0.07 
Backward 
Compression 
Wave Integral 
W/m2 -111.5 ±72.4 -148.5 ±117.3 P=0.17 
Forward 
Expansion Wave 
Peak 
W/m2 2.0 ±1.0 1.6 ±1.2 P=0.07 
Forward 
Expansion Wave 
Integral 
W/m2 59.5 ±27.9 49.9 ±42.1 P=0.38 
Backward 
Expansion Wave 
Peak 
W/m2 -0.4 ±0.3 -0.6 ±0.5 P=0.30 
Backward 
Expansion Wave 
Integral 
W/m2 -13.8 ±7.4 -17.5 ±13.4 P=0.48 
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The Marfan population were significantly younger than our normal population (29.4±10.8 
years vs 47.7±13.7 years, p<0.001) and the proportion of females higher (67% vs 38%, 
p<0.05).   
The heart rates, systolic, diastolic and mean arterial blood pressures were the same 
between groups and were normal.  The two local stiffness indices, beta and epsilon were 
significantly lower in the Marfan group (p<0.05) which was unexpected.  Local wave speed 
was higher in the Marfan group (10.7±21.6 m/s vs 6.7±3.8 m/s, p=0.49) but not statistically 
significant.  This was probably in part due to the high standard deviation in the Marfan 
group which was double the mean.   
Augmentation index, expected to be higher in the Marfan group, was similar between the 
two groups.  The amplitude of the forward compression wave (FCW), an index of left 
ventricular function, was lower in the Marfan group (8.9±15.2 W/m2  vs 9.2±13.7 W/m2, 
p=0.67) but was not statistically significant.  The backward compression wave (BCW), an 
index of reflections from the peripheral vascular bed, displayed a trend of being higher in 
the Marfan group (-3.5±3.0 W/m2 vs -2.2±1.6 W/m2, p=0.07) than the normal group but 
again did not reach statistical significance.  The forward expansion wave (FEW) displayed 
a trend of being lower in the Marfan group.  The ratio of the amplitudes of the BCW to the 
FCW was 26% (normals) and 44% (Marfan group).  The differences between the two 
groups with regard the backward expansion wave (BEW) did not reach significance.   
The overall Intraobserver variability was 20%.  
 
Discussion   
Firstly, it must be highlighted that the two groups were significantly different with regard 
age and sex.  The Marfan group were significantly younger with a higher female 
preponderance.  This is due to the difficulty in getting normal age-matched controls for the 
Marfan group as described in earlier chapters.  The normal population used in this study 
were originally from another study.  It was difficult to use the younger members of the 
normal group because even they were significantly older than the Marfan population.  This 
is a flaw in the study.   
The most significant finding in this study was that the stiffness indices were higher in the 
normal group than the Marfan group.  This reflects local common carotid artery stiffness 
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and was an unexpected finding.  These results probably reflect the difference in age and 
sex between the groups.  The haemodynamics on a whole were more reflective of a 
healthy population and the measurements in both groups reflected this.  For example, the 
mean Augmentation indices in our groups of 9.2% (normals) and 8.9% (Marfans) were far 
lower than the normal controls (13.1%) in a paper looking at arterial wave reflection in a 
hypertensive group before and after treatment with barnidipine216 where the control group’s 
mean age was 58 years. 
There was a trend for the backward compression wave to be higher in the Marfan group 
which is a marker of wave reflections from the peripheral arterial bed back to the heart.  
The amplitude of BCW/FCW was also higher in the Marfan group.  Higher reflections may 
be expected in the Marfan group but the timings of the reflections would have given more 
information.  If the reflections return to the heart before aortic valve closure this increases 
left ventricular afterload and can impact on coronary perfusion. 
As described, the major limitation in this study is the difference in ages and sexes of the 
two groups.  The mean age of the Marfan group (29.4 years) was 18 years younger than 
our normal controls (47.7 years).  The normal group also contained more men: increasing 
age and male sex are positively correlated to impaired arterial haemodynamics and so the 
two groups may have been artificially similar due to these two important baseline 
characteristics.  Alternatively, the Marfan group had similar haemodynamics to a normal 
population group almost 20 years older.   
However, the results do lead to important questions concerning the validity of arterial 
measurements at the common carotid artery in a Marfan population where the pathological 
effects are seen maximally in the largest elastic arteries, namely the aorta.  Can we 
extrapolate data from the carotid and assume it accurately reflects the aorta in this group?  
We also know from previous studies that the carotid measurements are affected by 
cerebral vasomotor tone.217 
The acquisition of the data was not particularly difficult once trained and a little experience 
gained.  However, the software used is only available through one company (Aloka) at 
present and the post-processing is time-consuming.  The separation of the waves was 
done by a single person who wrote a programme specifically for this purpose - this again 
takes time.  The wave intensity signals were intrinsically noisy and affected by patient 
factors such as depth of the carotid artery and suboptimal windows.  Variation in 
respiration, movement and physiological changes also impede the signals.  Once filtering 
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and averaging procedures are introduced to decrease the noise you can lose some 
integrity of the data.  Another factor for discussion is the intraobserver and interobserver 
variabilities.  My own intraobserver variability was 20% and variability has been a large 
problem with this technique in the past.218 
Whilst theoretically Wave Intensity Analysis would be a very interesting tool to aid 
evaluation of our Marfan population, at present there are too many unanswered questions.  
These include the validity of the carotid artery to assess the aorta - although assessment 
of the proximal aorta itself is currently technically impossible.   
The variability is too high to be used routinely and the acquisition and post-processing of 
the data needs to be made more available, efficient and accurate.  Overall, this technique 
cannot be used in the routine assessment of a Marfan patient but may be in the future if 
the problems highlighted are remedied.
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CHAPTER 3.4.1 
The Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular 
Function in Marfan Syndrome – A Randomised Double-Blind Crossover Trial 
 
Introduction 
Almost exclusively, medical therapy to date in Marfan Syndrome has been with β-blockers, 
based on limited reports suggesting a reduced rate of aortic dilatation compared with no 
treatment.219  More recent data suggest that β-blockers have less effect than other 
antihypertensives on central aortic pulse pressure 220 which is one of the main 
determinants of ascending aortic dilatation 221.  Angiotensin converting enzyme inhibitors 
(ACEI) and calcium channel blockers (CCB) reduce central systolic pressure and conduit 
arterial stiffness when compared to β-blockers, in adults with hypertension.222  There are 
some recent reports of  beneficial effects of ACEI on central aortic stiffness in patients with 
Marfan syndrome 223,224  but no studies have been reported that compare the effects of 
these three classes of drugs on estimated central aortic systolic pressure and pulse 
pressure in Marfan syndrome. 
The objectives of my study were to compare the effects of an angiotensin converting 
enzyme inhibitor (perindopril), a non-dihydropyridine calcium channel blocker (verapamil) 
and a β-blocker (atenolol) on central aortic pressure, augmentation of central pressure, 
conduit arterial stiffness, and left ventricular function, in patients with Marfan syndrome. 
 
Methods 
My twenty-one Marfan patients described in Chapter 2.1 agreed to participate in the trial, 
which was conducted at the Bristol Congenital Heart Centre and the Congenital Heart 
Disease Centre, University Hospital of Wales.  18 patients started the trial (figure 1).  All 
patients received detailed written information and gave written informed consent.  The 
protocol was approved as reported in Chapter 2.1. 
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Figure 1:  Recruitment 
Inclusion criteria were subjects aged 16-60 years, who were either on no treatment, or 
were taking a β-blocker or other monotherapy only.  Patients with previous aortic 
dissection or aortic surgery, severe heart valve regurgitation, aortic diameter at the 
sinotubular junction ≥ 5.0 cm, contraindications to specific drug treatment (such as 
asthma), and women who were pregnant or at risk of pregnancy, were excluded. 
At baseline, essential anthropometric data such as height, weight, age, and disease 
severity were recorded.  Beta blockade or other monotherapy was withdrawn over a period 
of two weeks in subjects already on treatment, and then all subjects had a two-week 
period off all treatment, during which they received a placebo single-blind.  Subjects were 
then randomised double-blind to atenolol 75 mg, or perindopril 4 mg, or sustained release 
verapamil 240 mg, in a cross-over design.  These drugs and doses were selected because 
of their long half-life, to improve compliance and efficacy, and each patient was instructed 
to take the medication once daily as a single dose, at 8 a.m.  An established computer-
generated randomisation process specified the drug allocation sequence.  There was a 
two-week washout period after each treatment before a new baseline recording, during 
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which patients again received matched placebo tablets in an attempt to ensure 
compliance.  Clinical investigations were performed in the same order at each visit, 
starting 2 hours after the last dose of treatment (i.e. at peak drug concentration).  Each 
treatment was administered for 4 weeks with a total study duration for each patient of 18 
weeks (figure 2).  Each patient was requested to attend for non-invasive investigations on 
6 occasions (as a baseline before each treatment, and to assess drug effects after 4 
weeks of each treatment), and for simple blood tests alone on 3 occasions (2 weeks after 
starting treatment, to check renal function). 
 
Figure 2:  Summary of the design of the trial 
Echocardiographic Measurements 
At each visit, transthoracic echocardiography was performed as described in Chapter 2.1 
according to the recommendations of the European Association of Echocardiography.  
Aortic root diameter, left ventricular function (by conventional and tissue Doppler 
parameters), left-ventricular stroke volume (by both Doppler and Simpson techniques), 
isovolumic acceleration, peak systolic velocities and E/e’ ratio were all measured.  The 
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amplitude and timing of expansion in the aortic arch and abdominal aorta were measured 
using pulsed tissue Doppler, as previously described in chapter 1.3. 
 
Blood pressure, pulse wave analysis and pulse wave velocity 
Blood pressure in the brachial artery was measured after the subject had rested supine for 
10 minutes.  We used the Millar tonometer, Applanation Tonometry and SphygmoCor 
software to derive central aortic pressure, Augmentation index and pulse pressure 
amplification as described in Chapter 1.4.  Carotid-to-radial and carotid-to-femoral pulse 
wave velocities were also obtained, as an index of aortic stiffness.   
 
Conduit arterial stiffness (beta and epsilon indices) was estimated in the right common 
carotid artery by Wave Intensity Analysis (Chapter 1.5). 
 
Data were acquired and collected by two trained personnel (myself and Dr Damien Kenny 
in Bristol).  The statistics was performed by Prof Frank Dunstan (Professor of statistics at 
Cardiff University).   
 
Statistical analysis 
Data were checked for outlying values.  Results are expressed as mean values with 95% 
confidence intervals, unless otherwise indicated. 
Within a single period, the effect of each drug on each parameter was assessed by 
carrying out a paired t-test and calculating a confidence interval for the mean difference.  
The comparison of the three drugs was performed using a crossover analysis, with drug, 
period and subject effects, and using the baseline value as a covariate.  Residuals were 
checked for normality.  Probability values <0.05 were considered significant.  Using the 
data from published literature Ahimastos et al223, in order to detect a 10% change in 
arterial stiffness parameters and a 5% change in aortic diameters with an α=0.05, the 
study had 80% power. 
 
Results 
Fourteen of the 18 patients who were recruited, completed the trial; 4 discontinued 
because of social reasons (figure 1).  No significant adverse effects were observed.  The 
baseline characteristics of the study population are summarised in table 1. 
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Table 1: Baseline characteristics of the study population 
 
Gender Female 8, Male 6 
Age (yrs) 30.4 (11.7) 
Weight (kg) 77.7 (14.8) 
Height (m) 1.86 (0.13) 
Body Mass Index (kg/m2) 22.7 (3.8) 
Smokers 1 
Family history of dissection 6 
Urea (mmol/l) 4.60 (0.92) 
Creatinine (µmol/l) 77.3 (14.6) 
Results are expressed as mean (s.d.) 
 
Hemodynamic effects and measurements of arterial function are shown in table 2.  
Atenolol reduced resting heart rate by 16% (p=0.006) while perindopril and verapamil had 
no effect (p<0.001 for between-drug comparison). Mean cardiac output fell by 17% after 
atenolol but there were no significant changes (p=0.1). 
Although baseline blood pressure measurements were within the normal range, atenolol, 
perindopril, and verapamil all lowered both peripheral (brachial arterial) blood pressure and 
calculated central arterial pressure (all, p<0.05 for within-drug comparisons). The 
differences between the drugs were not significant – atenolol lowered central pressure by 
a mean of 7% compared with 10% after perindopril and 9% after verapamil. There were 
similar non-significant trends in augmentation index which was reduced by 44% after 
atenolol, 52% after perindopril, and 69% after verapamil. 
Aortic function as assessed by pulse wave velocity was not altered by atenolol, perindopril, 
or verapamil. Carotid arterial stiffness was also unaffected by treatment – no significant 
between-drug effects were observed in the beta index or in Peterson’s elastic modulus 
(epsilon), although a reduction in epsilon was documented after atenolol (p=0.005). 
The time interval from the onset of systole to the peak velocity of aortic systolic expansion 
was delayed by atenolol, by an average of 8% in the aortic arch and by 11% in the upper 
abdominal aorta (table III), while it was unaltered by perindopril and verapamil (p<0.01 and 
p<0.05 respectively, for between-drug comparisons). 
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Table 2:   Arterial effects of atenolol, perindopril and verapamil 
 Atenolol Perindopril Verapamil 
 Pre Post Change Pre Post Change Pre Post Change P value 
Heart rate (bpm) 61.1 51.6 -9.5* (-15.7, -3.3) 64.5 63.9 -0.62 (-8.3, 7.1) 61.4 61.4 0.0(-5.2, 5.2) <0.001 
Brachial systolic BP  
(mmHg) 122.4 110.6 -11.8* (-19.0, -4.6) 118.9 108.6 -10.3* (-17.0, -3.6) 120.1 112.8 -7.3* (-13.5, -1.1) 0.685 
Brachial diastolic BP  
(mmHg) 72.7 66.5 -6.2* (-11.6, -0.9) 72.1 67.0 -5.1* (-9.8, -0.5) 73.9 69.1 -4.8* (-8.8, -0.8) 0.967 
Mean arterial pressure  
(mmHg) 89.3 81.2 -8.1  (-13.4, -2.7) 87.7 80.9 -6.8  (-11.5, -2.2) 89.3 83.7 -5.6  (-9.3, -1.9) 0.306 
 
Peripheral pulse pressure  
(mmHg) 49.7 44.1 -5.6  (-11.4, 0.3) 46.8 41.6 -5.2  (-10.9, 0.6) 46.2 43.7 -2.5   (-9.1, 4.1) 0.630 
 
Pulse wave velocity 
(carotid-radial) (m/s) 7.9 7.6 -0.3 (-0.9, 0.2) 7.7 7.9 0.2 (-0.5, 0.8)  7.7 7.9 0.2 (-0.5, 1.0) 0.582 
 
Pulse wave velocity 
(carotid-femoral) (m/s) 7.2 6.6 -0.6 (-1.3, 0.2) 6.8 6.6 -0.2 (-0.7, 0.3) 6.8 6.8 0 (-0.4, 0.5) 0.724 
Augmentation index (%) 7.3 4.0 -3.2 (-7.0, 0.6) 12.2 5.9 -6.3 (-12.8, 0.2) 8.0 2.5 -5.5 (-11.6, 0.7) 0.780 
Central systolic BP (mmHg) 103.9 96.8 -7.1* (-12.3, -1.9) 105.8 95.4 -10.3* (-16.1, -4.6) 104.9 95.8 -9.2* (-14.6, -3.7) 0.776 
Central pulse pressure (mmHg) 32 30.3 -1.7 (-6.9, 3.6) 30.6 27.8 -2.8 (-7, 1.3) 29.8 26.7 -3.2 (-8.1, 1.8) 0.180 
Pulse pressure 
amplification (mmHg) 1.48 1.39 -0.09 (-0.27, 0.09) 1.51 1.45 -0.06 (-0.31, 0.19) 1.52 1.47 -0.09  (-0.29, 0.20) 0.084 
Beta (units) 6.81 5.79 -1.02 (-2.04, 0.00) 6.20 5.65 -0.54 (-1.56, 0.47) 6.76 6.13 -0.64 (-2.34, 1.06) 0.487 
Epsilon (kPa) 86.9 66.9 -20.0* (-32.1, -7.9) 78.0 71.5 -6.6 (-19.0, 5.9) 84.7 75.4 -9.3 (-24.8, 6.3) 0.198 
The Values expressed as means (95% confidence intervals).  
* p<0.05 for changes from baseline for each drug.  P value (in last column) = summary for comparison between drugs. 
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Table 3:  Echocardiographic comparisons of atenolol, perindopril and verapamil 
 
 
 Atenolol Perindopril Verapamil 
 Pre Post       Change Pre Post     Change Pre Post      Change P value 
Aortic root diameter 
(at sinuses of Valsalva) (cm) 3.77 3.78 0.01 (-0.11, 0.12) 3.77 3.75 -0.02 (-0.13, 0.09) 3.83 3.80 -0.03 (-0.17, 0.10) 0.848 
Aortic root diameter 
(at sinotubular junction) (cm) 3.49 3.59 0.1 (-.08, 0.27) 3.63 3.39 -0.23* (-0.43, -0.04) 3.48 3.50 -0.02 (-0.09, 0.13) 0.059 
Doppler LV stroke volume (ml) 71.9 63.5 -8.5 (-22.8, 5.9) 69.8 68.0 -1.8 (-9.6, 5.9) 69.6 71.0 1.4 (-8.8, 11.5) 0.210 
Doppler cardiac output (l/min) 4.6 3.8 -0.8 (-2.2, 0.6) 4.4 4.5 0.1 (-0.6, 0.8) 4.6 4.5 -0.1 (-0.9, 0.7) 0.110 
LV ejection fraction (%) 53.2 57.5 4.2 (-4.9, 13.2) 55.3 54.2 -1.1 (-9.0, 6.9) 57.9 52.4 -5.5 (-11.9, 0.8) 0.052 
Vs mean (cm/s) 5.5 5.5 0.0 (-0.5, 0.5) 5.9 6.1 0.2 (-0.3, 0.7) 5.9 5.8 -0.0 (-0.6, 0.5) 0.180 
Isovolumic acceleration (m/s
2
) 3.0 2.3 -0.8 (-1.8, 0.3) 2.6 2.8  0.3 (-0.8, 1.3) 2.8 2.8 -0.04 (-1.1, 1.0) 0.211 
E/e’ ratio (units) 6.1 6.4 0.3 (-0.7, 1.3) 6.2 6.3 0.1 (-0.7, 0.9) 6.0 5.7 -0.3 (-1.2, 0.7) 0.450 
Time to peak systolic velocity 
(aortic arch) (ms) 119 129 10* (0, 20) 120 123  3 (-12, 19) 115 112 -3 (-12, 6) 0.003 
Time to peak systolic velocity 
(abdominal aorta) (ms) 180 200 20* (11, 28) 184 189 5 (-2, 12) 179 190 11*(1, 21) 0.043 
 
Values expressed as means (95% confidence intervals). * p<0.05 for changes from baseline for each drug;  P value (in last column) = summary for comparison 
between drugs. Vs mean: peak systolic velocity of longitudinal function, averaged at 6 sites around the mitral annulus. E mitral inflow velocity, e’ lateral mitral annular 
velocity, both measured in early diastole.
Page | 114  
 
Echocardiographic studies 
The results of the detailed echocardiographic studies are shown in table 3. 
Global left ventricular function (ejection fraction), longitudinal left ventricular function 
(mean velocity of long-axis systolic shortening), and estimated mean filling pressure 
(E/e’) as an index of diastolic function, were not altered by atenolol, perindopril, or 
verapamil.  Isovolumic acceleration was reduced by an average of 27% after atenolol 
while it was unchanged or increased with the other drugs, but there were no significant 
differences. 
After four weeks of treatment with perindopril, a small reduction (-6%) was observed in 
the mean diameter of the aorta at the level of the sino-tubular junction (p=0.024), but 
no change was observed after perindopril in the diameter at the sinuses of Valsalva 
and there were no significant differences between drugs. 
 
Discussion 
The results of this small study must be interpreted with caution but the detailed non-
invasive comparisons that were performed raise interesting questions.  Unexpectedly, 
we demonstrated that in young patients with Marfan syndrome, central arterial pressure 
was reduced by atenolol as well as by perindopril and verapamil, although to a lesser 
extent. 
A strength of our trial was its cross-over, double-blind design, but the protocol was 
demanding of patients since they were asked to attend for 6 visits within 18 weeks; its 
weakness was that of 55 eligible patients who were asked to participate, only 21 
initially agreed to do so and fewer completed the study.  For ethical considerations, 
subjects were restricted to those whose aortic root dimensions were <5 cm.  Many 
previous pharmacologic studies in Marfan syndrome have had similar numbers of 
subjects 225, however, and it would be impractical to undertake similarly detailed 
investigations in a large clinical trial. 
 
Rationale of the study design 
The primary goal of medical treatment in patients with Marfan syndrome is to reduce 
the rate of dilatation of the aortic root.  Since a major determinant is central pulse 
pressure 221 we selected classes of drugs that have been demonstrated to lower central 
pulse pressure in subjects with hypertension 220,226 – an ACEI (perindopril) and a CCB 
(verapamil) – and preparations with a long half-life so that they could be given once 
daily in order to optimise compliance. 
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After our trial was started, experimental studies in an animal model demonstrated that 
the angiotensin receptor blocker (ARB), losartan, may prevent or delay the phenotypic 
expression of Marfan syndrome 227 by antagonising TGF-β and slowing or even 
reversing defragmentation of the elastic fibres of the aorta.  ACE inhibitors have similar 
effects on TGF-β signalling. 223,228 They also reduce angiotensin II levels which are 
associated with cystic medial degeneration contributing to aortic rupture in Marfan 
syndrome 229.  The scientific rationale for testing an ARB in children with Marfan 
syndrome is strong 230 and initial clinical experience is promising 231, but the benefit is 
unproven, and in older subjects ACEI may be an effective alternative. 
CCBs reduce central aortic pressures in adult hypertensive patients 226 but similar 
effects in patients with Marfan syndrome have not been described.  One small study of 
combined treatment demonstrated a slower rate of aortic enlargement compared with 
placebo 232.  We chose a CCB with negative chronotropic and dromotropic properties. 
Atenolol was included as standard treatment of patients with Marfan syndrome, yet this 
practice is based on few reports 225.  The strongest evidence comes from a prospective 
randomised trial comparing propranolol with no treatment, by Shores et al 219.  They 
concluded that the benefit of β-blockade in Marfan patients was caused by a reduced 
rate of rise of central arterial pressure (+dp/dt).  Further reports have demonstrated 
reduced aortic root dilatation 233,234 but the effects of β-blockade on aortic compliance 
have been varied 235,236 and one study reported an increase in central aortic pressure 
and wall stress 237.  In young patients, side-effects such as excessive tiredness may 
reduce compliance.  Since atenolol is not the most effective drug at lowering central 
pressure in patients with hypertension, its routine use in Marfan syndrome has been 
questioned. 
Our study is the first formal comparison of an ACEI, CCB and β-blocker in Marfan 
syndrome.  Our hypothesis was that the ACEI and CCB would both lower central aortic 
pressure, whereas the β-blocker would not, but this was not confirmed. 
 
Central hemodynamic effects 
In healthy young people, blood pressure measured in the arm by sphygmomanometry 
is an uninformative indicator of pressure in the ascending aorta, because of the 
phenomenon of peripheral pulse pressure amplification,238 in older subjects it may also 
be inaccurate, due to augmentation of central pressures caused by earlier wave 
reflections in stiffer aortas.  We therefore used applanation tonometry to estimate 
central arterial pressure.  We demonstrated that all three drugs lowered both peripheral 
and central pressures. 
Perindopril and verapamil reduced systolic pressure in the ascending aorta, as 
expected.  They reduced augmentation index more than atenolol did, but the changes 
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were not significant, perhaps because the within-subject variability of some 
measurements in our study was quite high, as reflected in their confidence intervals, 
and this reduced the power for identifying differences between the drugs.  Ahimastos et 
al compared perindopril with placebo over 24 weeks in a double-blind trial in 17 
patients with Marfan syndrome; they observed only small reductions (-1 mmHg) in 
mean brachial blood pressure and in carotid arterial pulse pressure, and they did not 
report central aortic pressure 223.  In patients with hypertension, changes in carotid 
pressure with ACEI have correlated with reductions in peripheral blood pressure.239  
ACEIs may alter reverse remodelling in small arteries 238, and a distal shift in the origin 
of peripheral reflections would delay wave travel and reduce augmentation of central 
pressures, without any change in conduit arterial function. 
None of the drugs significantly reduced central pulse wave velocity, which is an index 
of aortic stiffness.  In the other recent study, perindopril did reduce pulse wave velocity 
and increase aortic compliance in patients with Marfan syndrome, but after 24 
weeks223, and so it is possible that our study was too short to demonstrate these 
effects. The measurements of wave velocity and augmentation index that we obtained 
were similar to those reported in Marfan patients by Kiotsekoglou et al 240 and higher 
than those observed in normal age-matched controls.241  Pulse wave velocity was also 
unaltered in hypertensive subjects who were given atenolol, perindopril, lercanidipine 
and bendroflumethiazide.242 
This study was not designed to examine the longer term impact of treatment on the 
rate of aortic root dilatation, but we noted a small but significant reduction in the 
diameter of the aorta at the level of the sino-tubular junction after perindopril had been 
given for only 4 weeks. Ahimastos et al reported a greater effect after 24 weeks, with 
reductions in diameter of 3-7 mm 223 that correlated with reduced circulating levels of 
TGF-β and matrix metalloproteinase-3.243  Similar changes have not been reported and 
would not be expected with verapamil, and since it reduced central pressures in our 
study but did not slow heart rate, it would not have any advantage over an ACEI in the 
treatment of patients with Marfan syndrome. 
Indices of local arterial stiffness in the common carotid artery (beta and epsilon) were 
not altered.  We observed a reduction in epsilon after treatment with atenolol (-23%; 
compared with -8% after perindopril, and -11% with verapamil) but there were no 
significant differences between drugs.  It is now uncertain if the carotid arteries are 
significantly affected by Marfan syndrome, and it is possible that stiffness is increased 
especially in the thicker-walled aorta where there is more elastic tissue. More studies 
are needed to investigate regional variations in conduit arterial function in Marfan 
syndrome 244, in order to identify indices that can best serve as surrogate targets for 
monitoring treatment. 
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Beta-blockade in Marfan syndrome 
This study tested the hypothesis that β-blockade would not lower central pressure, 
because it causes vasoconstriction that shifts arterial reflection sites proximally, 
compared with ACEI and/or CCB,245 and because it is not as effective at lowering 
central pressure in arterial hypertension.220  Atenolol did reduce central arterial 
pressure, however, to a lesser degree than was observed with the ACEI and CCB.  
This might be explained by a reduction in cardiac output (which fell by a mean of 17%, 
p=0.24) related to the reduction in heart rate (by a mean of 16%, p=0.006) more than to 
any change in stroke volume (-12%, p=0.22).  Alternatively, a negative inotropic effect 
would be expected to reduce the amplitude of aortic wave reflections during systole.  It 
has been demonstrated using non-invasive measurements of wave intensity that the 
amplitude of the forwards-travelling compression wave during ejection correlates well 
with LV +dp/dt246, and also that the energy of mid-systolic wave reflections (the 
backwards-travelling compression wave, which augments central aortic systolic 
pressure) can largely be accounted for by the amplitude of the forward compression 
wave.247  Baumgartner et al observed improved aortic elastic properties in 70% of 30 
patients treated with atenolol for an average of 39 months, particularly in those with 
smaller aortic root diameters.244 
Isovolumic acceleration (IVA) is a non-invasive indicator of LV contractility 248 but it has 
high variability.249  In our study, there was a trend for IVA to be reduced with atenolol 
whereas it was unchanged with perindopril and verapamil.  The mean velocity of long-
axis shortening of the left ventricle, which is inversely related to arterial stiffness, was 
lower than normal values for age-matched subjects, but was unaltered by treatment. 
The timing of the onset of systolic expansion in the aorta can be measured accurately 
with tissue Doppler, as first reported in children with Marfan syndrome by Harada et 
al.250  We report the first use of this measurement in adults with Marfan syndrome.  
Atenolol but not perindopril or verapamil delayed wave travel in the arch and abdominal 
aorta.  The clinical significance of this finding is uncertain but it suggests that atenolol 
reduced +dp/dt. 
In engineering, the fatiguing effect of cyclic stressors depends on the number of cycles 
as well as the amplitude of stress. Beneficial effects on aortic dilatation with β-blockers 
may be due to a reduction in heart rate rather than in the amplitude of central 
distending forces. Lowering brachial systolic pressure and pulse pressure does not 
appear to affect aortic dilatation.251 
It may be premature to abandon β-blockers in Marfan patients, and nebivolol, a beta-1 
receptor blocker with nitric oxide potentiating vasodilatory effects, may be a more 
appropriate choice than atenolol.  In patients with hypertension, it reduces central pulse 
Page | 118  
 
pressure and augmentation index more than atenolol252, and it reduces central arterial 
pressure and left ventricular hypertrophy more than metoprolol.253 
 
Conclusions 
Recent experimental studies have prompted several large prospective clinical trials of 
ARBs in children and adults with well-characterised Marfan syndrome.  The results are 
eagerly awaited and may change clinical practice.  This study adds weight to the 
argument that ACEI may also be effective, but more importantly, perhaps, it suggests 
that a combination of a β-blocker with an ARB or an ACEI may be the most effective. 
This strategy is also being tested.254  While an ARB or ACEI may lower central 
pressures by reducing or delaying peripheral reflections, a β-blocker may reduce 
reflections by an effect on the left ventricle.
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CHAPTER 4 
DISCUSSION 
 
What The Results Show 
We have investigated several new parameters and three new tools –Tissue Doppler 
Imaging; Applanation Tonometry; and Wave Intensity Analysis- to assess Marfan 
patients in order to extract more information about the pathology of the aorta and the 
left ventricle and the interaction between the two.  This has the aim of better 
quantitative assessment of a Marfan aorta’s properties to improve the timing of surgery; 
aiding a clinician’s evaluation of risk in Marfan patients; and assessing the effects of 
medical therapy.  The ultimate aim is to improve the mortality and morbidity associated 
with aortic dissection and rupture in Marfan Syndrome.   
 
Tissue Doppler Imaging 
Chapter 3.1.1 showed that there is considerable variability in myocardial velocities and 
deformation between different echocardiography machines, used by different 
operators, in the same patients.   There appears to be no consensus amongst Industry 
to standardise their machines.  The poor intermachine correlations were especially 
marked with strain and strain rate (r=0.19 and 0.18) but improved with peak systolic 
velocities (up to r=0.64 with high frame rates). 
With such low correlations, it must be considered whether the use of strain and strain 
rate is reliable enough to be used in echocardiography labs that have more than one 
type of machine or if a patient changes hospital.  Certainly, the lack of equivalence 
between machines must be highlighted and remembered clinically.  The causes of 
these differences need to be understood and overcome by standard acquisition, 
tracking and signal averaging if the diagnostic potential of Tissue Doppler is to be 
optimised. 
Chapter 3.1.2 looked specifically at two parameters of left ventricular function by tissue 
Doppler imaging.  IVA, which is unaffected by loading and peak systolic mitral annular 
velocities which are.  These two parameters were investigated because of their ability 
to detect subclinical left ventricular impairment and also because they can assess 
regionality, two important aspects which the currently used Ejection fraction cannot 
assess.  IVA had considerable problems with variability.  We calculated an 
intraobserver variability of 28% and interobserver variability of 30% and these figures 
are consistent with the Margulescu paper.255  Acquisition of the trace was not difficult 
but there were problems in calculating the slope needed and this has been shown to 
worsen as left ventricular function reduces (Margulescu).  I conclude that IVA may be 
used as a research tool but the clinical applicability is hampered by low reproducibility.   
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Peak systolic velocity at the mitral annulus however did exhibit significant differences 
between the normal control group and the three abnormal populations in all six 
ventricular walls.  The measurements were far easier to acquire and measure and the 
intraobserver (5% for the normal group and 8% for the abnormal group) and 
interobserver (10% for both groups) variabilities were much lower compared to that 
seen with IVA.  Therefore, peak systolic velocity may have a role in the future 
assessment of Marfan Syndrome. 
The last study looking specifically at tissue Doppler imaging was reported in Chapter 
3.1.3.  I was excited by the Harada paper investigating tissue Doppler measurements 
in the abdominal aorta in Marfan Syndrome and wanted to reproduce their findings.256  
However, as the abdominal aorta is less affected than the ascending aorta and arch in 
Marfan Syndrome, we designed a study to investigate the more proximal part of the 
aorta and to calculate tissue doppler-derived timings as a marker of stiffness.  In 
practice, there was a high intraobserver variability (CV of 35%) when measuring the 
timings.  This was caused by poor echo windows in a population known to have 
thoracic musculoskeletal abnormalities and difficulty in knowing exactly where you 
place your sample volume.  If these aspects can be addressed this may be an 
interesting parameter to revisit. 
 
Applanation Tonometry 
Chapter 3.2 investigated the tool of Applanation Tonometry.  It can give measurements 
of central aortic pressures and stiffness that usually would have to be made invasively.  
There seems to be a change in thinking in the Hypertension world when it comes to 
accurately assessing blood pressure away from peripheral measurements and there 
are similarities between the hypertensive and Marfan populations.  I found the 
Sphygmocor system easy to use and did not take a lot of training which is important in 
a new tool like this.  My intraobserver reproducibility for central systolic blood pressure 
was 1%, for Augmentation index it was 18% and for Pulse Wave Velocity it was 6%.  
This remains an exciting new tool used increasingly frequently in hypertensive research 
and starting to be used clinically.  It would certainly add to the assessment in Marfan 
Syndrome. 
 
Wave Intensity Analysis 
Wave Intensity was studied in Chapter 3.3.1 because it can measure the interaction 
between the left ventricle and the aorta giving measurements equating to left 
ventricular function, peripheral reflections and aortic stiffness indices.  However, we 
found that the signals were very noisy and as such the intraobserver variability was 
20%.  The validity of the carotid artery to assess the aorta is a problem with WIA but 
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currently it cannot be used at the aortic root.  A further problem is the acquisition and 
post-processing of the data, which needs to be made more available, efficient and 
accurate.  Overall, this technique cannot be used in the routine assessment of a 
Marfan patient but may be in the future especially if the aorta itself can be scanned and 
if the variability is reduced. 
 
Study Limitations 
Chapter 3.1.1 showed intermachine variation in some important echocardiography 
parameters used in clinical practice including those that would be theoretically useful in 
Marfan Syndrome.  I have described the problems with statistical help in the chapter 
and the lack of statistics is an issue.  Four different echocardiographers were employed 
and each used the same echo machine.  This is an important confounder and requires 
more advanced statistical help.   
 
A major drawback to the sub-studies undertaken (Chapters 3.1.3, 3.2.1, 3.3.1) was the 
lack of a normal, age-matched control group.  As described before, this was due to the 
main study Chapter 3.4.1 using a cross-over design and therefore, the Marfan subjects 
were their own controls.  This showed a lack of foresight on my part at the start of the 
MD.  Chapter 3.1.2 studied TDI in patients with medical disorders chosen due to their 
similarity to Marfan Syndrome in producing subclinical left ventricular dysfunction.  
However, these groups were dissimilar due to the nature of the disorders themselves 
and by the age and sex of patients who suffer from these disorders.  Ideally, I should 
have studied groups or a single group of similar age and sex to our Marfan population. 
 
The main limitation of the medical intervention study, Chapter 3.4.1, is the low number 
of Marfan subjects.  However, this was much more difficult to amend.  I approached 
everyone that met the inclusion criteria known to the UHW Genetics team in Cardiff 
and wrote to all Cardiology Consultants in South Wales as part of the recruitment drive.  
I also involved a second regional centre in Bristol to increase the numbers using their 
South West England cohort which went as far as Cornwall.  I was also involved in 
discussions with the Institute of Child Health, London but the logistics of me travelling 
to London became too much and we couldn’t find a local fellow to help.  It therefore, 
must be accepted that there will not be enough Marfan patients who meet the inclusion 
criteria in one or even two regional centres.    
 
Regional Aortic Variation 
The characteristics of Marfan Syndrome are caused by abnormal fibrillin in elastic 
tissues and therefore, tissues that contain a lot of elastin are affected (for example, the 
Page | 122  
 
eyes, aorta).  We also know that the arterial system contains progressively less elastin 
the more distally you go.  What is uncertain, however, is how these different vessels 
are affected.  We investigated three tools, two of which looked at other arteries as 
surrogates for central aortic effects.  Using the radial, carotid and femoral arteries may 
be misleading if the lack of pathology in these more distal arteries belies pathology 
proximally.  I feel there is a need for a post-mortem study looking at the regionality of 
arterial involvement in Marfan Syndrome and also robust testing of Applanation 
Tonometry and Wave Intensity Analysis in the Marfan population. 
 
What Drugs To Use 
Chapter 3.4 investigated three drugs used in Marfan Syndrome and their effects on 
some of the parameters from the three different tools of Tissue Doppler Imaging, 
Applanation Tonometry and Wave Intensity Analysis.  Atenolol was investigated as the 
current treatment of choice in many practices but also because I believed it would 
perform badly in comparison with the other two drugs due to its relatively smaller effect 
on central aortic pressure and increased peripheral reflections.  I chose perindopril 
because it does reduce central aortic pressure and also reduces vascular smooth 
muscle cell apoptosis.  The third drug chosen was verapamil because it reduces 
central aortic pressure and it is negatively chronotropic. 
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Table 1:  Advantages and Disadvantages of the Medical Therapies in Marfan 
Syndrome 
 
Drug Advantages Disadvantages 
Beta Blockers -Negatively chronotropic 
-Antiarrhythmic 
-Less effective in reducing 
central arterial pressure 
(CAP). 
-Increase peripheral 
reflections 
-Side effect profile 
-No effect on TGF-β 
ACEIs -↓CAP 
-↓VSMC apoptosis 
-low side effect profile 
-benefits poor LV function 
-no effect on TGF-β 
-no effect on HR 
Calcium Channel Blockers -↓CAP 
-↓heart rate 
-low side effect profile 
-no effect on TGF-β 
ARBs -↓CAP 
-↓TGF-β 
-low side effect profile 
-benefits poor LV function 
-no effect on HR 
-no anti-arrhythmic effects 
Nitrates -↓CAP -no effect on TGF-β 
-no effect on LV 
-no effect on HR 
-moderate side effect 
profile 
 
In the medical treatment study I found that the beta blocker, Atenolol, did reduce CAP, 
although less than verapamil and perindopril, and that this may be due to its negatively 
chronotropic and inotropic effect.  Basically, if the heart beats less often and less hard 
then there will be less of an impact on the abnormal aorta, especially over the course of 
many years. 
As shown in table 1, there are a number of currently available drugs that may have 
benefits in retarding aortic dilatation in Marfan Syndrome.  A caveat is that none of the 
drugs above have been proven to slow dilatation, reduce dissection or improve 
mortality in a blinded, randomised control trial in humans.  ARBs have only proven to 
be of benefit if you are a mouse with Marfan Syndrome.  The beta blockers have less 
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effect in reducing central aortic pressure; have had mixed results in the literature; and 
the landmark Shores paper 257, which is the evidence given for taking beta blockers, 
has no mortality data.258  ACEIs may be of benefit but do not antagonise TGF-β which 
seems an important property as it had such an impact on the mouse model of Marfan 
Syndrome. 
 
The answer to the drug question would appear to be in 2 parts.  Firstly, design and run 
a large, multicentre, multinational blinded, randomised control trial in order to get the 
patient numbers needed to see the effects.  We managed to investigate only 14 
patients recruiting from Camarthen to Cornwall and using the resources of two large 
tertiary referral centres.  Investigators need to measure the correct parameters using 
the most appropriate tools: aortic dilatation and subtle left ventricular impairment using 
TTE including TDI; central aortic pressure and aortic stiffness using Applanation 
Tonometry and run it over many years to get morbidity (aortic surgery, dissection) and 
mortality data.  Secondly, use drugs that may theoretically benefit.  We now know that 
there are certain factors to target –Heart rate; CAP and stiffness; TGF-β; and VSMC 
apoptosis.  There is added benefit if a drug is anti-arrhythmic or has a beneficial effect 
on left ventricular function.  These factors may only be fully targeted by using 
combination therapy and so this also should be further investigated.  For example, the 
beta blocker Nebivolol, which has arterial vasodilatory properties, may be a good 
choice plus an ARB/ACEI; or if asthmatic Verapamil plus an ARB/ACEI. 
 
Further Problems 
There are other issues in addition to the lack of randomised control trial data in 
humans; not knowing what drug(s) to prescribe; and only using the older, more 
traditional assessments of left ventricular and aortic pathology. 
 
Diagnostic Problems 
The third version of diagnostic criteria since 1986 have recently been published–firstly 
the Berlin criteria were used, then the Ghent criteria and now the Revised Ghent 
criteria.  The authors describe in their paper that the latest criteria “may delay a 
definitive diagnosis of Marfan Syndrome but will facilitate worldwide discussion of risk 
and follow-up/management guidelines.”     
The diagnosis is, of course, very important.  It has all sorts of implications from 
stigmatisation (especially in exercise-restricted children) to insurance and mortgage 
issues.  It can lead to restriction in career aspirations and an increased financial burden 
from frequent outpatient appointments.  The anticipated reduction in lifespan can lead 
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to anxiety and depression.  There are also issues around marital and reproductive 
decisions in this autosomal dominant condition.   
However, the diagnosis can also be comforting.  These patients are often in the 
medical system for years pre-diagnosis not knowing what is wrong with them and living 
in uncertainty often visiting a number of different medical specialities.  Just having a 
concrete diagnosis often reduces anxiety and stress and enables the patient to contact 
helpful organisations such as the Marfan Association UK. 
The diagnosis, however, is difficult and in our own Marfan population, one subject was 
taken out of the trial because he did not have Marfan Syndrome despite being 
followed-up for some time with serial echocardiography in the local Cardiology clinic.   
 
Follow-Up Problems 
Other patients in our group were followed up in a variety of clinics including Cardiology, 
Rheumatology, Genetics, under the care of the General Practitioner or Opticians or 
under no follow-up at all.  This reveals another problem in this syndrome, that is, the 
lack of a multi-team approach to a multisystem problem.  This seems to become more 
of an issue when the Marfan children reach adulthood and have to leave the more 
generalist paediatric clinic.   
I believe there should be regional centres for patients with Marfan Syndrome with a 
multi-team approach to clinics led by an expert in Marfan Syndrome, with input from 
ophthalmology, rheumatology, cardiology and genetics.  Ideally, this would be in a 
tertiary centre with inpatient access to cardiothoracic surgery where the surgeons 
perform high volume aortic work.   
There should also be a national registry so we know who has the diagnosis which 
would make research easier, especially as the process of research is being made more 
difficult with increasing amounts of form-filling (Chapter 2.1). 
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The Future 
The future assessment of people with a possible diagnosis of Marfan Syndrome should 
involve: 
 
The right patient – with a firm diagnosis of Marfan Syndrome by the Revised Ghent 
Nosology or being followed-up appropriately due to a possible diagnosis but not yet 
fulfilling the full diagnostic criteria; 
being monitored by the right Consultants – ophthalmology, rheumatology, cardiology 
and genetics in a specific Marfan multi-disciplinary clinic in a tertiary centre with 
cardiothoracic surgeons experiencing high volumes of aortic and chest wall surgery 
with a research ethos;  
having the right assessment – TTE looking at aortic dimensions serially using the 4 
Roman aortic measurements indexed for BSA.  Using the same echo machines in a 
department which monitors/audits the measurements it’s echocardiographers make.  
Using TDI to monitor for subclinical left ventricular systolic dysfunction.  Using 
Applanation tonometry to evaluate central aortic pressure, augmentation, amplification 
and stiffness indices by Pulse Wave Velocity.  Researching some of the other 
parameters I have looked at such as WIA and IVA; 
taking the right medications – I suggest beta blockers at present or ACEIs or ARBs if 
they cannot take beta blockers.  Ongoing trials will hopefully tell us whether BBs or 
ARBs or combination therapy reduces aortic dilatation, aortic dissection, cardiovascular 
surgery and death; 
all based on the right trials – Multicentre, multinational, randomised, prospective, 
blinded controlled trials investigating BBs, ACEIs, ARBs, CCBs and combinations 
looking at left ventricular and aortic parameters, TGF-β, MMP, VSMC apoptosis in 
genotyped subjects over a long enough time period so we see the hard end-points of 
aortic dilatation, aortic dissection, cardiovascular surgery and death.  If there are 
deaths then I feel it would be important for a thorough post-mortem to determine 
causality. 
 
With the number and quality of ongoing and recently started trials looking into the 
medical therapy in Marfan Syndrome (Table 1) I feel the future is as bright as it has 
been since that famous Medical Society Meeting in Paris in 1896. 
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Table 1:  Ongoing or Future Marfan Syndrome Trials March 2012:  www.clinicaltrials.gov and www.nhs.uk  
 
 
 
 
Title Investigators Medication Patient 
number 
Start 
Date 
End 
Date 
Age 
years 
Trial Type 
1 Atenolol vs Losartan in the Prevention of 
Progressive Dilation of the Aorta in MFS (LO-AT-
ARFAN01). 
Dr Albert Forteza, Spain Atenolol vs 
Losartan 
140 Oct 
2008 
Feb 
2013 
5-60 Echo: 
Aortic diameter. 
2 Effects of Losartan vs Atenolol on Aortic and 
Cardiac Muscle Stiffness in Adults with MFS. 
Mark Creager, Boston, 
Mass, USA 
Atenolol vs 
Losartan 
50 Oct 
2007 
Jan 
2012 
>25 Echo, 
AT: 
Aortic stiffness, 
LV diastolic function. 
 
3 Study of the Efficacy of Losartan on Aortic 
Dilatation in Pts with MFS (MARFANSARTAN). 
 
Guillaume Jondeau, Paris, 
France 
Losartan vs 
Placebo 
300 Sept 
2008 
March 
2014 
≥10 Echo: 
Aortic diameter. 
4 Losartan vs Atenolol for the Treatment of MFS. George Sandor, 
Vancouver, BC, Canada 
Losartan vs 
Atenolol 
17 Jan 
2008 
Dec 
2011 
12-25 PWV 
Echo. 
5 Comparison of 2 Medications Aimed at Slowing 
Aortic Root Enlargement in Individuals with MFS 
– Pediatric Heart Network. 
Lynn Sleeper, New 
England Research 
Institutes 
(NHLBI, NMF) 
Losartan vs Atenolol 604 Jan  
2007 
March 
2014 
6 
month 
to 25 
Echo 
Single-blind. 
6 A Randomised, Open-Label, Losartan therapy 
on the Progression of Aortic Root Dilation in Pts 
with MFS. 
Mei-Hwan Wu, Taipei, 
Taiwan 
Losartan plus atenolol or 
propranolol vs Atenolol or 
propranolol 
44 Feb 
2007 
Jun 
2011 
≥1yr Echo 
Open-label. 
7 Nebivolol vs Losartan vs Nebivolol+Losartan 
Against Aortic root Dilation in Genotyped MFS 
Pts (MaNeLo). 
Eloisa Arbustini, Pavia, 
Italy 
Nebivolol vs Losartan vs 
Nebivolol+Losartan 
291 Jul 
2008 
Jul 2013 1-55 Echo, 
TGF-β, 
Gene expression, 
Carotid arterial stiffness. 
8 Randomised, Double-Blind study for the 
Evaluation of the effect of Losartan vs Placebo 
on Aortic Root Dilatation in Pts with MFS under 
Treatment with Beta-blockers. 
Julie De Backer, Ghent, 
Belgium 
Losartan or 
Placebo added to β-blocker 
174 Jun 
2009 
Dec 
2014 
≥10 Echo, Aortic stiffness by MRI, Genetic 
polymorphisms (losartan). 
9 The Effects of Irbesartan on Aortic Dilatation in 
MFS. 
Michael Mullen, Royal 
Brompton Hospital, UK 
Irbesartan vs 
Placebo 
490 Sept 
2010 
 >6<40 Echo. 
10 Losartan and MFS –the COMPARE Study. M Groenink, Amsterdam, 
Netherlands 
Losartan + normal meds vs 
no treatment + normal meds  
330 Feb 
2008 
 Adult MRI, Echo, Skin biopsy-for gene + protein 
expression. Open-label. 
 
 
Page | 128  
 
PUBLICATIONS RELATED TO THE THESIS 
 
 
Stuart AG, Williams A. Marfan syndrome and the heart. Arch Dis Child 2007:92;351-
356. 
 
 
Williams A, Davies S, Stuart AG, Wilson DG, Fraser AG. Medical treatment of Marfan 
syndrome: a time for change. Heart 2008:94;414-421. 
 
 
Williams A, Kenny D, Wilson D, Fagenello G, Nelson M, Dunstan F, Cockcroft J, 
Stuart G, Fraser AG.  Effects of atenolol, perindopril and verapamil on haemodynamic 
and vascular function in Marfan syndrome - a randomised, double-blind, crossover trial.  
Eur J Clin Invest. 2012 Aug;42(8):891-9.  
 
 
Williams A, Rohani AM, Anderson T, Andersson T, Edwards J, Gherginescu C, Rajiv 
C, McDicken N, Roberts A, Fraser AG. The M4 Study – An echocardiographic 
intermachine comparison of myocardial velocity and strain.  With supervisor awaiting 
submission. 
 
 
Williams A, Fraser AG.  Intermachine and interoperator variability in measuring 
myocardial velocities and deformation.  International Presentation at Euroecho 9, 
European Society of Cardiology, Florence in December 2005 and printed in European 
Journal of Echocardiography 2005:Vol 6 (Supp 1) S90.
Page | 129  
 
REFERENCES 
CHAPTER 1.1 
 
1 Marfan AB. Un cas de deformation congenitale des quatre membres, plus 
prononcee aux extremites, characterisee par l'allongement des os avec un certain 
degre d'amincissement. Bull Soc Mem Hop Paris 1896;13:220-226. 
2 Mery H, Babonneix L. Un cas de deformation congenitale des quatres membres 
hyperchondroplasie. Bull Soc Med Hop Paris 1902; 19:671. 
3 Salle V. Ueber einen fall von angeborner abnormen Grosse der Extremitaten 
mit einen an Akronemegalia erinerden Symptomenkomplex. Jahrb Kinderkeilk 
1912;75,540-550. 
 
4 Pyeritz RE. The Marfan syndrome. Annu Rev Med 2000;51:481-510. 
 
5 McKusick VA. The cardiovascular aspects of Marfan Syndrome. Circulation 
1955;11:321-342. 
6 Murdock JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA. Life 
expenctancy and causes of death in Marfan Syndrome. NEJM 1972;286:804-808. 
7 Judge DP, Dietz HC. Marfan's syndrome. Lancet 2005; 366(9501):1965-1976. 
8 http://www.umd.be 
9 Dietz HC, Pyeritz RE, Hall BD, Cadhe RG, Hamosh A, Schwartz J et al. The 
Marfan syndrome locus: confirmation of assignment to chromosome 15 and 
identification of tightly linked markers at 15q15-q21.3. Genomics 1991;9:355-361. 
10 Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, 
Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, Spevak PJ, Cameron DE, De 
Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, 
De Paepe AM, Dietz HC.  A syndrome of altered cardiovascular, craniofacial, 
neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. 
Nature Genetics 2005:37(3);275-281. 
11 Ramirez F, Rifkin DB. Cell signaling events: a view from the matrix. Matrix Biol 
2003;22(2):101-107. 
12 DePaepe A, Devereux RB, Dietz H, Hennekamn R, Pyeritz R. Revised 
diagnostic criteria for the Marfan Syndrome. Am J Med Genet 1996;62:417-426. 
13 Beighton P, de Paepe A, Danks D, Finidori G, Gedde-Dahl T, Goodman R, Hall 
JG, Hollister DW, Horton W, McKusick VA. International Nosology of Heritable 
Disorders of Connective Tissue, Berlin. Am J Med Genet 1988:29;581-594. 
14 Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, 
Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, 
Wordsworth P, De Paepe AM. The revised Ghent nosology for the Marfan syndrome. J 
Med Genet 2010:47;476-485. 
15 Koenigsberg M, Factor S, Cho S, Herskowitz A, Nitowsky H, Morecki R. Fetal 
Marfan syndrome:prenatal ultrasound diagnosis with pathological confirmation of 
skeletal and aortic lesions. Prenatal Diagnosis 1981;1:241-247. 
16 Lipscomb KJ, Clayton-Smith J, Harris R. Evolving phenotype of Marfan's 
syndrome. Archives of Disease in Childhood 1997;76:41-46. 
Page | 130  
 
17 Anonymous. American Academy of Pediatrics - Committee on genetics.  Health 
Supervision for children with Marfan Syndrome. Pediatr 1996;98(5):978-982. 
18 Hennekam RC. Severe infantile Marfan syndrome versus neonatal Marfan 
syndrome. Am J Med Genet A 2005;139(1):1. 
19 ter Heide H, Schrander-Stumpel CT, Pals G, Delhaas T. Neonatal Marfan 
syndrome: clinical report and review of the literature. Clin Dysmorphol 2005;14(2):81-
84. 
20 Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, Giampietro 
PF, Zaleski C, Estrera AL, Safi HJ, Shete S, Willing MC, Raman CS, Milewicz DM.  
Mutations in Transforming Growth Factor-[beta] Receptor Type II Cause Familial 
Thoracic Aortic Aneurysms and Dissections. Circn 2005;112:513-520. 
21 Gray JR, Bridges AB, West RR. Life expenctancy in British Marfan Syndrome 
populations. Clin Genet 1998;54:124-128. 
 
22 www.gad.gov.uk/Life_Tables 
 
23 Silverman DI, Burton BS, Gray J.  Life expectancy in the Marfan Syndrome. Am 
J Cardiol 1995;75:157-160. 
 
24 Januzzi JL, Marayati F, Mehta RH. Comparison of aortic dissection in patients 
with and without Marfan Syndrome. Am J Cardiol 2004;94:400-402. 
25 Radford DJ, Izukawa T. Atrial fibrillation in children. Pediatr 1977;59(2):250-256. 
26 Johnson CD. The Wolff-Parkinson-White syndrome associated with Marfan's 
syndrome. Bol Asoc Med P R 1989;81(9):361-364. 
27 Tsai-Goodman B, Wilson DG, Davies S, Stuart AG. ECG abnormalities in 
children with Marfan Syndrome: Is QT dispersion a useful measurement of 
arrhythmogenicity? Cardiol in the Young 2001;11[suppl 1],309.  
 
28 Chen S, Fagan LF, Nouri S, Donahoe JL. Ventricular dysrhythmias in children 
with Marfan's syndrome. Am J Dis Child 1985;139(3):273-276. 
29 Savolainen A, Kupari M, Toivonen L, Kaitila I, Viitasalo M. Abnormal ambulatory 
electrocardiographic findings in patients with the Marfan syndrome. J Intern Med 
1997;241(3):221-226. 
30 Yetman AT, Bornemeier RA, McCrindle BW. Long-term outcome in patients 
with Marfan syndrome: is aortic dissection the only cause of sudden death? J Am Coll 
Cardiol 2003;41(2):329-332. 
31 Robinson TF, Cohen-Gould L, Remily RM, Capasso JM, Factor SM. 
Extracellular structures in heart muscle. Adv Myocardiol 1985;5:243-255. 
32 Savolainen A, Nisula L, Keto P, Hekali P, Viitasalo M, Kaitila I et al. Left 
ventricular function in children with the Marfan syndrome. Eur Heart J 1994;15(5):625-
630. 
33 De Backer JF, Devos D, Segers P, Matthys D, Francois K, Gillebert TC et al. 
Primary impairment of left ventricular function in Marfan syndrome. Int J Cardiol 
2006;112(3):353-358. 
Page | 131  
 
34 Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional 
echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 
1989;64(8):507-512. 
35 Rozendaal L, Groenink M, Naeff MS, Hennekam RC, Hart AA, Van der Wall EE 
et al. Marfan syndrome in children and adolescents: an adjusted nomogram for 
screening aortic root dilatation. Heart 1998;79(1):69-72. 
36 Groenink M, Rozendaal L, Naeff MS, Hennekam RC, Hart AA, Van der Wall EE 
et al. Marfan syndrome in children and adolescents: predictive and prognostic value of 
aortic root growth for screening for aortic complications. Heart 1998;80(2):163-169. 
37 Roman MJ, Rosen SE, Kramer-Fox R, Devereux RB. Prognostic significance of 
the pattern of aortic root dilatation in the Marfan Syndrome. J Am Coll Cardiol 
1993;22(5):1470-1476. 
38 Knirsch W, Kurtz C, Haffner N, Binz G, Heim P, Winkler P et al. Dural ectasia in 
children with Marfan syndrome: a prospective, multicenter, patient-control study. Am J 
Med Genet A 2006;140(7):775-781. 
39 Oosterhof T, Groenink M, Hulsmans FJ, Mulder BJ, Van der Wall EE, Smit R et 
al. Quantitative assessment of dural ectasia as a marker for Marfan syndrome. 
Radiology 2001;220(2):514-518. 
40 Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. 
Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, 
and Marfan syndrome. J Am Coll Cardiol 2005;45(8):1340-1345. 
41 Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity 
enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 
2003;42(11):1959-1963. 
42 Hirth A, Reybrouck T, Bjarnason-Wehrens B, Lawrenz W, Hoffmann A. 
Recommendations for participation in competitive and leisure sports in patients with 
congenital heart disease: a consensus document. Eur J Cardiovasc Prev Rehabil 
2006;13(3):293-299. 
43 Fletcher GF, Balady G, Blair SN, Blumenthal J, Caspersen C, Chaitman B et al. 
Statement on exercise: benefits and recommendations for physical activity programs 
for all Americans. A statement for health professionals by the Committee on Exercise 
and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart 
Association. Circulation 1996;94(4):857-862. 
44 Moriguchi J, Itoh H, Harada S, Takeda K, Hatta T, Nakata T et al. Low 
frequency regular exercise improves flow-mediated dilatation of subjects with mild 
hypertension Hypertens Res 2005;28(4):315-321. 
45 Mason NJ, Jenkins AJ, Best JD, Rowley KG. Exercise frequency and arterial 
compliance in non-diabetic and type 1 diabetic individuals. Eur J Cardiovasc Prev 
Rehabil 2006;13(4):598-603. 
46 Raitakari OT, Ronnemaa T, Jarvisalo MJ, Kaitosaari T, Volanen I, Kallio K et al. 
Endothelial function in healthy 11-year-old children after dietary intervention with onset 
in infancy: the Special Turku Coronary Risk Factor Intervention Project for children 
(STRIP). Circulation 2005;112(24):3786-3794. 
47 Cuevas AM, Germain AM. Diet and endothelial function. Biol Res 
2004;37(2):225-230. 
Page | 132  
 
48 Adams JN, Brooks M, Redpath TW, Smith FW, Dean J, Gray J et al. Aortic 
distensibility  and stiffness index measured by magnetic resonance imaging in patients 
with Marfan's syndrome. British Heart Journal 1995;(73):265-269. 
49 Groenink M, Lohuis TA, Tijssen JG, Naeff MS, Hennekam RC, Van der Wall EE 
et al. Survival and complication free survival in Marfan's syndrome: implications of 
current guidelines. Heart 1999;82(4):499-504. 
50 Nollen GJ, Groenink M, Tijssen JG, Van der Wall EE, Mulder BJ. Aortic stiffness 
and diameter predict progressive aortic dilatation in patients with Marfan syndrome. Eur 
Heart J 2004;25(13):1146-1152. 
51 Tsang VT, Pawade A, Karl TR, Mee RBB. Surgical management of Marfan 
syndrome in children. J Card Surg 1994;9:50-54. 
52 Bentall H, De Bono A. A technique for complete replacement of the ascending 
aorta. Thorax 1968;23(4):338-339 
53 Birks EJ, Webb C, Child A, Radley-Smith R, Yacoub MH. Early and long-term 
results of a valve-sparing operation for Marfan syndrome. Circulation 1999;100(19 
Suppl):II29-II35. 
54 Patel ND, Williams JA, Barreiro CJ, Bethea BT, Fitton TP, Dietz HC et al. Valve-
sparing aortic root replacement: early experience with the De Paulis Valsalva graft in 
51 patients. Ann Thorac Surg 2006;82(2):548-553. 
55 de Oliveira NC, David TE, Ivanov J, Armstrong S, Eriksson MJ, Rakowski H et 
al. Results of surgery for aortic root aneurysm in patients with Marfan syndrome. J 
Thorac Cardiovasc Surg 2003;125(4):789-796. 
56 Vricella LA, Williams JA, Ravekes WJ, Holmes KW, Dietz HC, Gott VL et al. 
Early experience with valve-sparing aortic root replacement in children. Ann Thorac 
Surg 2005;80(5):1622-1626. 
57 Golesworthy T, Lamperth M, Mohiaddin R, Pepper J, Thornton W, Treasure T. 
The Tailor of Gloucester: a jacket for the Marfan's aorta. Lancet 2004;364(9445):1582. 
58 Shaddy RE, Hawkins JA. Immunology and failure of valved allografts in 
children. Ann Thorac Surg 2002;74(4):1271-1275. 
59 Stark J. The use of valved conduits in pediatric cardiac surgery. Pediatr Cardiol 
1998;19(4):282-288. 
60 Treasure T. Cardiovascular surgery for Marfan syndrome. Heart 
2000;84(6):674-678. 
61 Lemaire SA, Carter SA, Volguina IV, Laux AT, Milewicz DM, Borsato GW et al. 
Spectrum of Aortic Operations in 300 Patients With Confirmed or Suspected Marfan 
Syndrome. Ann Thorac Surg 2006;81(6):2063-2078. 
62 Cattaneo SM, Bethea BT, Alejo DE, Spevak PJ, Clauss SB, Dietz HC et al. 
Surgery for aortic root aneurysm in children: a 21-year experience in 50 patients Ann 
Thorac Surg 2004;77(1):168-176. 
CHAPTER 1.2   
 
63 Hirata K, Triposkiadis F, Sparks E, Bowen J, Wooley CF, Boudoulas H. The 
Marfan Syndrome: abnormal elastic properties. J Am Coll Cardiol 1991;18(1):57-63. 
 
Page | 133  
 
64 Bridges AB, Gray JR, McLaren M, et al. Endothelial and platelet function in 
Marfan Syndrome.  Endothelium 1993;1;203-206. 
 
65 Wilson DG, Bellamy MF, Ramsey MW, Goodfellow J, Brownlee M, Davies S et 
al. Endothelial function in Marfan syndrome: selective impairment of flow-mediated 
vasodilation. Circulation 1999;99(7):909-915. 
 
66 Neptune ER, Frischmeyer PA, Arking DE, et al.  Dysregulation of TGF-β1 
activation contributes to pathogenesis in Marfan Syndrome.  Nat Genet 2003:33;407-
411. 
 
67 Ng CM, Cheng A, Myers LA, et al.  TGF-β1-dependent      pathogenesis of 
mitral valve prolapse in a mouse model of Marfan Syndrome.  J Clin Invn 
2004:114;1586-1592. 
 
68 Habashi JP, Judge DP, Holm TM, et al.  Losartan, an AT1 antagonist, prevents 
aortic aneurysm in a mouse model of Marfan Syndrome.  Science 2006:312;117-121. 
 
69 Halpern BL, Char F, Murdoch JL, et al.  A prospectus on the prevention of aortic 
rupture in the Marfan Syndrome with data on survivorship without treatment.  Johns 
Hopkins Med J 1971:129;123-129. 
 
70 Ose L, McKusick VA.  Prophylactic use of propranolol in the Marfan Syndrome 
to prevent aortic dissection.  Birth Defects Orig Artic Ser 1977:13(3C);163-169. 
 
71 Reed CM, Alpert BS. Assessment of ventricular performance after chronic beta-
adrenergic blockade in the Marfan Syndrome. Am J Cardiol 1992:70;541-2. 
 
72 Reed CM, Fox ME, Alpert BS. Aortic biomechanical properties in paediatric 
patients with the Marfan Syndrome, and the effects of atenolol. Am J Cardiol 
1993:71;606-8. 
 
73 Tahernia AC. Cardiovascular anomalies in Marfan’s Syndrome: the role of 
echocardiography and beta blockers. Southern Med J 1993:86;305-310.  
 
74 Shores J, Berger KR, Murphy E, et al. Progression of aortic dilatation and the 
benefit of long-term beta-adrenergic blockade in Marfan Syndrome. N Eng J Med 
1994:330;1335-1341. 
 
75 Salim MA, Alpert BS, Ward JC, et al. Effect of beta-adrenergic blockade on 
aortic root dilatation in the Marfan Syndrome. Am J Cardiol 1994:74;629-632. 
 
76 Silverman DI, Burton KL, Gray J, et al.  Life expectancy in the Marfan’s 
Syndrome. Am J Cardiol 1995:75;157-160. 
 
77 Legget ME, Unger TA, O’Sullivan CK, et al.  Aortic root complications in Marfan 
Syndrome:identification of a lower risk group.  Heart 1996:75;389-395.  
 
78 Haouzi A, Berglund H, Pelikan PCD, et al. Heterogeneous aortic response to 
acute beta-adrenergic blockade in Marfan Syndrome. Am Heart J 1997:133;60-63. 
 
79 Groenink M, de Roos A, Mulder BJ, et al. Changes in aortic distensibility and 
pulse wave velocity assessed with magnetic resonance imaging following beta-blocker 
therapy in the Marfan Syndrome. Am J Cardiol 1998:82;203-8. 
 
Page | 134  
 
80 Rossi-Foulkes R, Roman MJ, Rosen SE, et al. Phenotypic features and impact 
of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan 
Syndrome. Am J Cardiol 1999:83;1364-1368. 
 
81 Rios AS, Silber EN, Bavishi N, et al. Effect of long-term beta-blockade on aortic 
root compliance in patients with Marfan Syndrome. Am Heart J 1999:137;1057-61. 
 
82 Nollen GJ, Westerhof BE, Groenink M, et al. Aortic pressure-area relation in 
Marfan patients with and without β blocking agents: a new non-invasive approach. 
Heart 2004:90;314-318. 
 
83 Yetman AT, Bornemeier RA, McCrindle BW.  Usefulness     of enalapril versus 
propranolol or atenolol for the prevention of aortic dilation in patients with the Marfan 
Syndrome.  Am J Cardiol 2005:95;1125-1127. 
 
84 Ladouceur M, Fermanian C, Lupoglazoff J-M, et al. Effect of beta-blockade on 
ascending aortic dilatation in children with the Marfan Syndrome. Am J Cardiol 
2007:99;406-409. 
 
85 Tierney ESS, Feingold B, Printz BF, et al.  Beta-blocker therapy does not alter 
the rate of aortic root dilatation in pediatric patients with Marfan Syndrome. J Pediatr 
2007:150;77-82. 
 
86 Ahimastos AA, Aggarwal A, D’Orsa KM, et al.  Effect of perindopril on large 
artery stiffness and aortic diameter in patients with Marfan Syndrome.  JAMA 
2007:298(13);1539-1547. 
 
87 Brooke BS, Habashi JP, Judge DP et al.  Angiotensin II blockade and aortic root 
dilation in Marfan’s Syndrome.  NEJM 2008:358(26);2787-2831 
 
88 Ringer RK.  Influence of reserpine on early growth, blood pressure and 
dissecting aneurysms in turkeys.  CIBA Summit, NJ 1959;21-28. 
 
89 Wheat MW, Palmer RF, Bartley TD, et al.  Treatment of dissecting aneurysms 
of the aorta without surgery.  J Thorac Cardiovasc Surg 1965:50;364. 
 
90 Cholley BP, Shroff SG, Sandelski J, et al.  Aortic and other vascular disease: 
differential effects of chronic oral antihypertensive therapies on systemic arterial 
circulation and ventricular energetics in African-American patients.  Circulation 
1995:91;1052-1062. 
 
91 London GM, Asmar RG, O’Rourke MF, et al.  Mechanism(s) of selective systolic 
blood pressure reduction after a low-dose combination of perindopril/indapamide in 
hypertensive subjects: comparison with atenolol.  JACC 2004:43;92-9.  
 
92 Hirata K, Vlachopoulos C, Adji A, et al.  Benefits from angiotensin-converting 
enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond 
the brachial artery?  J of Hypert 2005:23;551-556. 
 
93 Dhakam Z, McEniery CM, Yasmin, et al.  Atenolol and Eprosartan: differential 
effects on central blood pressure and aortic pulse wave velocity.  AJH 2006:19;214-
219. 
 
94 Murdoch JL, Walker BA, Halpern BL, et al. Life expectancy and causes of death 
in the Marfan Syndrome. N Engl J Med 1972:286;804-808. 
 
Page | 135  
 
95 Joannides R, Richard V, Moore N, et al.  Influence of sympathetic tone on 
mechanical properties of muscular arteries in humans.  Am J Physiol 
1995:268(2Pt2);H794-801. 
 
96 Yin FC, Brin KP, Ting CT, et al. Arterial haemodynamic indexes in Marfan’s 
Syndrome. Circulation 1989:79;854-62. 
 
97 Meijboom LJ, Westerhof BE, Nollen GJ, et al. Eur J Cardiothorac Surg 
2004:26;901-906. 
 
98 Gersony DR, McClaughlin MA, Jin Z, Gersony WM. Int J Cardiol 2007:114;303-
308. 
 
99 Robinson RF, Nahata MC, Batisky DL, et al.  Pharmacologic treatment of 
chronic paediatric hypertension.  Paediatr Drugs 2005:7(1);27-40. 
 
100 Roman MJ, Rosen SE, Kramer-Fox R, Devereux RB. Prognostic significance of 
the pattern of aortic root dilatation in the Marfan’s Syndrome. J Am Coll Cardiol 
1993:22;1470-1476. 
 
101 American Academy of Paediatrics, Committee on Genetics. Health supervision 
for children with Marfan Syndrome. Pediatrics 1996:98;978-982. 
 
102 Lacourciere Y, Beliveau R, Conter HS, et al.  Effects of perindopril on elastic 
and structural properties of large arteries in essential hypertension.  Can J Cardiol 
2004:20;795-799. 
 
103 Nagashima H, Sakomura Y, Aoka Y, et al.  Angiotensin 2 type receptor 
mediated vascular smooth muscle cell apoptosis in cystic medial degeneration 
associated with Marfan’s Syndrome. Circulation 2001:104(Suppl I);I-282-7. 
 
104 Nagashima H, Uto K, Sakomura Y, et al. An angiotensin-converting enzyme 
inhibitor, not an angiotensin 2 type 1 receptor blocker, prevents -aminopropionitrile 
monofumarate-induced aortic dissection in rats. J Vasc Surg 2002:36;818-23. 
 
105 Schieffer B, Bunte C, Witte J, et al.  Comparative effects of angiotensin-1 
antagonism and angiotensin-converting enzyme inhibition on markers of inflammation 
and platelet aggregation in patients with coronary artery disease.  J Am Coll Cardiol 
2004:44;362-368. 
 
106 Dzau VJ.  Significance of the vascular renin-angiotensin pathway.  
Hypertension 1986:8;553-559. 
 
107 Lavoie P, Robitaille G, Agharazii M, et al.  Neutralisation of transforming growth 
factor-beta attenuates hypertension and prevents renal injury in uraemic rats.  J 
Hypertens 2005:23;1895-1903. 
 
108 Lim D-S, Lutucuta S, Bachireddy P, et al.  Angiotensin II blockade reverses 
myocardial fibrosis in a transgenic mouse model of human hypertrophic 
cardiomyopathy.  Circulation 2001:103;789-791. 
 
109 http://www.marfan.org/nmf. 
 
110 Yang HHC, Kim JM, Chum E et al. Effectiveness of combination of losartan 
potassium and doxycycline versus single-drug treatments in the secondary prevention 
of thoracic aortic aneurysm in Marfan Syndrome. J Thorac Cardiovasc Surg 
2010:140;305-312. 
Page | 136  
 
 
111 http://www.controlled-trials.com (ISRCTN28168217). 
 
112 Benjamin IJ.  Matrix Metalloproteinases: From biology to therapeutic strategies 
in cardiovascular disease.  J Inv Med 2001:49(5);381-397. 
 
113 Segura AM, Luna RE, Horiba K, et al.  Immunohistochemistry of matrix 
metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of 
patients with Marfan’s Syndrome.  Circulation 1998:98;II331-337. 
 
114 Thompson RW, Baxter BT.  MMP inhibition in abdominal aortic aneurysms.  
Rationale for a prospective, randomised clinical trial.  Ann N Y Acad Sci 1999:878;159-
178. 
 
115 Curci JA, Mao D, Bohner DG, et al.  Preoperative treatment with doxycycline 
reduces aortic wall expression and activation of matrix metalloproteinases in patients 
with abdominal aortic aneurysms.  J Vasc Surg 2000:31;325-342. 
 
116 Xiong W, Knispel RA, Dietz HC et al. Doxycycline delays aneurysm rupture in a 
mouse model of Marfan Syndrome. J Vasc Surg 2008:47;166-172 
 
117 Chung AWY, Yang HHC, Radomski MW, van Breemen C. Long-term 
doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in 
Marfan Syndrome through the inhibition of Matrix Metalloproteinase-2 and -9. Circ Res 
2008:102;e73-85.  
 
117 Zieman SJ, Kass DA.  Advanced glycation endproduct crosslinking in the 
cardiovascular system.  Drugs 2004:64(5);459-470.  
 
118 Vaitkevicius PV, Lane M, Spurgeon H, et al.  A cross-link breaker has sustained 
effects on arterial and ventricular properties in older rhesus monkeys.  Proc Natl Acad 
Sci USA 2001:98(3);1171-1175. 
 
119 Kass DA, Shapiro EP, Kawaguchi M, et al.  Improved arterial compliance by a 
novel advanced glycation end-product crosslink breaker.  Circulation 2001:104;1464-
1470. 
 
120 Giusti B, Porciani MC, Brunelli T, et al.  Phenotypic variability of cardiovascular 
manifestations in Marfan Syndrome. Possible role of hyperhomocysteinaemia and 
C677T MTHFR gene polymorphism.  Eur Heart J 2003:24(22);2038-2045. 
 
122 www.nhs.uk 
 
 
CHAPTER 1.3 
123 Chambers J, Masani N, Hancock J, Wharton G, Ionescu A. A Minimum dataset 
for a standard adult transthoracic echocardiogram from the British Society of 
Echocardiography Education Committee. Web page 2005. http://www.bsecho.org/. 
 
124 Roman MJ, Devereux RB, Kramer-Fox R, O’Loughlin J. Two-dimensional 
echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 
1989:64(8):507-521. 
 
125 Groenink M, Lohuis TA, Tijssen JG et al. Survival and complication free survival 
in Marfan’s syndrome: implications of current guidelines. Heart 1999;82:499-504. 
Page | 137  
 
 
126 Nollen GJ, Groenink M, Tijssen JG, et al. Aortic stiffness and diameter predict 
progressive aortic dilatation in patients with Marfan syndrome. Eur Heart J 
2004;25:1146-1152. 
 
127 Roman MJ, Rosen SE, Kramer-Fox R, et al. Prognostic significance of the 
pattern of aortic root dilatation in the Marfan syndrome. J Am Coll Cardiol 
1993;22:1470-1476. 
 
128 Pacini, L, Digne F, Boumendil A, Muti C, Detaint D, Boileau, Jondeau G. 
Maternal complication of pregnancy in Marfan Syndrome. Int J Cardiol 
2009;136(2):156-161. 
 
129 Oosterhof T, Groenink M, Hulsmans FJ et al. Quantitative assessment of dural 
ectasia as a marker for Marfan syndrome. Radiology 2001;220:514-518. 
 
130 Judge DP, Dietz HC. Marfan’s syndrome. Lancet 2005;366:1965-1976. 
 
131 Lemaire SA, Carter SA, Volguina IV, et al. Spectrum of aortic operations in 300 
patients with confirmed or suspected Marfan syndrome. Ann Thorac Surg 2006;81:674-
678. 
 
132 Child AH. Marfan Syndrome-current medical and genetic knowledge: how to 
treat and when. J Card Surg 1997;12:131-135. 
 
133 Rozendaal L, Groenink M, Naeff MS, Hennekam RC, Hart AA, Van der Wall EE 
et al. Marfan syndrome in children and adolescents: an adjusted nomogram for 
screening aortic root dilatation. Heart 1998;79(1):69-72. 
 
134 Vinereanu D, Khokhar A, Fraser AG. Reproducibility of pulsed wave tissue 
Doppler echocardiography. J Am Soc Echocardiogr. 1999;12:492-499. 
 
135 Galiuto L, Ignone G, DeMaria AN. Contraction and relaxation velocities of the 
normal left ventricle using pulsed-wave tissue Doppler echocardiography. Am J Cardiol 
1998;81:609-614.  
 
136 Yamada H, Oki T, Tabata T, Iuchi A, Ito S. Assessment of left ventricular 
systolic wall motion velocity with pulsed tissue Doppler imaging: comparison with peak 
dP/dt of the left ventricular pressure curve. J Am Soc Echocardiogr 1998;11:442-449. 
 
137 Pasquet A, Armstrong G, Beachler L, Lauer MS, Marwick TH. Use of segmental 
tissue Doppler velocity to quantitate exercise echocardiography. J Am Soc 
Echocardiogr 1999;12:901-912. 
 
138 Altinmakas S, Dagdeviren B, Uyan C, Keser N, Gumus V, Pektas O. Prediction 
of viability by pulsed-wave Doppler tissue sampling of asynergic myocardium during 
low-dose dobutamine challenge. Int L Cardiol 2000;74:107-113.  
 
139 Greenbaum RA, Ho SY, Gibson DG, Becker AE, Anderson RH. Left ventricle 
fibre architecture in man. Br Heart J 1981;45:248-258. 
 
140 Marwick TH. Measurement of strain and strain rate by echocardiography. 
Ready for prime time? J Am Coll Cardiol 2006;47:1313-1327. 
  
141 Sun JP, Popovic ZB, Greenberg NL et al. Non-invasive quantification of regional 
myocardial function using Doppler-derived velocity, displacement, strain rate and strain 
in healthy volunteers: effects of aging. J Am Soc Echocardiogr 2004;17:132-138. 
Page | 138  
 
 
142 Urheim S, Edvardsen T, Torp H, Angelsen B, Smiseth OA. Myocardial strain by 
Doppler echocardiography. Validation of a new method to quantify regional myocardial 
function. Circulation 2000;102:1158-1164. 
 
143 Edvardsen T, Gerber BL, Garot J, Bluemke DA, Lima JA, Smiseth OA. 
Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain 
rate echocardiography in humans: validation against three-dimensional tagged 
magnetic resonance imaging. Circulation 2002;106:50-56. 
 
144 Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed 
by tissue velocity, strain and strain rate tissue Doppler echocardiography in patients 
with AL (primary) cardiac amyloidosis. Circulation 2003;107:2446-2452. 
 
145 Weidemann F, Eyskens B, Mertens L, et al. Quantification of regional right and 
left ventricular function by ultrasonic strain rate and strain indexes in Freidreich’s 
ataxia. Am J Cardiol 2003;91:622-626. 
 
146 Kato TS, Noda A, Izawa H et al. Discrimination of nonobstructive hypertrophic 
cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain 
rate imaging by tissue Doppler ultrasonography. Circulation 2004;110:3808-3814. 
 
147 Rajiv C, Vinereanu D, Fraser AG. Tissue Doppler imaging for the evaluation of 
patients with hypertrophic cardiomyopathy. Current Opin Cardiol 2004;19:430-436. 
 
148 Weidemann F, Breunig F, Beer M et al. Improvement of cardiac function during 
enzyme replacement therapy in patients with Fabry disease: a prospective strain rate 
imaging study. Circulation 2003;108:1299-1301. 
 
149 Sohn DW, Chai IH, Lee DJ, Kim HC, Oh BH, Lee MM, Park YB, Choi YS, Seo 
JD, Lee YW. Assessment of mitral annulus velocity by Doppler tissue imaging in the 
evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997;30:474-480. 
 
150 Vogel M, Schmidt MR, Kristiansen SB et al. Validation of myocardial 
acceleration during isovolumic contraction (IVA) as a novel noninvasive index of RV 
contractility: comparison with ventricular pressure-volume relations in an animal model. 
Circulation 2002;105:1693-1699. 
 
151 Vogel M, Cheung MMH, Li J, Kristiansen SB, Schmidt MR, White PA, Sorensen 
K, Redington AN. Noninvasive assessment of left ventricular force-frequency 
relationships using tissue Doppler-derived isovolumic acceleration. Validation in an 
animal model. Circulation 2003;107:1647-1652. 
 
152 Margulescu AD, Thomas DE, Ingram TE, Vintila VD, Egan MA, Vinereanu D, 
Fraser AG. Can isovolumic acceleration be used in clinical practice to estimate 
ventricular contractile function? Reproducibilty and regional variation of a new 
noninvasive index. J Am Soc Echocardiogr 2010;23(4):423-431. 
 
153 Harada K, Yasuoka K, Shimada Y. Usefulness of tissue Doppler imaging for 
assessing aortic wall stiffness in children with the Marfan Syndrome. Am J Cardiol 
2004;93:1072-1075. 
CHAPTER 1.4 
154  O’ Rourke MF. Principles and deﬁnitions of arterial stiffness, wave reﬂections 
and pulse pressure ampliﬁcation. In Safar ME, O’Rourke MF (editors), Arterial stiffness 
in hypertension. Handbook of Hypertension. Elsevier; 2006.Vol 23:3–19. 
 
Page | 139  
 
155 The Task force for the management of Arterial Hypertension on the European 
Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 
guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-
1053. 
 
156 Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive 
drug classes on central aortic pressure. Am J Hypertens 2004; 
17:118–123. 
 
157 The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT) Investigators, CAFE Steering Committee and Writing Committee, Williams B, 
Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, 
O’Rourke M. Differential Impact of blood pressure-lowering drugs on central aortic 
pressure and clinical outcomes: Principal Results of the Conduit Artery Function 
Evaluation (CAFE) Study. Circulation 2006;113:1213-1225. 
 
158 Nichols WW, O’Rourke MF. McDonald’s Blood Flow in Arteries. Theoretical, 
experimental and clinical principles. 1998, 4th Edition. Arnold. London. 
 
159 Chen CH, Nevo E, Fetics B et al. Estimation of central aortic pressure waveform 
by mathematical transformation of radial tonometry pressure. Validation of generalised 
transfer function. Circulation 1997:195(7);1827-1836. 
 
160 Siebenhofer A, Kemp CRW, Sutton AJ, William B.  The reproducibility of central 
aortic blood pressure measurements in healthy subjects using applanation tonometry 
and sphygmocardiography. J Human Hypertension 1999:13;625-629. 
 
161 Karamanoglu M, O’Rourke MF, Avolio AP et al. An analysisi of the relationship 
between central aortic and peripheral upper limb pressure waves in man. Eur Heart J 
1993;14:160-167.  
 
162 Takazawa K, O’Rourke MJ, Fujita M et al. Estimation of ascending aortic 
pressure from radial arterial pressure using a generalised transfer function. Zeitschrift 
fur Kardiologie 1996:85(Suppl 3);137-139.  
 
163 Roman MJ, Kizer JR. Centralblood pressure better predicts cardiovascular 
events than does peripheral blood pressure: The Strong Heart Study. Circulation 
2005;112:3362. 
 
164 Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, 
Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, 
Ostergren J for the ASCOT Investigators. Prevention of cardiovascular events with an 
antihypertensive regimen of amlodipine adding perindopril as required versus atenolol 
adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac outcomes 
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised 
controlled trial. Lancet 2005;366:895-906. 
 
165 Bramwell JC, Hill AV. The velocity of the pulse wave in man. Proceedings of the 
Royal Society, London, Ser B. 1992;93:298-306. 
 
166 Moens AI. Die Pulskurve. Leiden ed. 1878. 
167 Korteweg DJ. Uber die Fortpflanzungsgesschwindigkeit des Schalles in 
elastischen Rohren. Annals of Physics and Chemistry(NS). 1878;5:520-537. 
 
168 O’Rourke MF, Staessen JA, Vlachopoulos C, et al. Clinical Applications of 
Arterial Stiffness; definitions and reference values. Am Journal of Hyperte. 2002;5:770-
798. 
Page | 140  
 
 
169 Laurent S, Cockcroft JR, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, 
Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H. Expert consensus 
document on arterial stiffness: methodological issues and clinical applications. Eur 
Heart J. 2006;27:2588-2605.  
 
170 Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact 
of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-
2439. 
 
171 Yin FCP, Brin KP, Ting C-T, Pyeritz RE. Arterial haemodynamic indexes in 
Marfan’s Syndrome. Circulation 1989;79:854-862. 
 
172 Mortensen K, Aydin MA, Rybczynski M, Baulmann J, Schahidi NA, Kean G, 
Kuhne K, Bernhardt AM, FranzenO, Mir T, Habermann C, Koschyk D, Ventura R, 
Willems S, Robinson PN, Berger J, Reichenspurner H, Meinertz  T, Von Kodolitsch Y. 
Augmentation index relates to progression o aortic disease in adults with Marfan 
Syndrome. Am J Hypertens 2009;22(9):971-979. 
 
173 Jondeau G, Boutouyrie P, Lacolley P, Laloux B, Dubourg O, Bourdarias J-P, 
Laurent S. Central pulse pressure is a major determinant of ascending aorta dilation in 
Marfan Syndrome. Circulation 1999;99:2677-2681. 
 
174 Kiotsekoglou A, Moggridge JC, Kapetanakis V, Newey VR, Kourliouros A, 
Mullen MJ, Kaski JC, Nassiri DK, Camm J, Sutherland GR, Child AH. Assessment of 
carotid compliance using real time vascular ultrasound image analysis in Marfan 
Syndrome. Echocardiography 2009;26(4):441-451. 
 
175 Groenink M, de Roos A, Mulder BJ, Verbeeten B, Timmermans J, Zwinderman 
AH, Spaan JAE, van der Wall EE. Biophysical properties of the normal-sized aorta in 
patients with Marfan Syndrome: Evaluation with MR flow mapping. Radiology 
2001;219:535-540. 
 
176 Segers P, De Backer J, Devos D, Rabben SI, Gillebert TC, Van Bortel LM, De 
Sutter J, De Paepe A, Verdonck PR. Aortic wave reflection coeeficients and their 
association with global indexes of ave reflection in healthy controls and patients with 
Marfan Syndrome. Am J Physiol Heart Circ Physiol 2006;290:H2385-H2392. 
 
177 Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of Enalapril versus 
Propranolol or Atenolol for prevention of aortic dilation in patients with the Marfan 
Syndrome. Am J Cardiol 2005;95:1125-1127. 
 
178 Ahimastos AA, Aggarwal A, D’Orsa KM, Formosa MF, White AJ, Savarirayan R, 
Dart AM,Kingwell BA. Effects of perindopril on large artery stiffness and aortic root 
diameter in patients with Marfan Syndrome: a randomised controlled trial. JAMA 
2007;298(13):1539-1547. 
 
 
 
CHAPTER 1.5 
179 Parker KH, Jones CJH. Forwards and backwards running waves in the arteries: 
analysis using the method of characteristics. ASME J Biomech Eng 1990;112:322-326. 
  
Page | 141  
 
180 Bleasedale RA, Parker KH, Jones CJH. Chasing the wave. Unfashionable but 
important new concepts in arterial wave travel. Am J Physiol Heart Circ Physiol 
2003;284:H1879-H1885. 
 
181 Sugawara M, Niki K, Furuhata H, Ohnishi S, Suzuki S. Relationship between 
the pressure and diameter of the carotid artery in humans. Heart Vessels 2000;15:49-
51. 
 
182 Matlab 6.1. The Maths Works Inc, Natick, MA, USA. 
 
183 Khir AW, O’Brien A, Gibbs JS, Parker KH. Determination of wave speed and 
wave separation in the arteries. J Biomech 2001;34:1145-1155. 
 
184 Liang Y-L, Teede H, Kotsopoulos D, Shiel L, Cameron JD, Dart AM, McGrath 
BP. Non-invasive measurements of arterial structure and function: repeatability, 
interrelation and trial sample size. Clin Sci 1998;95:669-679. 
 
185 Ohte N, Narita H, Sugawara M, Niki K, Okada T, Harada A, Hayano J, Kimura 
G. Clinical usefulness of carotid arterial wave intensity in assessing left ventricular 
systolic and early diastolic performance. Heart Vessels 2003;18:107-111. 
 
186 Parker KH, Jones CJH, Dawson JR, Gibson DG. What stops the flow of blood 
from the heart? Heart Vessels 1988;4:241-245. 
 
187 Jones CJH, Sugawara M, Kondoh Y, Uchida K, Parker KH. Compression and 
expansion wavefronts in canine ascending aortic flow: wave intensity analysis. Heart 
Vessels 2002;15:91-98. 
 
188 Avgeropoulou C, Illmann A, Schumm-Draeger PM, Kallikazaros J, Von Bibra H. 
Assessment of arterio-ventricular coupling by tissue Doppler and wave intensity in type 
2 diabetes. Br L Diabetes Vasc Dis 2006;6:271-278. 
 
189 Curtis SL, Zambanini A, Mayet J, Thom SA, Foale R, Parker KH, Hughes AD. 
Reduced systolic wave generation and increased peripheral wave reflections in chronic 
heart failure. Am J Physiol Heart Circ Physiol 2007;293:H557-H562. 
  
190 Fujimoto S, Mizuno R, Saito Y, Nakamura S. Clinical application of wave 
intensity for the treatment of essential hypertension. Heart Vessels 2004;19:19-22. 
 
191 Swampillai J, Rakebrandt F, Morris K, Jones CJH, Fraser AG. Acute effects of 
caffeine and tobacco on arterial function and wave travel. Eur J Clin Invest 
2006;36:844-849. 
 
192 Bleasedale RA, Mumford CE, Campbell RI, Fraser AG, Jones CJ, Frenneaux 
MP. Wave intensity analysis from the common carotid artery: a new non-invasive index 
of cerebral vasomotor tone. Heart Vessels 2003;18:202-206. 
 
193 Rakebrandt F, Palombo C, Swampillai J, Schon F, Donald A, Kozakova M, Kato 
K, Fraser AG. Arterial wave intensity and ventricular-arterial coupling by vascular 
ultrasound: rationale and methods for the automated analysis of forwards and 
backwards running waves. Ultrasound in Med and Bio 2009;35(2):266-277. 
 
CHAPTER 2.1 
194 www.corec.org.uk 
 
Page | 142  
 
195 Niki K, Sugawara M, Chang D, Harada A, Okada T, Sakai R, Uchida K, Tanaka 
R, Mumford CE. A new non-invasive measurement system for wave intensity: 
evaluation of carotid arterial wave intensity and reproducibility. Heart Vessels 
2002;17:12-21. 
 
196 Selzer RH, Hodis HN, Kwong-Fu H, Wendy JM, Lee PL, Liu CR, Liu CH. 
Evaluation of computerized edge tracking for quantifying intima-media thickness of the 
common carotid artery from B-mode ultrasound images. Atherosclerosis 1994;111:1-
11. 
 
CHAPTER 3.1.1 
197 Manovel A, Dawson D, Smith B, Nihoyannopoulos N. Assessment of left 
ventricular function by different speckle-tracking software. Eur J Echo 2009:11(5);417-
421. 
 
198 Marwick TH, Leano RL, Brown J, Sun JP, Hoffmann R, Lysyansky P, Becker M, 
Thomas JD. Myocardial strain measurement with 2-dimensional speckle-tracking 
echocardiography:definition of normal range. J Am Coll Cardiol Cardiovasc Imaging. 
2009:2(1);80-84. 
 
199 Kjaergaard J, Korinek J, Belohlavek M, Oh JK, Sogaard P, Hassager C. 
Accuracy, Reproducibility and Comparability of Doppler tissue imaging by two high-end 
ultrasound systems. J Am Soc Echo 2006,19;3,322-328 
 
200 Walker A, Olsson E, Wranne B, Ringqvist I, Ask P. Accuracy of spectral 
Doppler flow and tissue velocity measurements in ultrasound systems. US Med Biol 
2004:30(1);127-132. 
 
201 Kornaat PR, Koo S, Andriacchi TP, Bloem JL, Gold GE. Comparison of 
quantitative cartilage measurements acquired on two 3.0T MRI systems using different 
manufacturers. J Magn Reson Imaging 2006:23(5);770-773. 
 
CHAPTER 3.1.2 
 
202 Vogel M, Cheung MMH, Li J, Kristiansen SB, Schmidt MR, White PA, et al. 
Model using tissue Doppler-derived isovolumic acceleration: validation in an animal 
noninvasive assessment of left ventricular force-frequency relationships. Circulation 
2003;107:1647-1652. 
 
203 Li X, Jones M, Wang H-F, Davies CH, Swanson JC, Hashimoto I, et al. Strain 
rate acceleration yields a better index for evaluating left ventricular contractile function 
as compared with tissue velocity acceleration during isovolumic contraction time: an in 
vivo study. J Am Soc Echocardiogr 2003;16:1211-1216. 
 
204 Dalsgaard M, Snyder EM, Kjaergaard J, Johnson BD, Hassager C, Oh JK. 
Isovolumic acceleration measured by tissue Doppler echocardiography is preload 
independent in healthy subjects. Echocardiography 2007;24:572-579. 
 
205 Vogel M, Schmidt MR, Kristiansen SB, Cheung M, White PA, Sorensen K, et al. 
Validation of myocardial acceleration during isovolumic contraction as a novel index of 
right ventricular contractility: comparison with ventricular pressure-volume relations in 
an animal model. Circulation 2002;105:1693-1699. 
 
Page | 143  
 
206 Galiuto L, Ignone G, DeMaria AN. Contraction and relaxation velocities of the 
normal left ventricle using pulsed-wave tissue Doppler echocardiography. Am J Cardiol 
1998;81:609-614.  
 
207 Yamada H, Oki T, Tabata T, Iuchi A, Ito S. Assessment of left ventricular 
systolic wall motion velocity with pulsed tissue Doppler imaging: comparison with peak 
dP/dt of the left ventricular pressure curve. J Am Soc Echocardiogr 1998;11:442-449. 
 
208 Pasquet A, Armstrong G, Beachler L, Lauer MS, Marwick TH. Use of segmental 
tissue Doppler velocity to quantitate exercise echocardiography. J Am Soc 
Echocardiogr 1999;12:901-912. 
 
209 Altinmakas S, Dagdeviren B, Uyan C, Keser N, Gumus V, Pektas O. Prediction 
of viability by pulsed-wave Doppler tissue sampling of asynergic myocardium during 
low-dose dobutamine challenge. Int L Cardiol 2000;74:107-113.  
 
210 Margulescu AD, Thomas DE, Ingram TE, Vintila VD, Egan MA, Vinereanu D, 
Fraser AG. Can isovolumic acceleration be used in clinical practice to estimate 
ventricular contractile function? Reproducibility and regional variation of a new 
noninvasive index. J Am Soc Echocardiogr 2010;23(4):423-431. 
 
CHAPTER 3.1.3 
211 Harada K, Yasuoka K, Shimada Y. Usefulness of tissue Doppler imaging for 
assessing aortic wall stiffness in children with the Marfan Syndrome. Am J Cardiol 
2004;93:1072-1075. 
 
212 DePaepe A, Devereux RB, Dietz HC, Hennekamn R, Pyeritz R. Revised 
diagnostic criteria for the Marfan Syndrome. Am J Med Genet 1996;62:417-426. 
 
213 Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux 
RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, 
Wordsworth P, De Paepe AM. The revised Ghent nosology for the Marfan syndrome. J 
Med Genet 2010:47;476-485. 
 
CHAPTER 3.2.1 
 
214 Kiotsekoglou A, Saha SK, Moggridge JC, Kapetanakis V, Bijnens BH, Mullen 
MJ, Camm J, Sutherland GR, Wilkinson IB, Child AH. Effect of aortic stiffness on left 
ventricular long-axis function in adults with Marfan Syndrome. Hellenic J Cardiol 
2010;51:501-511. 
 
215 The Reference Values for Arterial Stiffness’ Collaboration. Determinants of 
pulse wave velocity in healthy people and in the presence of cardiovascular risk 
factors: ‘establishing normal and reference values.’ Eur Heart J 2010;31:2338-2350. 
 
CHAPTER 3.3.1 
216 Palombo C, Malshi E, Morizzo C, Rakebrandt F, Corretti V, Santini F. Arterial 
wave reflection during antihypertensive therapy with barnidipine: a 6-month, open-label 
study using an integrated cardiovascular ultrasound approach in patients with newly 
diagnosed hypertension. Clin Thera 2009;31(12):2873-2885. 
 
Page | 144  
 
217 Bleasedale RA, Mumford CE, Campbell RI, Fraser AG, Jones CJ, Frenneaux 
MP. Wave intensity analysis from the common carotid artery: a new non-invasive index 
of cerebral vasomotor tone. Heart Vessels 2003;18:202-206. 
 
218 Swampillai J, Rakebrandt F, Morris K, Jones CJH, Fraser AG. Acute effects of 
caffeine and tobacco on arterial function and wave travel. Eur J Clin Invest 
2006;36:844-849. 
 
CHAPTER 3.4.1 
 
219 Shores J, Berger KR, Murphy E, et al. Progression of aortic dilatation and the benefit of 
long-term beta-adrenergic blockade in Marfan Syndrome. N Eng J Med 1994;330:1335-41. 
 
220 Williams B, Lacy PS, Thom SM, et al; CAFE Investigators; Anglo-Scandinavian 
Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing 
Committee. Differential impact of blood pressure-lowering drugs on central aortic 
pressure and clinical outcomes: principal results of the Conduit Artery Function 
Evaluation (CAFE) study. Circulation 2006;113:1213-25.  
 
221 Jondeau G, Boutouyrie P, Lacolley P, et al. Central pulse pressure is a major 
determinant of ascending aorta dilation in Marfan syndrome. Circulation 1999;99:2677-
81. 
 
222 Morgan T, Lauri J, Bertram D, et al. Effect of different antihypertensive drug 
classes on central aortic pressure. Am J Hypertens 2004;17:118-23. 
 
223 Ahimastos AA, Aggarwal A, D'Orsa KM, et al. Effect of perindopril on large 
artery stiffness and aortic root diameter in patients with Marfan syndrome: a 
randomized controlled trial. JAMA 2007;298:1539-47. 
 
224 Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus 
propranolol or atenolol for the prevention of aortic dilation in patients with the Marfan 
syndrome. Am J Cardiol 2005;95:1125–7. 
 
225 Williams A, Davies S, Stuart AG, et al. AG. Medical treatment of Marfan 
Syndrome: a time for change. Heart 2008;94:414-421. 
 
226 Cholley BP, Shroff SG, Sandelski J, et al. Aortic and other vascular disease: 
differential effects of chronic oral antihypertensive therapies on systemic arterial 
circulation and ventricular energetics in African-American patients. Circulation 
1995;91:1052–62. 
 
227 Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents 
aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117–21. 
 
228 Ahimastos AA, Dart AM, Kingwell BA. Angiotensin II blockade in Marfan's 
syndrome. N Engl J Med 2008;359:1732.  
 
229 Nagashima H, Sakomura Y, Aoka Y, et al. Angiotensin II type 2 receptor 
mediates vascular smooth muscle cell apoptosis in cystic medial degeneration 
associated with Marfan’s syndrome. Circulation 2001;104(suppl 1):I282-I287. 
 
230 Lacro RV, Dietz HC, Wruck LM, et al, Pediatric Heart Network Investigators. 
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) 
versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan 
syndrome. Am Heart J 2007;154:624-31. 
Page | 145  
 
 
231 Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-
root dilation in Marfan's syndrome. N Engl J Med 2008;358:2787-95. 
 
232 Rossi-Foulkes R, Roman MJ, Rosen SE, et al. Phenotypic features and impact 
of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan 
syndrome. Am J Cardiol 1999;83:1364–8. 
 
233 Salim MA, Alpert BS, Ward JC, et al. Effect of beta-adrenergic blockade on 
aortic root dilatation in the Marfan syndrome. Am J Cardiol 1994;74:629–32. 
 
234 Haouzi A, Berglund H, Pelikan PCD, et al. Heterogeneous aortic response to 
acute beta-adrenergic blockade in Marfan syndrome. Am Heart J 1997;133:60–3. 
 
235 Reed CM, Fox ME, Alpert BS. Aortic biomechanical properties in paediatric 
patients with the Marfan syndrome, and the effects of atenolol. Am J Cardiol 
1993;71:606–8. 
 
236 Rios AS, Silber EN, Bavishi N, et al. Effect of long-term beta-blockade on aortic 
root compliance in patients with Marfan syndrome. Am Heart J 1999;137:1057–61. 
 
237 Yin FC, Brin KP, Ting CT, et al. Arterial haemodynamic indexes in Marfan’s 
syndrome. Circulation 1989;79:854–62. 
 
238 Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of pulse pressure 
amplification in arterial hypertension. Hypertension 2009;54:1-9. 
 
239 Topouchian J, Brisac AM, Pannier B, et al. Assessment of the acute arterial 
effects of converting enzyme inhibition in essential hypertension: a double-blind, 
comparative and crossover study. J Hum Hypertens 1998;12:181-7. 
 
240 Kiotsekoglou A, Saha SK, Moggridge JC, et al. Effect of aortic stiffness on left 
ventricular long-axis function in adults with Marfan Syndrome. Hellenic J Cardiol 
2010;51:501-511. 
 
241 The reference values for arterial stiffness collaboration. Determinants of pulse 
wave velocity in healthy people and in the presence of cardiovascular risk factors: 
establishing normal and reference values. Eur Heart J 2010;31:2338-2350. 
 
242 Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of 
antihypertensive agents on central blood pressure and arterial stiffness in isolated 
systolic hypertension. Hypertension 2009;54:409-413. 
 
243 Ahimastos AA, Aggarwal A, Savarirayan R, et al. A role for plasma transforming 
growth factor-beta and matrix metalloproteinases in aortic aneurysm surveillance in 
Marfan syndrome? Atherosclerosis 2010;209:211-4. 
 
244 Baumgartner D, Baumgartner C, Schermer E, et al. Different patterns of aortic 
wall elasticity in patients with Marfan syndrome: a noninvasive follow-up study. J 
Thorac Cardiovasc Surg 2006;132:811-9. 
 
245 Ting CT, Cho CY, Chang MS, et al. Arterial hemodynamics in human 
hypertension: effects of adrenergic blockade. Circulation 1991;84:1049 –1057. 
 
246 Ohte N, Narita H, Sugawara M, et al. Clinical usefulness of carotid arterial wave 
intensity in assessing left ventricular systolic and early diastolic performance. Heart 
Vessels 2003;18:107-11. 
Page | 146  
 
 
247 Rakebrandt F, Palombo C, Swampillai J, et al. Arterial wave intensity and 
ventricular-arterial coupling by vascular ultrasound: rationale and methods for the 
automated analysis of forwards and backwards running waves. Ultrasound Med Biol 
2009;35:266-77. 
 
248 Vogel M, Cheung MM, Li J, et al. Noninvasive assessment of left ventricular 
force-frequency relationships using tissue Doppler-derived isovolumic acceleration: 
validation in an animal model. Circulation 2003;107:1647-52.  
 
249 Margulescu AD, Thomas DE, Ingram TE, et al. Can isovolumic acceleration be 
used in clinical practice to estimate ventricular contractile function? Reproducibility and 
regional variation of a new noninvasive index. J Am Soc Echocardiogr 2010;23:423-31.  
 
250 Harada K, Yasuoka K, Shimada Y. Usefulness of tissue doppler imaging for 
assessing aortic wall stiffness in children with the Marfan syndrome. Am J Cardiol 
2004;93:1072-5. 
 
251 Roman MJ, Rosen SE, Kramer-Fox R, et al. Prognostic significance of the 
pattern of aortic root dilation in the Marfan syndrome. J Am Coll Cardiol 1993;22:1470 
–6. 
 
252 Mahmud A, Feely J. β-Blockers reduce aortic stiffness in hypertension but 
nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008;21:663-667. 
 
253 Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol 
on central aortic pressure and left ventricular wall thickness. Hypertension 
2011;57:1122-8. 
 
254 Gambarin FI, Favalli V, Serio A, et al. Rationale and design of a trial evaluating 
the effects of losartan vs. nebivolol vs. the association of both on the progression of 
aortic root dilation in Marfan syndrome with FBN1 gene mutations. J Cardiovasc Med 
(Hagerstown) 2009;10:354-62. 
 
CHAPTER 4 
255 Margulescu AD, Thomas DE, Ingram TE, Vintila VD, Egan MA, Vinereanu D, 
Fraser AG. Can isovolumic acceleration be used in clinical practice to estimate 
ventricular contractile function? Reproducibility and regional variation of a new 
noninvasive index. J Am Soc Echocardiogr 2010;23(4):423-431. 
 
256 Harada K, Yasuoka K, Shimada Y. Usefulness of tissue Doppler imaging for 
assessing aortic wall stiffness in children with the Marfan Syndrome. Am J Cardiol 
2004;93:1072-1075. 
 
257 Shores J, Berger KR, Murphy E, et al. Progression of aortic dilatation and the 
benefit of long-term beta-adrenergic blockade in Marfan Syndrome. N Eng J Med 
1994:330;1335-1341. 
 
258 Williams A, Davies S, Stuart AG, et al. AG. Medical treatment of Marfan 
Syndrome: a time for change. Heart 2008;94:414-421. 
